

Gregory P. Forlenza, MD, MS
Curriculum Vitae

Biographical Sketch

Current Position

Professor of Pediatrics, Barbara Davis Center, Division of Pediatric Endocrinology, Department of Pediatrics, University of Colorado Anschutz Medical Campus; Director of Pediatric Diabetes Technology Research; H. Peter Chase, MD Endowed Chair

Professional Address

1775 Aurora CT

MS A140

Aurora, CO 80045

Email: gregory.forlenza@cuanschutz.edu

Phone: 303-724-2323

Fax: 303-724-6779

Education

INSTITUTION AND LOCATION	DEGREE	YEAR	FIELD OF STUDY
Georgia Institute of Technology, Atlanta, GA	BS	05/2003	Chemistry
University of Florida, Gainesville, FL	MD	05/2007	Medicine
University of Florida, Gainesville, FL	Resident	06/2010	Pediatrics
University of Colorado Denver, Denver, CO	Fellow	06/2011	Pediatric Endocrinology
University of Minnesota, Minneapolis, MN	MS	06/2015	Clinical Research
University of Minnesota, Minneapolis, MN	Fellow	06/2015	Pediatric Endocrinology

Academic Appointments

2011-2013	Assistant Professor, Division of General Pediatrics, Department of Pediatrics, University of Florida College of Medicine, Gainesville, FL
2015-2021	Assistant Professor, Barbara Davis Center, Division of Pediatric Endocrinology, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO Co-Director of Pediatric Diabetes Technology Research (PANTHER) Program
2021-2026	Associate Professor, Barbara Davis Center, Division of Pediatric Endocrinology, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO Director of Pediatric Diabetes Technology Research (PANTHER) Program
2024-present	H. Peter Chase, MD Endowed Chair, Division of Pediatric Endocrinology, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO
2026-present	Professor, Barbara Davis Center, Division of Pediatric Endocrinology, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO Director of Pediatric Diabetes Technology Research (PANTHER) Program

Hospital Appointments

2011-2013	UF Health Shands Hospital, General Pediatrics, Gainesville, FL
2016-2026	St. Mary's Regional Hospital, Pediatric Endocrinology, Grand Junction, CO
2015-present	Children's Hospital Colorado, Pediatric Endocrinology, Aurora, CO
2016-present	University of Colorado Hospital, Pediatric Endocrinology, Aurora, CO

Honors, Special Recognitions and Awards

2007	Research Honors, University of Florida College of Medicine
2010	Outstanding Resident Teacher in Pediatrics, University of Florida College of Medicine
2012	Excellence in Customer Service Key, University of Florida College of Medicine
2014	Pediatric Endocrine Society - Competitive Travel Grant Award
2014	CAPER Pancreas Fest - Competitive Travel Grant Award
2015	Hostetter Award for Most Outstanding Research by a Fellow – University of Minnesota Pediatric Research, Education, and Scholarship Symposium (PRESS)
2017	American Diabetes Association - Young Investigator Travel Award
2019	International Society for Pediatric and Adolescent Diabetes - Young Investigator Award
2023	University of Colorado Pediatric Endocrinology Fellowship – Outstanding Faculty Teacher
2026	University of Colorado Pediatric Endocrinology Fellowship – Outstanding Research Mentor

Membership in Professional Organizations

2010-present	American Academy of Pediatrics
2013-present	Pediatric Endocrine Society (Membership Committee 2014-2017)
2013-present	The Endocrine Society
2014-present	American Diabetes Association
2015-present	The Society for Pediatric Research (elected)
2017-present	International Society for Pediatric and Adolescent Diabetes
2019-present	Association of Diabetes Care and Education Specialists

Major Committee and Service Responsibilities

Community Service

2003-2010	Florida Camp for Children and Youth with Diabetes – Counselor
2012-2013	Florida Camp for Children and Youth with Diabetes – Supervising Physician
2013-2015	Camp Needlepoint for Adolescents with Diabetes – Supervising Physician
2017-present	Camp Colorado Diabetes Camp – Senior Medical Staff Physician

Departmental

2017-present	Clinical Care Task Force, Barbara Davis Center - Member
2017-2023	Empowering Patients for Individualized Care (EPIC) Conference – Co-Chair for organizing committee
2019-2021	Barbara Davis Center Grand Rounds and Morbidity and Mortality Conference organizing chair
2017-present	Pediatric Endocrinology Fellowship Program Interview/Recruitment Committee – Member
2019-present	PANTHER Program Diabetes Technology Education Co-Funder and Advisor
2021-present	Barbara Davis Center Pediatric Research Committee – Member
2023-present	Practical Ways to Achieve Targets in Diabetes Care (ATDC) Keystone Conference – Organizing Committee Member

University

2012-2013	Pediatric Obesity Center of Excellence Development Committee, University of Florida - Member
2013-2015	Chronic Pancreatitis Working Group, University of Minnesota – Member

2021-present Clinical Translational Research Advisory Committee – BDC Representative
2025-present Department of Pediatrics Promotion and Tenure Committee

Hospital

2013-2015 Acute Care Diabetes Advisory Committee, University of Minnesota Hospitals – Member
2018-2020 Insulin Safety Committee, Children’s Hospital Colorado – Artificial Pancreas Advisor
2018-present Multidisciplinary Pancreatitis Working Group, Children’s Hospital Colorado – Founding Member

State

2016-present Colorado Kids with Diabetes Consensus School Guidelines for Diabetes Therapy – Diabetes Technology Advisor

National

2014-2017 Pediatric Endocrine Society Membership Committee – Member
2017 The Endocrine Society Pediatric Therapeutic Continuous Glucose Monitoring Task Force – Committee Member
2019-2021 American Diabetes Association Annual Scientific Sessions Pediatric Diabetes content committee - member
2020 IDEA 2.0 American Association of Clinical Endocrinologists CGM Education Committee – Pediatric CGM content advisor
2021-present AADE National Coverage Determination for Insulin Pumps and CGMs Advisory Committee – Member and Pediatric Advisor
2023 ISPAD Annual Scientific Sessions Planning Committee – Member
2025-present American Diabetes Association Technology Interest Group – Chair-Elect

Advisory Board and Consultant Roles

2015-present Abbott Diabetes Care – Consultant
2016-present Dexcom – Speaker, Consultant
2017-present Insulet – Speaker, Consultant
2017-present Medtronic Inc – Speaker, Advisory Board Member, Consultant
2017-present Tandem Diabetes – Speaker, Advisory Board Member, Consultant
2019-2021 Beta Bionics – Consultant
2020-2023 Lilly - Consultant
2024 Sequel – Advisory Board Member

Licensure and Board Certification

Medical Licenses

2010-present Colorado Medical License

Board Certification

2010 American Board of Pediatrics, General Pediatrics
2017 American Board of Pediatrics, Pediatric Endocrinology

Review and Referee Work

Journal Editorship

2020-2023 Pediatric Diabetes – Associate Editor
2023-present Diabetes Technology and Therapeutics – Associate Editor

Journal Editorial Board

2019-2023 Diabetes Technology and Therapeutics

Ad hoc Manuscript Reviewer

2011-2012 American Family Physician
2011-present Diabetes Technology and Therapeutics
2014-2015 Childhood Obesity
2015-present Diabetes Science and Technology
2016 American Journal of Ophthalmology
2016-present Sensors
2017-present Diabetes Care
2017-present Pediatric Diabetes
2017-present PLOS One
2017-present Lancet Diabetes and Endocrinology
2019-present Diabetes, Obesity, and Metabolism

Grant Review Activities

2022 JDRF/Breakthrough T1D Grant Review – Grant Reviewer
2023 JDRF/Breakthrough T1D Grant Review – Grant Reviewer and Review Committee Chair
2024 National Science Foundation – Grant Reviewer

Invited Extramural Lectures, Presentations, and Visiting Professorships

Local

1. University of Florida Grand Rounds, “Multiple Manifestations of Multisystem Mitochondrial Maladies,” Gainesville, FL 2010
2. University of Colorado Endocrinology Grand Rounds, “An Interesting Case of Polyuria,” Denver, CO 2011
3. Children’s Diabetes Foundation Guild, “Update on Artificial Pancreas Technology 2016,” Denver, CO 2016
4. University of Colorado Nursing Lecture Series, “Hemoglobin A1c,” Denver, CO 2017
5. Barbara Davis Center Research in Progress, “Update on Artificial Pancreas Research,” Denver, CO 2017
6. Colorado Optimist Club, “Diabetes Technology in 2017,” Denver, CO 2017
7. Colorado Association of School Nurses, “An Update on Diabetes Technology: Closed Loop, PLGS, and Pumps,” Denver, CO 2018
8. Barbara Davis Center Research in Progress, “Artificial Pancreas Research at the Barbara Davis Center – Update for 2018” Denver, CO 2018
9. University of Colorado Endocrine Division Grand Rounds, “Diabetes Technology in 2019: The Rapidly Changing Field of Continuous Glucose Monitors and Artificial Pancreas Systems,” Denver, CO 2019
10. Endocrine Division Educational Conference, “CGM in Non-T1D Patients,” Denver, CO 2021.
11. Colorado School Nurse Educational Series, “Diabetes Technology Update 2021,” Denver, CO 2021
12. Barbara Davis Center Research in Progress Series, “Optimizing Success with Hybrid Closed Loop Technology in Children with Type 1 Diabetes,” Denver, CO 2021.
13. Colorado Springs Educational Talk, “Type 1 Diabetes Technology Update 2022,” Virtual, CO, 2022.
14. Barbara Davis Center Grand Rounds, “Development, Testing, and Approval of Omnipod 5: From Academic Project to Real-World Use,” Virtual, 2022.

15. Barbara Davis Center Fellowship Lecture Series, "Fellows Technology Update Summer 2022," Denver, CO, 2022.
16. University of Colorado Grand Rounds, "From Concept to Clinical Practice: How Technology Reduces Burden and Improves Care for Children with Type 1 Diabetes," Denver, CO, 2023

Regional

1. University of Minnesota PRESS Conference, "Near Euglycemia can be achieved safely in pediatric total pancreatectomy islet auto-transplant recipients using an adapted intravenous insulin infusion protocol," Minneapolis, MN 2014
2. University of Minnesota PRESS Conference, "Success of Artificial Pancreas Use in Patients after TPIAT," Minneapolis, MN 2015
3. Western Association for Vitreoretinal Education/Ocular Imaging Conference (WAVE/OIC) Meeting, "Artificial Pancreas Technology in 2013," Maui, Hawaii 2013
4. WAVE/OIC Meeting, "Artificial Pancreas Technology in 2015," Maui, Hawaii 2015
5. Pediatric Endocrinology Nursing Society, "Islet Cell Allo-Transplantation," Denver, CO 2016
6. Diabetes Symposium for the Medical College of Wisconsin, "Artificial Pancreas Technology in 2017: The Dawn of the Automated Insulin Delivery Paradigm," Milwaukee, WI 2017
7. Practical Ways to Achieve Targets in Diabetes Care Conference, "More Than 1 Year of Hybrid Closed Loop in Pediatrics," Keystone, CO, 2017.
8. Practical Ways to Achieve Targets in Diabetes Care Conference, "Future Artificial Pancreas Systems," Keystone, CO, 2019.
9. Cedars Sinai Pediatric Grand Rounds, "Use of Technology to Improve management of Pediatric Diabetes," Virtual Talk, 2021.
10. Georgia Chapter of AACE Regional Conference, "The Latest on CGM, Insulin Pumps, and Hybrid Closed Loop Systems," Virtual Talk, 2021.
11. Practical Ways to Achieve Targets in Diabetes Care Conference, "Customizable AP Systems," Virtual Talk, 2021.
12. Diabetes Dialog Conference, "Future of Hybrid Closed Loop Systems," Denver, CO 2021.
13. Diabetes Dialogue, "New and Emerging Continuous Glucose Monitors in 2022," Denver, CO, 2022.
14. Practical Ways to Achieve Targets in Diabetes Care Conference, "Ultra-Rapid Acting Insulins for Prandial Glucose Control," Keystone, CO, 2026.

National

1. American Diabetes Association Annual Scientific Sessions, oral abstract presentation, "Inpatient Safety and Feasibility of the Tandem Predictive Low Glucose Suspend (PLGS) Insulin Pump," San Diego, CA, 2017.
2. American Diabetes Association Annual Scientific Sessions, oral abstract presentation, "Overnight to Early Morning Glycemic Outcomes in Children Using the MiniMed 670G System," Orlando, FL, 2018.
3. American Diabetes Association Annual Scientific Sessions, invited platform presentation, "Monitoring Glycemia in Youth with Type 1 Diabetes Mellitus – Meter Blood Glucose, Continuous Glucose Monitoring, or Both?" Orlando, FL, 2018.
4. American Diabetes Association Annual Scientific Sessions, invited platform presentation, "Continuous Glucose Monitor Use in Hospital Settings," Chicago, IL, 2020.
5. Pediatric Academic Society Annual Meeting, "The Changing Role of Diabetes Providers," Virtual Talk, 2021.
6. Medscape Advanced Therapy for Diabetes Conference Encore, "Automated Insulin Delivery with Dexcom CGM," Virtual Talk, 2021.
7. American Diabetes Association Annual Scientific Sessions, invited platform presentation, "Challenges and Benefits of Technology Use in High-Risk Youth Populations," New Orleans, LA, 2022.
8. American Diabetes Association Annual Scientific Sessions, invited platform presentation, "The Insulin-Only Bionic Pancreas Trial: The iLet Bionic Pancreas and Study Design," New Orleans, LA, 2022.

9. Endocrine Society Annual Conference, "Automated Insulin Delivery: The Future is Now," Atlanta, GA, 2022.
10. American Academy of Family Physicians Lecture Series, "Type 1 Diabetes – Pediatric," Virtual, 2022.
11. American Diabetes Association Annual Scientific Sessions, invited platform presentation, "Challenges and Benefits of Technology Use in High-Risk Youth Populations," New Orleans, LA, 2022.
12. American Diabetes Association Annual Scientific Sessions, invited platform presentation, "The Insulin-Only Bionic Pancreas Pivotal Trial: Study Design," New Orleans, LA, 2022.
13. American Diabetes Association Annual Scientific Sessions, invited platform presentation, "DIY is Not Necessary in Type 1 Diabetes Management," San Diego, CA, 2023.
14. American Diabetes Association Annual Scientific Sessions, invited Learning Byte, "Omnipod 5: Clinical Pearls for Pediatrics," San Diego, CA, 2023.
15. American Diabetes Association Annual Scientific Sessions, invited presentation, "Proven Outcomes for the Insulet Omnipod 5 Across Broad Populations of Type 1 Diabetes," Orlando, FL, 2024.
16. American Diabetes Association Annual Scientific Sessions, invited presentation, "Reducing Diabetes Burden with AID," Orlando, FL, 2024.
17. American Diabetes Association Annual Scientific Sessions, invited presentation, "Is It Time? Operationalizing Time in Tight Range for Youth with Type 1 Diabetes," Chicago, IL, 2025.
18. American Diabetes Association Annual Scientific Sessions, invited presentation, "General Tips for Optimizing your AID," New Orleans, LA, 2026.
19. American Diabetes Association Annual Scientific Sessions, "Omnipod Innovation Now and in the Future," New Orleans, LA, 2026.

International

1. Advanced Technologies and Treatments for Diabetes International Conference, "Evaluation of the MiniMed 670G System Predictive Low Glucose Management Feature in Children," Vienna, Austria, 2018
2. Advanced Technologies and Treatments for Diabetes International Conference, "ADVICE4U Pro Study – Decision Support Systems for Health Care Professionals: How Advisor Pro Works," Berlin, Germany, 2019
3. International Society for Pediatric and Adolescent Diabetes Conference, "Advice4U: Results of a Multinational Multicenter Study," Boston, MA, 2019 (*Invited*).
4. Advanced Technologies and Treatments for Diabetes International Conference, "Clinical Implementation and Utilization of Hybrid Closed-Loop Technology," Madrid, Spain, 2020 (*Invited*).
5. Advanced Technologies and Treatments for Diabetes International Conference, "Omnipod 5: Unique Features and Clinical Benefits of Tubeless Automated Insulin Delivery," Virtual Talk, 2021.
6. Rethinking "Candidate Selection" for Control-IQ Hybrid Closed Loop Technology, EASD Scientific Sessions, Virtual Talk, 2021.
7. Safety Evaluation of the Omnipod 5 Automated Insulin Delivery System over 3 Months of Use in Adults and Children with Type 1 Diabetes, EASD Scientific Sessions, Virtual Talk, 2021.
8. Advanced Technologies and Treatments for Diabetes International Conference, "Predicting 12-Month Success with a Second-Generation Hybrid Closed Loop (HCL) Artificial Pancreas System," Barcelona, Spain, 2022.
9. European Association for the Study of Diabetes, "Glycemic Outcomes over 15 Months with the Omnipod 5 Automated Insulin Delivery System," Stockholm, Sweden, 2022.
10. European Association for the Study of Diabetes, "Recently Diagnosed with Type 1 Diabetes: Glycemic Outcomes with the Omnipod 5 Automated Insulin Delivery System," Stockholm, Sweden, 2022.
11. Advanced Technologies and Treatments for Diabetes International Conference, "Real-World Data on Hybrid Closed-Loop in Type 2 Diabetes," Florence, Italy, 2024.
12. European Society for Pediatric Endocrinology, "Use of Verapamil in Newly Diagnosed T1D," Liverpool, England, 2024 (*Invited*).

13. Advanced Technologies and Treatments for Diabetes International Conference, "Impact of Lowering Target Glucose Settings with the Omnipod 5 Automated Insulin Delivery (AID) System: Evidence from Real-World Use," Amsterdam, Netherlands, 2025.
14. International Society for Pediatric and Adolescent Diabetes Conference, "Case Studies on Unique Pediatric Use of Control-IQ," Montreal, 2025.
15. Advanced Technologies and Treatments for Diabetes International Conference, "Settings Associated with Optimal Outcomes with the Omnipod 5 Automated Insulin Delivery (AID) System: Evidence from Real-World Users with Type 1 Diabetes (T1D)," Barcelona, 2026.
16. Advanced Technologies and Treatments for Diabetes International Conference, "Is Ultra-Rapid Acting Insulin Improving AID – The Evidence is Mixed, but There is a Catch," Barcelona, 2026 (*Invited*).

Visiting Professorships

1. McMaster University May 2026, Visiting Professor in Pediatric Endocrinology.
 - a. Grand Rounds, "From Concept to Standard of Care: Development of Current Technology and Future of Therapy for Children with Type 1 Diabetes."
 - b. Fellows Mentorship and Education: "Automated Insulin Delivery Cases."
 - c. Endocrinology Division Presentation: "Clinical Use and Tuning of Automated Insulin Delivery Systems."

Teaching Record

Major Presentations

Presentations to Medical Students

1. University of Colorado Pediatric Interest Group, "What it's like working as a general pediatrician and pediatric sub-specialist," 2017

Presentations to Residents and Fellows

1. University of Florida Noon Conference, "Eating Related Disorders in Pediatrics," 2009
2. University of Florida Intern Lecture Series, "Type 1 Diabetes," 2009
3. University of Colorado Fellowship Lecture Series, "Update on Type 1 Diabetes Epidemiology," 2011
4. University of Florida Pediatric Resident Lecture Series, "Reading a Growth Chart," 2011
5. University of Florida Family Medicine Lecture Series, "Well Child Care Guidelines," 2011
6. University of Florida Family Medicine Lecture Series, "Infant Feeding Guides," 2011
7. University of Florida Pediatric Resident Lecture Series, "Pediatric Obesity and Type 2 Diabetes," 2012
8. University of Minnesota Research in Progress Series, "Artificial Pancreas in Patients after TPIAT," 2014
9. University of Minnesota Fellowship Lecture Series, "Drug Induced Diabetes," 2015
10. University of Minnesota Fellowship Lecture Series, "Progress towards an Artificial Pancreas," 2015
11. University of Colorado Fellowship Lecture Series, "Drug Induced Diabetes," 2016-2022
12. University of Colorado Fellowship Lecture Series, "Updated on Diabetes Technology," 2016-2022

Morbidity and Mortality Conferences

1. University of Florida Morbidity and Mortality Conference, "Postprandial hypoglycemia in Children after Nissen Fundoplication," 2009
2. University of Minnesota Morbidity and Mortality Conference, "An Unusual Case of Headaches: Early Presentation of Autoimmune Hypophysitis," 2015
3. Barbara Davis Center Morbidity and Mortality Conference, "DKA with Hypokalemia," 2017
4. Barbara Davis Center Morbidity and Mortality Conference, "Suicide with HCL AP," 2019
5. Barbara Davis Center Morbidity and Mortality Conference, "COVID-19 in the Type 1 Diabetes Population, what is the evidence showing us?" 2021

Wards and Clinic Attending Duties

Outpatient Service

- 2 half-days per week: diabetes clinic at BDC
- 2 half-days per month: telemedicine with patients in Grand Junction, CO
- 1 half-day per month: COMPLEAT Kids Multidisciplinary Pancreatitis clinic
- 1 day every other month supervise fellows' clinic for 2-3 fellows

Inpatient Service

- 6 weeks per year including 3 weekends per year: Provide consulting care to hospitalized children with type 1 diabetes and hospitalized children with hyperglycemia. See new onset T1D patients in clinic at BDC for outpatient education. Outside consulting calls from pediatricians and other hospitals.
 - Precept Pediatric Endocrinology fellows on rounds at Children's Hospital Colorado and serve as backup for overnight calls.

Other Educational Activities

2012-2013	University of Florida Second Year Medical Student Introductions to Pediatrics – Course Director
2013-2015	University of Minnesota Pediatric Endocrinology Case Conferences for Medical Students – Small Group Leader and Speaker
2015-present	University of Colorado Pediatric Endocrinology Small Groups for Second Year Medical Students – Small Group Leader for growth and puberty workshops
2015-present	University of Colorado Pediatric Endocrinology Residency Half-Day – Small Group Leader
2015-present	University of Colorado Pediatric Endocrinology Fellowship Lecture Series – Present 2-3 sessions per year
2015-present	University of Colorado Pediatric Endocrinology Fellows Continuity Clinic – Precept fellows clinic 6 times per year
2019-2021	Director of the Barbara Davis Center Grand Rounds and Morbidity and Mortality conference series
2021-present	University of Colorado Clinical Trials Research Advisory Committee – BDC Representative

Trainees and Mentees

Undergraduate Students

1. Aria Saunders – Undergraduate Biomedical Engineering Student 2019
Project: MiniMed 670G Hybrid Closed Loop Artificial Pancreas System for the Treatment of Diabetes Mellitus: Overview of Its Safety and Efficacy
Role: Faculty mentor for undergraduate biomedical engineering summer research student.
Publication: **Saunders A**, Messer LH, Forlenza GP. MiniMed 670G Hybrid Closed Loop Artificial Pancreas System for the Treatment of Type 1 Diabetes Mellitus: Overview of Its Safety and Efficacy. Expert Rev Med Devices. 2019. Epub 2019/09/22. doi: 10.1080/17434440.2019.1670639. PubMed PMID: 31540557.
2. Kasserine Taylor – Undergraduate Student 2019-2020
Project: Use of machine learning and hybrid closed loop systems at diabetes camps
Role: Faculty mentor for pre-medical undergraduate student.
Publication: **Taylor KA**, Forlenza GP. Use of Machine Learning and Hybrid Closed Loop Insulin Delivery at Diabetes Camps. Diabetes technology & therapeutics. 2020. Epub 2020/02/15. doi: 10.1089/dia.2020.0026. PubMed PMID: 32058821.
3. Carson Wedding – Undergraduate Quantitative Biology Student 2023-2024
Project: Pattern recognition in type 1 diabetes technology data
Role: Faculty mentor

4. Rishika Kartik – Undergraduate Inclusive Design Student 2024
 Project: Impact of visual disability on use of diabetes technologies.
 Role: Faculty mentor for pre-medical undergraduate student.
 Publication: **Kartik R**, Akturk HK, Stewart MW, **Forlenza GP**. Seeing the Road Ahead-The Need to Address Accessibility of Diabetes Technology. Diabetes technology & therapeutics. 2024. Epub 20241223. doi: 10.1089/dia.2024.0412. PubMed PMID: 39714954.

Medical Students

1. Indira Sriram, PhD – Medical Student 2015-2018
 Role: Faculty advisor to medical student
2. Marisa Sobczak – Medical Student 2021
 Project: Glycemic Control in Relation to Technology Use in a Single Center Cohort of Children with Type 1 Diabetes
 Role: Project advisor
 Publication: Sawyer A, **Sobczak M**, Forlenza GP, Alonso GT. Glycemic Control in Relation to Technology Use in a Single Center Cohort of Children With Type 1 Diabetes. Diabetes technology & therapeutics. 2022. Epub 20220131. doi: 10.1089/dia.2021.0471. PubMed PMID: 35099306.

Residents

1. Elizabeth Mann, MD – Pediatric Resident 2013-2015
 Project: QI Project. Improvements in Training for Diabetes Camp. University of Minnesota Camp Needlepoint
 Role: During fellowship provided mentorship to a pediatric resident with an interest in pediatric endocrinology on a QI project to improve training of volunteers and counselors at Camp Needlepoint.
2. Indira Sriram, MD, PhD – Pediatric Resident 2019-2022
 Role: Career advisor to pediatric resident
3. Alexandra Sawyer, MD – Pediatric Resident 2021
 Project: Glycemic Control in Relation to Technology Use in a Single Center Cohort of Children with Type 1 Diabetes
 Role: Project advisor
 Publication: **Sawyer A**, Sobczak M, Forlenza GP, Alonso GT. Glycemic Control in Relation to Technology Use in a Single Center Cohort of Children With Type 1 Diabetes. Diabetes technology & therapeutics. 2022. Epub 20220131. doi: 10.1089/dia.2021.0471. PubMed PMID: 35099306.
4. James Schuler, MD, PhD – Pediatric Resident 2022-2025
 Role: Faculty Advisor
 Current Status: Accepted for Pediatric Endocrinology Fellowship at University of Colorado starting July 2025

Fellows

1. Jenna Sopfe, MD – Pediatric Heme/Onc Fellow 2015-2018
 Project: Prospective and retrospective analysis of malglycemia in the pediatric bone marrow transplant population
 Role: Primary faculty mentor for Dr. Sopfe's fellowship projects and Masters of Clinical Research projects.
 Publications:
 - **Sopfe J**, Pyle L, Keating AK, Campbell K, Liu AK, Wadwa RP, Verneris MR, Giller RH, Forlenza GP. Malglycemia is associated with poor outcomes in pediatric and adolescent hematopoietic stem cell transplant patients. Blood Adv. 2019;3(3):350-9. Epub 2019/02/06. doi:

10.1182/bloodadvances.2018021014. PubMed PMID: 30718242.

- **Sopfe J**, Campbell K, Keating AK, Pyle L, Liu AK, Verneris MR, Giller RH, Forlenza GP. Glycemic variability is associated with poor outcomes in pediatric hematopoietic stem cell transplant patients. *Pediatr Blood Cancer*. 2020;67(11):e28626. Epub 2021/01/23. doi: 10.1002/pbc.28626. PubMed PMID: 33480469.

- **Sopfe J**, Vigers T, Pyle L, Giller RH, Forlenza GP. Safety and Accuracy of Factory Calibrated Continuous Glucose Monitoring in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation. *Diabetes technology & therapeutics*. 2020. Epub 2020/02/28. doi: 10.1089/dia.2019.0521. PubMed PMID: 32105513.

2. Kalie Tommerdahl, MD – Pediatric Endocrinology fellow 2017-2020
Project: Metabolic and Renal Effects of Automated Insulin Delivery Systems in Youth with Type 1 Diabetes Mellitus.
Role: Co-faculty mentor for Dr. Tommerdahl's fellowship projects; Career Advisor
Publication: Pauley ME, **Tommerdahl KL**, Snell-Bergeon JK, Forlenza GP. Continuous Glucose Monitor, Insulin Pump, and Automated Insulin Delivery Therapies for Type 1 Diabetes: An Update on Potential for Cardiovascular Benefits. *Curr Cardiol Rep*. 2022. Epub 20221024. doi: 10.1007/s11886-022-01799-x. PubMed PMID: 36279036
3. Soohee Cho, MD – Pediatric Heme/Onc Fellow 2019-2022
Project: Feasibility and Safety Study of a Hybrid Closed Loop Insulin Delivery System for Children and Young Adults with High Risk Acute Lymphoblastic Leukemia
Role: Primary faculty mentor for Dr. Cho's fellowship project and Masters of Clinical Research projects.
Publication: **Cho S**, Vigers T, Pyle L, Franklin A, Demedis J, Jeney F, Forlenza GP. Composite Metric of Glycemic Control Q-Score is Elevated in Pediatric and Adolescent/Young Adult Hematopoietic Stem Cell Transplant Recipients. *Diabetes technology & therapeutics*. 2022. Epub 20221213. doi: 10.1089/dia.2022.0246. PubMed PMID: 36511871.
4. Meghan Pauley, DO – Pediatric Endocrinology Fellow 2020-2023
Project: Barriers to Uptake of Insulin Technologies and Novel Solutions
Role: Manuscript advisor
Publication: **Pauley ME**, Tommerdahl KL, Snell-Bergeon JK, Forlenza GP. Continuous Glucose Monitor, Insulin Pump, and Automated Insulin Delivery Therapies for Type 1 Diabetes: An Update on Potential for Cardiovascular Benefits. *Curr Cardiol Rep*. 2022. Epub 20221024. doi: 10.1007/s11886-022-01799-x. PubMed PMID: 36279036
5. Ideen Tabatabai, MD – Pediatric Endocrinology Fellow 2022-2025
Project: Real World Implementation of the Beta Bionics iLet
Role: Faculty research mentor
Publications:
- Forlenza GP, **Tabatabai I**, Lewis D. Point-Counterpoint: The Need for Do-It-Yourself (DIY) Open Source (OS) AID Systems in Type 1 Diabetes Management. *Diabetes Technol Ther*. 2024. Epub 20240426. doi: 10.1089/dia.2024.0073. PubMed PMID: 38669472.
- **Tabatabai I**, Forlenza G. Current State of Automated Insulin Delivery Options For Diabetes Management: A Primer For The Clinician. *SMART-MD Journal of Precision Medicine*. 2025;2(2):e139 - e48. doi: 10.69734/92xeed68.
6. Alexandra Sawyer, MD – Pediatric Endocrinology Fellow 2023-2026
Project: Using Simplified Meal Boluses versus Carbohydrate Counting in Adolescents with Hybrid Closed Loop Systems: A Randomized Crossover Trial
Role: Faculty research mentor
Publications:
- **Sawyer A**, Wilmot EG, Do D, Miller KM, Ly TT, Forlenza GP. Settings Associated with Optimal

Glycemic Outcomes with the Omnipod® 5 Automated Insulin Delivery System: Evidence from Real-World Users with Type 1 Diabetes. *Diabetes technology & therapeutics*. 2026.

- **Sawyer A**, Wilmut EG, Do D, Miller KM, Ly TT, Forlenza GP. Settings Associated with Optimal Glycemic Outcomes with the Omnipod® 5 Automated Insulin Delivery System: Evidence from Real-World Users with Type 1 Diabetes. *Diabetes technology & therapeutics*. 2026.

- **Sawyer A**, Forlenza GP, Wadwa RP. An overview of the t:slim X2 and Mobi insulin pumps with Control-IQ technology: patient safety and device efficacy. *Expert Rev Med Devices*. 2025.

7. Hillary Connell, MD – Pediatric Endocrinology Fellow 2024-present
Project: Physiologic Assessment of Beta-Hydroxybutyrate Change in Response to Exercise in Children and Young Adults with and without Type 1 Diabetes
Role: Faculty research mentor
8. James Schuler, MD, PhD – Pediatric Endocrinology Fellow 2025-present
Project: Analysis of Type 1 Diabetes Physiology and Technology Use During Extreme Physical Activity in Adolescents
Role: Faculty research mentor

Graduate and PhD Students

1. Mausam Patidr, MSPH – Pharmacology Graduate Student 2017-2018
Project: Investigation of Self Monitoring of Blood Glucose in Type 1 Diabetes.
Role: Graduate committee member and medical advisor for thesis
2. Taisa Kushner – Computer Science PhD Student 2017-2020
Project: Rigorous Synthesis and Verification of Decisions using Data-Driven Models
Role: Medical advisor for type 1 diabetes and artificial pancreas modeling and systems. Member of PhD Thesis committee.
Publication: Forlenza GP, **Kushner T**, Messer LH, Wadwa RP, Sankaranarayanan S. Factory-Calibrated Continuous Glucose Monitoring: How and Why It Works, and the Dangers of Reuse Beyond Approved Duration of Wear. *Diabetes technology & therapeutics*. 2019. Epub 2019/03/01. doi: 10.1089/dia.2018.0401. PubMed PMID: 30817171
3. Aria Saunders – Masters Biomedical Engineering Student 2021-2023
Project: Design and development of an interface tool designed to reduce vehicular accidents due to hypoglycemia in people with diabetes
Role: Masters project advisor
Publication: **Saunders AL**, Bodine C, Snell-Bergeon J, Forlenza GP, Shah VN. Higher Prevalence of Hypoglycemia and Unsafe Driving Practices in Adults With Type 1 Diabetes. *Diabetes Care*. 2023. Epub 20230127. doi: 10.2337/dc22-2035. PubMed PMID: 36706058

Faculty

1. Cari Berget, RN, MPH, CDE – Instructor and Research Nurse 2020-present
Role: Ms. Berget serves as the head research nurse and manager of the BDC Pediatric Diabetes Technology Research team. I serve as her direct supervisor and primary academic mentor.
2. Laurel Messer, RN, CDE, PhD – Assistant Professor 2020-2022
Role: Dr. Messer conducts research on diabetes education, treatment adherence, and diabetes technology. I provide her with career and academic mentorship as well as collaboration on numerous academic and industry projects.
3. Erin Cobry, MD – Associate Professor 2019-present
Role: Dr. Cobry conducts research on the impact of T1D on sleep and the role of diabetes technology

in improving health in children and their parents. I work with Dr. Cobry on her career development projects and provide academic and career mentorship.

4. Kalie Tommerdahl, MD – Associate Professor 2020-present
Role: Dr. Tommerdahl conducts research on the metabolic and cardiovascular benefits of technology in the T1D population. I am the technology mentor on her NIH K23 grant.
5. Samantha Lange, FNP, RN, CDCES – Instructor 2021-present
Role: Ms. Lange serves as a research and clinical nurse practitioner. I serve as her direct supervisor and primary academic mentor.
6. Taylor Triolo, MD – Associate Professor 2022-present
Role: Dr. Triolo conducts research on the impact of diabetes genes on islet survival. I am a technology mentor on her NIH K23 grant.
7. Alexandra Sawyer, MD – Assistant Professor 2026-present
Role: Dr. Sawyer conducts research on the clinical implementation, development, and tuning of Automated Insulin Delivery Systems. I am the primary mentor on her NIH K12 DiabDocs grant looking at evidence-based tuning of AID systems.

Grant Support

Active Grants

Academic Funding

3-SRA-2026-1846-M-B, Breakthrough T1D (JDRF) Forlenza (PI) 07/01/26-06/30/29

3 years total \$3,900,000 (30% effort)

Use of Adaptive Learning with Ultra-Rapid-Acting U500 Insulin AT278 for Personalized Fully Closed-Loop Glycemic Control in Type 1 Diabetes

This project will develop and test an AI-Based Advanced Hybrid Closed Loop System working with a concentrated faster insulin in a randomized controlled trial.

Role: Primary Investigator

Pending, ARPA-H Kushner (PI) 07/01/26-06/30/29

3 years total \$1,413,561 (25% effort)

Healthy Docs: Secure Interoperable Health Data Management

This federally funded project aims to develop and test integration between diabetes technologies such as CGM and AID systems with major electronic health record systems such as Epic.

Role: Site Primary Investigator

2206-05306, Helmsley Charitable Trust Polsky (PI) 11/01/21-10/31/27

6 years total \$2,713,114 (20% effort)

SEEDS Pathway: Shared Empowerment of Early Device Success

This project involves creating a clinical pathway to help healthcare providers onboard persons with diabetes onto diabetes devices

Role: Co-Investigator

Industry Funding

25B7459, Insulet Corporation Forlenza (PI) 02/28/26-02/27/31

5 years total \$275,832 (5% effort)

Efficacy of the Omnipod 6 System Compared with the Omnipod 5 System in Individuals with Type 1 or Type 2 Diabetes and Suboptimal Glycemia

This is a pre-marketing trial for the Omnipod 6 system looking at efficacy in a broad spectrum of users with elevated baseline HbA1c values.

Role: Protocol Chair; PI

CIP351, MiniMed (Medtronic) Forlenza (PI) 02/01/26-12/31/31

5 years total \$371,877 (5% effort)

GATEWAY: Safety Evaluation of the MiniMed NM8-AID System in Children and Adults Living with Diabetes

This is the pivotal trial for the new MiniMed fully closed loop algorithm along with a new pump form factor in adults and children down to 7 years.

Role: Site-PI

260882, Mannkind Forlenza (PI) 01/01/26-12/31/31

5 years total \$257,922 (5% effort)

INHALE-1st: Technosphere Insulin (Afrezza) in Combination with Basal Insulin for Youth with Newly-Diagnosed Type 1 Diabetes

This randomized controlled trial will establish the safety and efficacy of inhaled insulin as a novel therapy for insulin initiation in children with new onset T1D.

Role: Protocol Co-Chair; PI

25B6573, Tandem Diabetes Care DeBoer (PI) 02/28/25-02/27/30

5 years total \$209,975 (5% effort)

Safety and Feasibility Testing of AIDANET in Children Age 6-13 years

This is an investigator-initiated pre-pivotal safety and efficacy trial of the AIDANET Fully Closed Loop algorithm in school aged children.

Role: Site Primary Investigator

G240213, Insulet Corporation Forlenza (PI) 03/01/25-02/28/30

5 years total \$180,580 (5% effort)

Safety and Efficacy of the Omnipod SmartAdjust 2.0 System Compared to the Omnipod 5 System in Individuals with Type 1 Diabetes (STRIVE)

This is the pivotal trial for the Omnipod 5 2.0 algorithm for adults, children, and young children with Type 1 Diabetes for FDA approval in the United States.

Role: Protocol Chair; Site Primary Investigator

CIP344, Medtronic Inc. Forlenza (PI) 08/30/24-08/29/29

5 years total \$130,532 (2% effort)

Safety Evaluation of the MiniMed 780G System Used in Combination with the DS5 CGM in Children 2-6 years of Age (SUCCEED2)

This is the pivotal trial of the Medtronic 780G system in young children with Type 1 Diabetes for FDA approval in the United States.

Role: Site Primary Investigator

TP-0011713, Tandem Diabetes Care Forlenza (PI) 12/21/22-12/20/27

5 years total \$137,636 (5% effort)

Control IQ 2.0 Feasibility Study #2: Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers with Type 1 Diabetes

This clinical trial tests the CIQ algorithm with a lower target and late meal module in an outpatient setting with meal and exercise challenges.

Role: Site Primary Investigator

AWD-223799, Tandem Diabetes Care

Forlenza (PI)

10/04/22-10/03/27

5 years total \$238,151 (2% effort)

Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev with the Tandem t:slim X2 with Control-IQ in Adults, Adolescents, and Children with Type 1 Diabetes

This project is the FDA approval trial to use an ultra-rapid acting insulin in the CIQ HCL system.

Role: Site Primary Investigator

CIP335, Medtronic Inc.

Forlenza (PI)

08/25/22-08/24/27

5 years total \$180,780 (2% effort)

CIP335: Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects Using Lyumjev

This project is the FDA approval trial to use an ultra-rapid acting insulin in the 780G AHCL system.

Role: Site Primary Investigator

CIP337, Medtronic Inc.

Forlenza (PI)

02/14/23-02/13/28

5 years total \$99,618 (2% effort)

Safety and Effectiveness Evaluation of the MiniMed 780G System used in Combination with the DS5 CGM

This study tests the use of the Synergy disposable sensor with the 780G system.

Role: Site Primary Investigator

Prior Support

Academic Funding

1R01AT012288-01, NIH

Voida (PI)

9/20/22-6/30/26

4 years total \$1,194,505 (5% effort)

CAPE2: Enhancing Physiological Closed Loops with Cognitive and Psychosocial-Informed Interventions for Blood Glucose Level Control in Type-1 Diabetes

This explores trust and privacy issues critical to developing personalized physiological and cognitive models of T1D patients, to improve the effectiveness of closed-loop control algorithms and improve patient-device interaction through the delivery of timely and pertinent “nudges” encouraging self-management behaviors that improve glycemic control.

Role: Co-Investigator

AWD-244338, Endocrine Fellows Foundation

Sawyer (PI)

07/1/24-06/30/26

2 years total \$10,000 (0% effort)

Using Simplified Meal Boluses versus Carbohydrate Counting in Adolescents with Hybrid Closed Loop Systems: A Randomized Control Trial

This fellowship project looks at the ability of AID systems to manage meal-time control with simplified vs conventional carbohydrate counting among adolescents with T1D.

Role: Mentor

2-SRA-2023-1275-M-B, Breakthrough T1D (JDRF)

Forlenza (PI)

10/01/22-06/30/25

2 years total \$1,000,000 (10% effort)

Expanding Technology Success into Novel Populations: Safety and Feasibility Testing of a Fully Closed Loop System in Adolescents and Young Adults with High Baseline HbA1c Values

This JDRF Project Award is to investigate the use of an advanced fully closed loop AP system in young adults and adolescents with HbA1c values 9-12% and a focus on historically underrepresented populations.

Role: Primary Investigator

3-SRA-2019-852-M-R, Breakthrough T1D (JDRF) Moran (PI) 09/01/19-10/31/25

6 years total \$624,579 (10% effort)

Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer)

This JDRF Project Award is to investigate the role of advance hybrid closed loop AP systems as well as oral calcium channel blockers in a factorial design in new onset children with T1D. Now in Extension Phase.

Role: Site Primary Investigator; Protocol Co-Chair

1U01DK127551-01, NIH/NIDDK Breton (PI) 9/17/20-6/30/24

3 years total \$1,105,312 (10% effort)

Translation of the UVA Advanced Automated Insulin Delivery Systems to Clinical Care in Young Children: Glycemic Control, Regulatory Acceptance and Optimization of Day to Day Use

The goal of this multi-center study is to examine the efficacy and safety of the UVA Advanced Automated Insulin Delivery System in the clinical management of young children under age 6 years with type 1 diabetes

Role: Co-Investigator

5-ECR-2019-736-A-N, JDRF Forlenza (PI) 03/01/19-02/28/24

5 years total \$750,000 (50% effort)

Promotion of Successful Artificial Pancreas Utilization via Predictive Modeling and Targeted Behavioral Interventions in Children, Adolescents, and Young Adults with Type 1 Diabetes.

This JDRF Early Career Patient-Oriented Diabetes Research Award is focused on development of multi-component predictive models to identify patients likely to need additional supports with clinical implementation of hybrid closed loop artificial pancreas technology. These models will then be used to provide targeted behavioral interventions to support successful adoption of this technology.

Role: Primary Investigator

Patten-Davis Foundation Forlenza (PI) 03/01/19-02/28/24

5 years total \$200,000 (1% effort)

Promotion of Successful Artificial Pancreas Utilization via Predictive Modeling and Targeted Behavioral Interventions in Children, Adolescents, and Young Adults with Type 1 Diabetes.

This award provides additional project support for the JDRF ECPODRA.

Role: Primary Investigator

ECCS-2037267, NSF Zhou (PI) 9/15/20-11/30/23

4 years total \$176,051 (5% effort)

SenSE: Closed-Loop Artificial Pancreas with Noninvasive Monitoring of Glucose and Diet

This NSF project award is to develop noninvasive sensors for glucose sensing using light refraction and meal detection using an ear-worn device and machine-learning algorithms.

Role: Site Primary Investigator

P30DK116073, NIH/NIDDK

Messer (PI)

04/01/21-03/31/23

2 years total \$100,000 (0.5% effort)

Development of a “Cognitive Awareness Artificial Pancreas Enhancement” (CAPE) to Help Adolescents with Type 1 Diabetes Optimize their use of Artificial Pancreas Systems

This project involves determining predictors of diabetes self-management that can be leveraged to create a unique “nudge” intervention for adolescents with type 1 diabetes using hybrid closed loop.

Role: Co-Investigator

Cystic Fibrosis Foundation

Chan (PI)

07/01/19-08/31/22

3 years total \$450,000 (5% effort)

Sensor Augmented Pump Therapy in Inpatients with CFRD

This project is a randomized controlled trial of sensor augmented pump therapy compared against multiple daily injections to improve glucose control in children with Cystic Fibrosis Related Diabetes (CFRD) hospitalized for cystic fibrosis exacerbation.

Role: Co-Investigator

CCF-1815983, NSF

Sankaranarayanan (PI) 06/01/18-05/31/21

3 years total \$122,927 (2% effort)

Rigorous Synthesis and Verification Decision using Data-Driven Models

PhD Thesis work for Dr. Kushner focusing on data driven modeling to verify and improve automated decision making for type 1 diabetes

Role: Co-Investigator

UC4DK108612, NIH/NIDDK

Damiano (PI)

09/30/15-09/29/19

2 years total \$171,050 (2% effort)

Final clinical studies for submission of a pre-market approval application to the FDA for a Bionic Pancreas that automates type 1 diabetes management

This project is the pivotal trial of the Damiano iLet system in children and adults. It includes insulin-only and dual-hormone studies.

Role: Co-Investigator

1-SRA-2019-817-S-B, JDRF

Bequette (PI)

06/01/16-06/30/20

1 year total \$29,193 (5% effort)

Analysis of a large patient dataset to improve probabilistic-based modeling for automated insulin delivery

This project will use the large Tidepool dataset and expert review by investigators at two sites to develop train and test automated machine learning algorithms to detect pump infusion site failures and CGM sensor anomalies.

Role: Site Primary Investigator

AWD-172034, Helmsley Charitable Trust

Phillip (PI)

3/26/17-5/25/20

3 years total \$198,278 (2% effort)

Evaluation of the DreaMed Advice4U for Automated Insulin Pump Settings Adjustments in Children and Adolescents with Type 1 Diabetes – The Advice4U Study

Pilot randomized controlled clinical trial of automated decision support systems to adjust pump settings for adolescents on SAP therapy.

Role: Co-Investigator

UC4DK108520, NIH/NIDDK Hovorka (PI) 09/01/15-03/30/20

3 years total \$626,133 (2% effort)

Day-and-night home closed loop in young people with type 1 diabetes

This study is the pivotal trial of the Hovorka MPC HCL AP platform.

Role: Co-Investigator

UC4DK108483, NIH/NIDDK Kovatchev (PI) 01/01/16-12/30/19

4 years total \$847,917 (2% effort)

Clinical Acceptance of the Artificial Pancreas: The International Diabetes Closed Loop (iDCL) Trial

This multi-national effort is a series of trials on the TypeZero Kovatchev MPC algorithm containing a pivotal trial of the Tandem HCL MPC AP system.

Role: Co-Investigator

K12DK094712, NIH/NIDDK Steck (PI) 08/01/16-07/31/19

3 years total \$434,700 (75% effort)

Developing Pediatric Diabetes Investigators for the Future

My research projects for this grant focus on clinical implementation of artificial pancreas systems and on the impact of malglycemia in patients after bone marrow transplantation.

Role: Trainee

DP3DK104059, NIH/NIDDK Buckingham (PI) 09/01/14-06/30/19

4 years total \$568,175 (2% effort)

Using a Closed-Loop System Plus Behavioral Supports in Preschoolers with Diabetes

This study is a behavioral-intervention adherence trial of multi-component interventions to improve technology use in young children.

Role: Site Primary Investigator

UC4DK101132, NIH/NIDDK Meyer-Davis (PI) 09/01/13-06/30/18

5 years total \$2,156,974 (10% effort)

FL3X: An Adaptive Intervention to Improve Outcomes for Youth with Type 1 Diabetes

Randomized controlled adaptive trial of behavioral coaching for high-risk teens with T1D.

Role: Co-Investigator

R01DK102188, NIH/NIDDK Bequette (PI) 04/01/14-03/31/18

3 years total: \$203,301 (5% effort)

A probabilistic closed-loop artificial pancreas to handle unannounced meals

This project is a series of in-patient and hotel/house studies to further development of fully closed loop AP designs.

Role: Site Primary Investigator

Thrasher Research Fund Sopfe (PI) 07/01/17-06/30/18

1 year total: \$15,451 (2% effort)

Evaluation of Malglycemia via Continuous Glucose monitoring in the Pediatric Hematopoietic Stem Cell Transplant Population

Fellowship research project for Dr. Sopfe investigating the impact of malglycemia on outcomes in pediatric patients after HSCT.

Role: Mentor

Cancer League of Colorado

Sopfe (PI)

07/01/17-06/30/18

1 year total: \$29,961 (2% effort)

Evaluation of Malglycemia via Continuous Glucose monitoring in the Pediatric Hematopoietic Stem Cell Transplant Population

Fellowship research project for Dr. Sopfe investigating the impact of malglycemia on outcomes in pediatric patients after HSCT.

Role: Mentor

1446900, NSF

Sankaranarayanan (PI) 10/01/14-09/30/17

5 years total \$615,404 (7% effort)

CPS: Synergy: Collaborative Research: In-Silico Functional Verification of Artificial Pancreas Control Algorithms.

This NSF project involves formal verification of AP algorithms in a manner similar to that used for other control systems.

Role: Co-Investigator

University of Colorado Foundation

Maahs (PI)

04/01/16-03/31/17

1 year total: \$130,000 (5% effort)

Reducing Risks and Improving Glucose Control during Exercise in Youth with T1DM: The AP Ski Camp Foundation funded randomized controlled trial of the Kovatchev artificial pancreas system in children during extremes of exercise, temperature, and altitude.

Role: Co-Investigator

R01DK085591, NIH/NIDDK

Chase (PI)

09/01/09-08/30/16

7 years total: \$289,970 (7% effort)

In home closed loop reduction of nocturnal hypoglycemia and daytime hyperglycemia

Randomized controlled trial of home-use of PLGS and Hyper/hypo-glycemia minimization algorithms.

Role: Co-Investigator

17-2013-471, JDRF

Buckingham (PI)

11/01/13-10/30/15

2 years total: \$301,778 (10% effort)

Predicting Infusion Set and CGM Failure in Artificial Pancreas Systems

Trial testing home-use of a Zone MPC AP system as well as fault detection algorithms.

Role: Site Primary Investigator

T32DK065519, NIH/NIDDK

Moran (PI)

06/24/13-06/30/15

2 years total \$237,974 (75% effort)

Pre-Faculty Research Training in Pediatric Endocrinology

Funding for pediatric endocrinology fellows interested in a career in endocrinology clinical research.

My project for this award focused on use of artificial pancreas technology to control glucose in patients after total pancreatectomy with islet-auto transplantation.

Role: Trainee

University of Minnesota CTSI Bellin (PI) 06/24/13-06/30/15

2 year total: \$50,000 (5% effort)

Efficacy and Feasibility of Fully Automated Closed Loop Insulin Pump Therapy after Islet Auto-Transplantation

Funding for my fellowship project under Dr. Bellin investigating the role of artificial pancreas technology in patients after total pancreatectomy with islet auto-transplantation.

Role: Co-Investigator

Minnesota Vikings Research Award Bellin (PI) 06/24/13-06/30/15

2 year total: \$50,000 (5% effort)

Efficacy and Feasibility of Fully Automated Closed Loop Insulin Pump Therapy after Islet Auto-Transplantation

Funding for my fellowship project under Dr. Bellin investigating the role of artificial pancreas technology in patients after total pancreatectomy with islet auto-transplantation.

Role: Co-Investigator

University of Florida Pilot Award Silverstein (PI) 06/01/12-05/31/13

1 year total: \$62,000 (10% effort)

Fun & Fit Families- behavior modification for pediatric obesity

Role: Co-Investigator

American Academy of Pediatrics – CATCH Grant Silverstein (PI) 06/01/12-05/31/13

1 year total: \$12,000 (5% effort)

Fun & Fit Families- behavior modification for pediatric obesity

Role: Co-Investigator

Industry Funding

CIP331, Medtronic Inc. Forlenza (PI) 04/25/21-04/24/26

5 years total \$119,257 (2% effort)

Use of the Guardian Connect System with Smart Connected Devices (CIP331)

This study collects sensor, insulin, sleep, activity, and meal data for 3-9 months on participants using a novel connected smart-pen and CGM system.

Role: Site Primary Investigator

25B0534, Tandem Diabetes Care and Dexcom Forlenza (PI) 01/31/22-01/30/26

5 years total \$100,453 (2% effort)

Feasibility and Safety Study of a Hybrid Closed Loop Insulin Delivery System for Children and Young Adults with High Risk Acute Lymphoblastic Leukemia

This investigator-initiated pilot study tests the use of the Control-IQ HCl system in adolescents and young adults with hyperglycemia due to therapy for high risk Leukemia.

Role: Primary Investigator

G190270, Insulet Corporation	Forlenza (PI)	07/22/20-07/21/25
5 years total \$284,838 (5% effort)		
Evaluating the Safety and Effectiveness of the Omnipod Horizon Automated Insulin Delivery System in Very Young Children with Type 1 Diabetes		
This project is the pivotal-FDA approval study of the Insulin Horizon HCL AP system in children 2-5 years old.		
Role: Site Primary Investigator		
CIP321, Medtronic Inc.	Forlenza (PI)	05/08/19-05/07/25
6 years total \$739,532 (2% effort)		
Safety and Effectiveness Evaluation of the Advanced Hybrid Closed Loop (AHCL) system in Adult and Adolescent Subjects with Type 1 Diabetes		
This project is the pivotal trial of the ePID 4.0 HCL algorithm in pediatric patients.		
Role: Site Primary Investigator		
AWD-201140, Insulet Corporation	Forlenza (PI)	12/01/19-11/30/24
5 years total \$634,520 (5% effort)		
Evaluating the Safety and Effectiveness of the Omnipod Horizon Automated Insulin Delivery System in Patients with Type 1 Diabetes		
This project is the pivotal-FDA approval study of the Insulin Horizon HCL AP system in children and adults.		
Role: Site Primary Investigator		
AWD-200511, Tandem Diabetes Care	Forlenza (PI)	10/08/19-10/07/24
5 years total \$103,138 (5% effort)		
Safety of the Tandem t:slim X2 with Control-IQ Automated Insulin Delivery System in Children, age Two to Five Years Old		
This project is the first safety study of the Control-IQ HCL AP algorithm in pre-school aged children.		
Role: Site Primary Investigator		
CIP324, Medtronic Inc.	Forlenza (PI)	07/08/19-07/07/24
5 years total \$300,000 (2% effort)		
Evaluation of an Advanced Algorithm with CGM in Adults, Adolescents, and Pediatrics		
This project is a pre-pivotal test of an advanced Bayesian calibration filter in the Medtronic CGM system.		
Role: Site Primary Investigator		
CIP326, Medtronic Inc.	Forlenza (PI)	06/24/19-06/23/24
5 years total \$223,256 (2% effort)		
Feasibility Study on Safety Observations Related to Setting Changes Recommended by Personalized Closed Loop (PCL)		
This project is pre-pivotal refinement and testing of a cell phone and cloud based tuning algorithm to improve hybrid closed loop therapy.		
Role: Site Primary Investigator		
I8B-MC-ITSB, Lilly	Wadwa (PI)	03/21/19-03/20/24
5 years total \$217,330 (2% effort)		

A Prospective, Randomized Double-Blind Comparison of LY900014 to Humalog with an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents with Type 1 Diabetes PRONTO-Peds

Phase 3 pivotal trial of Lilly ultra-rapid acting insulin (FiAsp) in pediatrics.

Role: Co-Investigator

ADC-US-VAL-18175, Abbott Diabetes Care Forlenza (PI) 12/01/18-11/30/23

3 years total \$131,299 (5% effort)

FreeStyle Libre Flash Glucose Monitoring System Pediatric Accuracy Study

This project is the pediatric pivotal accuracy study for the Abbott FreeStyle Libre 2 Flash Glucose Monitor.

Role: Site Primary Investigator

CEP304, Medtronic Inc. Slover (PI) 10/12/17-10/11/22

5 years total \$160,000 (2% effort)

Multi-Center Randomized Controlled Trial in Adult and Pediatric Patients with Type 1 Diabetes Using Closed Loop System at Home Study

Phase 4 post-marketing randomized controlled trial of the 670G HCL AP system in patients previously on MDI, CSII, and SAP therapy.

Role: Co-Investigator

ADC-US-PMS-17168-002, Abbott Diabetes Care Forlenza (PI) 9/03/18-9/02/21

3 years total \$53,140 (3% effort)

FreeStyle Libre Flash Glucose Monitoring System Post Approval Study for Pediatric Patients

This project is a post-market randomized controlled trial of the Abbott FreeStyle Libre Flash Glucose Monitor in pediatric patients in a 1 year long out-patient observational period.

Role: Site Primary Investigator

CEP302-163889, Medtronic Inc Forlenza (PI) 05/01/16-12/30/20

2 years total \$435,000 (5% effort)

Safety Evaluation of the Hybrid Closed Loop (HCL) System in Pediatric Subjects with Type 1 Diabetes

This project is the pivotal trial of the Medtronic 670G HCL AP in patients 2-13 years of age.

Role: Site Primary Investigator

AWD-201530, Insulet Corporation Forlenza (PI) 12/01/19-11/30/20

1 year total \$98,680 (2% effort)

Prepivotal evaluation of the Safety and Effectiveness of the Omnipod Horizon Automated Glucose Control System in Patients with Type 1 Diabetes

This project is the prepivotal final evaluation of the complete Omnipod-Dexcom-Horizon integrated HCL AP platform prior to the pivotal trial.

Role: Site Primary Investigator

IDE3_AWD-175652, Insulet Corporation Forlenza (PI) 07/11/17-07/11/20

3 years total \$435,220 (5% effort)

Evaluating glucose control in patients with type 1 diabetes under free-living conditions with the Insulet automated glucose control system

This project is a pre-pivotal trial of the Omnipod HCL MPC AP system working with the Dexcom G4 CGM.
Role: Site Primary Investigator

AWD-175324, Tandem Diabetes Care Inc Forlenza (PI) 06/23/17-06/22/20
3 years total \$299,246 (5% effort)
Tandem PLGS Pivotal Home Randomized Crossover Study
This project is the pivotal out-patient trial of the Tandem PLGS system working on the T:slim X2 pump with the Dexcom G5 CGM.
Role: Site Primary Investigator

IDE_2, Insulet Corporation Forlenza (PI) 03/01/17-02/28/20
3 years total \$100,246 (2% effort)
Evaluating meal performance and effect of moderate intensity exercise in patients with type 1 diabetes with the Insulet automated glucose control system
This project is a small pre-pivotal trial of the Omnipod HCL MPC AP system working with the Dexcom G4 CGM.
Role: Site Primary Investigator

AWD-165278, Tandem Diabetes Care Inc Forlenza (PI) 08/19/16-11/09/19
3 years total \$119,958 (2% effort)
Tandem Predictive Low Glucose Suspend Inpatient Feasibility Study
This project is an in hospital safety trial of the Tandem PLGS algorithm.
Role: Site Primary Investigator

AP-IDE1, Insulet Corporation Forlenza (PI) 11/10/16-11/09/19
3 years total \$176,760 (2% effort)
A Prospective Early Feasibility Study to Assess the Performance of the Insulet Artificial Pancreas System Using the OmniPod Insulin Management System and the Dexcom G4 Share™ AP System
This project is an in hospital safety trial of the Omnipod HCL MPC AP system working with the Dexcom G4 CGM.
Role: Site Primary Investigator

AWD-175652, Tandem Diabetes Care Inc Forlenza (PI) 11/01/17-10/31/19
2 years total \$124,800 (2% effort)
Real-Time Monitoring and Glucose Control During Winter-Sport Exercise in Youth with Type 1 Diabetes: The AP Ski Camp Continued
This project is an investigator-initiated study of the Tandem AP system (Kovatchev algorithm) in children at a ski camp.
Role: Site Primary Investigator

CEP294, Medtronic Inc Slover (PI) 11/01/15-03/31/18
3 years total: \$250,000 (5% effort)
Safety Evaluation of the Hybrid Closed Loop (HCL) System in Type 1 Diabetes
This project is the pivotal trial for the Medtronic 670G HCL AP system in patients >= 14 years of age.
Role: Co-Investigator

CEP273, Medtronic Inc. Slover (PI) 06/16/15-08/15/16

1 year total: \$150,000 (5% effort)

In-Clinic Feasibility Study to Observe the Closed Loop System

Brief, 1 week, hotel pre-pivotal study of the HCL AP system in children with T1D.

Role: Co-Investigator

Medtronic Investigator Initiated Supplies Grant Bellin (PI) 06/24/13-06/30/15

2 year total: supplies only (n/a)

Efficacy and Feasibility of Fully Automated Closed Loop Insulin Pump Therapy after Islet Auto-Transplantation

Role: Co-Investigator

Relinquished Funding

Academic Funding

1K23DK120867-01, NIDDK Forlenza (PI) 04/01/19-03/30/23

4 year total \$802,700 (75% effort)

Promotion of Successful Artificial Pancreas Utilization via Predictive Modeling and Targeted Behavioral Interventions in Children, Adolescents, and Young Adults with Type 1 Diabetes.

This NIH K23 proposal was awarded by the NIH, but relinquished due to overlap with the JDRF ECPODRA.

Role: Primary Investigator

Bibliography

Peer-Reviewed Publications (Total: 164; h-index: 51)

First Author: 36

Senior Author: 32

Other Co-Author: 96

1. **Forlenza GP**, Paradise Black NM, McNamara EG, Sullivan SE. Ankyloglossia, exclusive breastfeeding, and failure to thrive. *Pediatrics*. 2010;125(6):e1500–4. Epub 2010/05/26. doi: 10.1542/peds.2009-2101. PubMed PMID: 20498175.
2. **Forlenza GP**, Rewers M. The epidemic of type 1 diabetes: what is it telling us? Current opinion in endocrinology, diabetes, and obesity. 2011;18(4):248–51. Epub 2011/08/17. doi: 10.1097/MED.0b013e32834872ce. PubMed PMID: 21844707.
3. **Forlenza GP**, Stewart MW. Diabetic retinopathy in children. *Pediatr Endocrinol Rev*. 2012;10(2):217–26. Epub 2013/04/02. PubMed PMID: 23539833.
4. **Forlenza GP**, Chinnakotla S, Schwarzenberg SJ, Cook M, Radosevich DM, Manchester C, Gupta S, Nathan B, Bellin MD. Near-euglycemia can be achieved safely in pediatric total pancreatectomy islet autotransplant recipients using an adapted intravenous insulin infusion protocol. *Diabetes technology & therapeutics*. 2014;16(11):706–13. doi: 10.1089/dia.2014.0061. PubMed PMID: 25068208; PMCID: 4201245.
5. **Forlenza GP**, Polgreen LE, Miller BS, MacMillan ML, Wagner JE, Petryk A. Growth hormone treatment of patients with Fanconi anemia after hematopoietic cell transplantation. *Pediatr Blood Cancer*. 2014;61(6):1142–3. Epub 2014/01/01. doi: 10.1002/pbc.24910. PubMed PMID: 24376097; PMCID: PMC3989390.
6. **Forlenza GP**, Calhoun A, Beckman KB, Halvorsen T, Hamdoun E, Zierhut H, Sarafoglou K, Polgreen LE, Miller BS, Nathan B, Petryk A. Next generation sequencing in endocrine practice. *Mol Genet Metab*. 2015;115(2-3):61–71. Epub 2015/05/11. doi: 10.1016/j.ymgme.2015.05.002. PubMed PMID: 25958132; PMCID: PMC4818590.
7. **Forlenza GP**, Sankaranarayanan S, Maahs DM. Refining the closed loop in the data age: research-to-practice transitions in diabetes technology. *Diabetes technology & therapeutics*. 2015;17(5):304–6. Epub 2015/04/07. doi: 10.1089/dia.2015.0055. PubMed PMID: 25844981.

8. **Forlenza GP**, Buckingham B, Maahs DM. Progress in Diabetes Technology: Developments in Insulin Pumps, Continuous Glucose Monitors, and Progress towards the Artificial Pancreas. *J Pediatr*. 2016;169:13–20. Epub 2015/11/09. doi: 10.1016/j.jpeds.2015.10.015. PubMed PMID: 26547403.
9. **Forlenza GP**, Nathan BM, Moran A, Dunn TB, Beilman GJ, Pruett TL, Kovatchev BP, Bellin MD. Accuracy of Continuous Glucose Monitoring in Patients After Total Pancreatectomy with Islet Autotransplantation. *Diabetes technology & therapeutics*. 2016;18(8):455–63. Epub 2016/04/23. doi: 10.1089/dia.2015.0405. PubMed PMID: 27105121.
10. **Forlenza GP**, Nathan BM, Moran AM, Dunn TB, Beilman GJ, Pruett TL, Bellin MD. Successful Application of Closed-Loop Artificial Pancreas Therapy After Islet Autotransplantation. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2016;16(2):527–34. Epub 2015/11/21. doi: 10.1111/ajt.13539. PubMed PMID: 26588810; PMCID: PMC4844547.
11. **Forlenza GP**, Pyle LL, Maahs DM, Dunn TC. Ambulatory glucose profile analysis of the juvenile diabetes research foundation continuous glucose monitoring dataset-Applications to the pediatric diabetes population. *Pediatr Diabetes*. 2016. Epub 2016/11/24. doi: 10.1111/pedi.12474. PubMed PMID: 27878929.
12. Karlin AW, Ly TT, Pyle L, **Forlenza GP**, Messer L, Wadwa RP, DeSalvo DJ, Payne SL, Hanes S, Clinton P, Maahs DM, Buckingham B. Duration of Infusion Set Survival in Lipohypertrophy Versus Nonlipohypertrophied Tissue in Patients with Type 1 Diabetes. *Diabetes technology & therapeutics*. 2016;18(7):429–35. Epub 2016/05/27. doi: 10.1089/dia.2015.0432. PubMed PMID: 27227290.
13. Beisang D, **Forlenza GP**, Luquette M, Sarafoglou K. Sporadic Insulinoma Presenting as Early Morning Night Terrors. *Pediatrics*. 2017;139(6). Epub 2017/06/01. doi: 10.1542/peds.2016-2007. PubMed PMID: 28562256.
14. Bellin MD, **Forlenza GP**, Majumder K, Berger M, Freeman ML, Beilman GJ, Dunn TB, Pruett TL, Murati M, Wilhelm JJ, Cook M, Sutherland DE, Schwarzenberg SJ, Chinnakotla S. Total Pancreatectomy With Islet Autotransplantation Resolves Pain in Young Children With Severe Chronic Pancreatitis. *J Pediatr Gastroenterol Nutr*. 2017;64(3):440–5. Epub 2017/02/24. doi: 10.1097/mpg.0000000000001314. PubMed PMID: 28231072; PMCID: PMC5327823.
15. Breton MD, Chernavvsky DR, **Forlenza GP**, DeBoer MD, Robic J, Wadwa RP, Messer LH, Kovatchev BP, Maahs DM. Closed Loop Control During Intense Prolonged Outdoor Exercise in Adolescents With Type 1 Diabetes: The Artificial Pancreas Ski Study. *Diabetes Care*. 2017. Epub 2017/09/01. doi: 10.2337/dc17-0883. PubMed PMID: 28855239.
16. Cameron FM, Ly TT, Buckingham BA, Maahs DM, **Forlenza GP**, Levy CJ, Lam D, Clinton P, Messer LH, Westfall E, Levister C, Xie YY, Baysal N, Howsmon D, Patek SD, Bequette BW. Closed-Loop Control Without Meal Announcement in Type 1 Diabetes. *Diabetes technology & therapeutics*. 2017;19(9):527–32. Epub 2017/08/03. doi: 10.1089/dia.2017.0078. PubMed PMID: 28767276.
17. **Forlenza GP**. Relevance of Bolus Calculators in Current Hybrid Closed Loop Systems. *Diabetes technology & therapeutics*. 2017;19(7):400–1. Epub 2017/07/08. doi: 10.1089/dia.2017.0216. PubMed PMID: 28686041.
18. **Forlenza GP**. Insulin Infusion Sets and Continuous Glucose Monitoring Sensors: Where the Artificial Pancreas Meets the Patient. *Diabetes technology & therapeutics*. 2017;19(4):206–8. Epub 2017/04/19. doi: 10.1089/dia.2017.0048. PubMed PMID: 28418732.
19. **Forlenza GP**, Argento NB, Laffel LM. Practical Considerations on the Use of Continuous Glucose Monitoring in Pediatrics and Older Adults and Nonadjunctive Use. *Diabetes technology & therapeutics*. 2017;19(S3):S13–S20. Epub 2017/06/07. doi: 10.1089/dia.2017.0034. PubMed PMID: 28585878.
20. **Forlenza GP**, Deshpande S, Ly TT, Howsmon DP, Cameron F, Baysal N, Mauritzen E, Marcal T, Towers L, Bequette BW, Huyett LM, Pinsker JE, Gondhalekar R, Doyle FJ, 3rd, Maahs DM, Buckingham BA, Dassau E. Application of Zone Model Predictive Control Artificial Pancreas During Extended Use of Infusion Set and Sensor: A Randomized Crossover-Controlled Home-Use Trial. *Diabetes Care*. 2017;40(8):1096–102. Epub 2017/06/07. doi: 10.2337/dc17-0500. PubMed PMID: 28584075.
21. **Forlenza GP**, Raghinaru D, Cameron F, Wayne Bequette B, Peter Chase H, Paul Wadwa R, Maahs DM, Jost E, Ly TT, Wilson DM, Norlander L, Ekhlaspour L, Min H, Clinton P, Njeru N, Lum JW, Kollman C, Beck RW, Buckingham BA. Predictive hyperglycemia and hypoglycemia minimization: In-home double-blind randomized controlled evaluation in children and young adolescents. *Pediatr Diabetes*. 2017. Epub 2017/11/22. doi: 10.1111/pedi.12603. PubMed PMID: 29159870.

22. Howsmon DP, Cameron F, Baysal N, Ly TT, **Forlenza GP**, Maahs DM, Buckingham BA, Hahn J, Bequette BW. Continuous Glucose Monitoring Enables the Detection of Losses in Infusion Set Actuation (LISAs). *Sensors*. 2017;17(1). Epub 2017/01/19. doi: 10.3390/s17010161. PubMed PMID: 28098839.
23. Huyett LM, Ly TT, **Forlenza GP**, Reuschel-DiVirgilio S, Messer LH, Wadwa RP, Gondhalekar R, Doyle FJ, 3rd, Pinsker JE, Maahs DM, Buckingham BA, Dassau E. Outpatient Closed-Loop Control with Unannounced Moderate Exercise in Adolescents Using Zone Model Predictive Control. *Diabetes technology & therapeutics*. 2017;19(6):331–9. Epub 2017/05/02. doi: 10.1089/dia.2016.0399. PubMed PMID: 28459617.
24. Laffel LM, Aleppo G, Buckingham BA, **Forlenza GP**, Rasbach LE, Tsalikian E, Weinzimer SA, Harris DR. A Practical Approach to Using Trend Arrows on the Dexcom G5 CGM System to Manage Children and Adolescents With Diabetes. *Journal of the Endocrine Society*. 2017;1(12):1461–76. Epub 2018/01/19. doi: 10.1210/js.2017-00389. PubMed PMID: 29344578; PMCID: PMC5760209.
25. Messer LH, **Forlenza GP**, Wadwa RP, Weinzimer SA, Sherr JL, Hood KK, Buckingham BA, Slover RH, Maahs DM. The dawn of automated insulin delivery: A new clinical framework to conceptualize insulin administration. *Pediatr Diabetes*. 2017. Epub 2017/06/29. doi: 10.1111/pedi.12535. PubMed PMID: 28656656.
26. Ohman-Hanson RA, **Forlenza GP**. Artificial Pancreas in Young Children. *Diabetes technology & therapeutics*. 2017;19(5):277–9. Epub 2017/05/19. doi: 10.1089/dia.2017.0126. PubMed PMID: 28520531.
27. Sarafoglou K, **Forlenza GP**, Addo OY, Kylo J, Lteif A, Hindmarsh PC, Petryk A, Gonzalez-Bolanos MT, Miller BS, Thomas W. Obesity in Children with Congenital Adrenal Hyperplasia in the Minnesota Cohort: Importance of Adjusting Body Mass Index for Height-Age. *Clin Endocrinol (Oxf)*. 2017;86(5):708–16. Epub 2017/02/16. doi: 10.1111/cen.13313. PubMed PMID: 28199739.
28. Spaic T, Driscoll M, Raghinaru D, Buckingham BA, Wilson DM, Clinton P, Chase HP, Maahs DM, **Forlenza GP**, Jost E, Hramiak I, Paul T, Bequette BW, Cameron F, Beck RW, Kollman C, Lum JW, Ly TT. Predictive Hyperglycemia and Hypoglycemia Minimization: In-Home Evaluation of Safety, Feasibility, and Efficacy in Overnight Glucose Control in Type 1 Diabetes. *Diabetes Care*. 2017. Epub 2017/01/20. doi: 10.2337/dc16-1794. PubMed PMID: 28100606.
29. Zhong VW, Crandell JL, Shay CM, Gordon-Larsen P, Cole SR, Juhaeri J, Kahkoska AR, Maahs DM, Seid M, **Forlenza GP**, Mayer-Davis EJ. Dietary intake and risk of non-severe hypoglycemia in adolescents with type 1 diabetes. *Journal of diabetes and its complications*. 2017;31(8):1340–7. Epub 2017/05/10. doi: 10.1016/j.jdiacomp.2017.04.017. PubMed PMID: 28476567.
30. Buckingham BA, Christiansen MP, **Forlenza GP**, Wadwa RP, Peyser TA, Lee JB, O'Connor J, Dassau E, Huyett LM, Layne JE, Ly TT. Performance of the Omnipod Personalized Model Predictive Control Algorithm with Meal Bolus Challenges in Adults with Type 1 Diabetes. *Diabetes technology & therapeutics*. 2018. Epub 2018/08/03. doi: 10.1089/dia.2018.0138. PubMed PMID: 30070928.
31. Buckingham BA, **Forlenza GP**, Pinsker JE, Christiansen MP, Wadwa RP, Schneider J, Peyser TA, Dassau E, Lee JB, O'Connor J, Layne JE, Ly TT. Safety and Feasibility of the OmniPod Hybrid Closed-Loop System in Adult, Adolescent, and Pediatric Patients with Type 1 Diabetes Using a Personalized Model Predictive Control Algorithm. *Diabetes technology & therapeutics*. 2018;20(4):257–62. Epub 2018/02/13. doi: 10.1089/dia.2017.0346. PubMed PMID: 29431513.
32. **Forlenza GP**. Ongoing Debate About Models for Artificial Pancreas Systems and In Silico Studies. *Diabetes technology & therapeutics*. 2018;20(3):174–6. Epub 2018/03/23. doi: 10.1089/dia.2018.0038. PubMed PMID: 29565720.
33. **Forlenza GP**, Cameron FM, Ly TT, Lam D, Howsmon DP, Baysal N, Kulina G, Messer L, Clinton P, Levister C, Patek SD, Levy CJ, Wadwa RP, Maahs DM, Bequette BW, Buckingham BA. Fully Closed-Loop Multiple Model Probabilistic Predictive Controller Artificial Pancreas Performance in Adolescents and Adults in a Supervised Hotel Setting. *Diabetes technology & therapeutics*. 2018;20(5):335–43. Epub 2018/04/17. doi: 10.1089/dia.2017.0424. PubMed PMID: 29658779.
34. **Forlenza GP**, Li Z, Buckingham BA, Pinsker JE, Cengiz E, Wadwa RP, Ekhlaspour L, Church MM, Weinzimer SA, Jost E, Marcal T, Andre C, Carria L, Swanson V, Lum JW, Kollman C, Woodall W, Beck RW. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial. *Diabetes Care*. 2018. Epub 2018/08/10. doi: 10.2337/dc18-0771. PubMed PMID: 30089663.
35. **Forlenza GP**, Messer LH, Berget C, Wadwa RP, Driscoll KA. Biopsychosocial Factors Associated With Satisfaction and Sustained Use of Artificial Pancreas Technology and Its Components: a

- Call to the Technology Field. Current diabetes reports. 2018;18(11):114. Epub 2018/09/28. doi: 10.1007/s11892-018-1078-1. PubMed PMID: 30259309.
36. **Forlenza GP**, Moran A, Nathan B. Other Specific Types of Diabetes. In: Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, Gregg EW, Knowler WC, Barrett-Connor E, Becker DJ, Brancati FL, Boyko EJ, Herman WH, Howard BV, Narayan KMV, Rewers M, Fradkin JE, editors. Diabetes in America. Bethesda (MD) interest. Dr. Forlenza served as a consultant for Abbott Diabetes Care. During the time this chapter was written, Dr. Moran held research grants from NIH and Pfizer, did consulting work for Vertex and Minimed Medtronic, and served on a data safety monitoring board for Novo Nordisk.: National Institute of Diabetes and Digestive and Kidney Diseases (US); 2018.
 37. **Forlenza GP**, Pinhas-Hamiel O, Liljenquist DR, Shulman DI, Bailey TS, Bode BW, Wood MA, Buckingham BA, Kaiserman KB, Shin J, Huang S, Lee SW, Kaufman FR. Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes. Diabetes technology & therapeutics. 2018. Epub 2018/12/27. doi: 10.1089/dia.2018.0264. PubMed PMID: 30585770.
 38. Howsmon DP, Baysal N, Buckingham BA, **Forlenza GP**, Ly TT, Maahs DM, Marcal T, Towers L, Mauritzen E, Deshpande S, Huyett LM, Pinsker JE, Gondhalekar R, Doyle FJ, 3rd, Dassau E, Hahn J, Bequette BW. Real-Time Detection of Infusion Site Failures in a Closed-Loop Artificial Pancreas. J Diabetes Sci Technol. 2018:1932296818755173. Epub 2018/02/03. doi: 10.1177/1932296818755173. PubMed PMID: 29390915.
 39. Messer LH, Berget C, Beatson C, Polsky S, **Forlenza GP**. Preserving Skin Integrity with Chronic Device Use in Diabetes. Diabetes technology & therapeutics. 2018;20(S2):S254–s64. Epub 2018/06/20. doi: 10.1089/dia.2018.0080. PubMed PMID: 29916740.
 40. Messer LH, **Forlenza GP**, Sherr JL, Wadwa RP, Buckingham BA, Weinzimer SA, Maahs DM, Slover RH. Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System. Diabetes Care. 2018;41(4):789–96. doi: 10.2337/dc17-1682.
 41. Sherr JL, Tauschman M, Battelino T, de Bock M, **Forlenza G**, Roman R, Hood KK, Maahs DM. ISPAD Clinical Practice Consensus Guidelines 2018 Diabetes Technologies. Pediatr Diabetes. 2018. Epub 2018/07/25. doi: 10.1111/pedi.12731. PubMed PMID: 30039513.
 42. Wood MA, Shulman DI, **Forlenza GP**, Bode BW, Pinhas-Hamiel O, Buckingham BA, Kaiserman KB, Liljenquist DR, Bailey TS, Shin J, Huang S, Chen X, Cordero TL, Lee SW, Kaufman FR. In-Clinic Evaluation of the MiniMed 670G System "Suspend Before Low" Feature in Children with Type 1 Diabetes. Diabetes technology & therapeutics. 2018. Epub 2018/10/10. doi: 10.1089/dia.2018.0209. PubMed PMID: 30299976.
 43. Anderson SM, Dassau E, Raghinaru D, Lum J, Brown SA, Pinsker JE, Church MM, Levy C, Lam D, Kudva YC, Buckingham B, **Forlenza GP**, Wadwa RP, Laffel L, Doyle FJ, 3rd, DeVries JH, Renard E, Cobelli C, Boscari F, Del Favero S, Kovatchev BP. The International Diabetes Closed-Loop Study: Testing Artificial Pancreas Component Interoperability. Diabetes technology & therapeutics. 2019. Epub 2019/01/17. doi: 10.1089/dia.2018.0308. PubMed PMID: 30649925.
 44. Berget C, Messer LH, **Forlenza GP**. A Clinical Overview of Insulin Pump Therapy for the Management of Diabetes: Past, Present, and Future of Intensive Therapy. Diabetes spectrum : a publication of the American Diabetes Association. 2019;32(3):194–204. Epub 2019/08/30. doi: 10.2337/ds18-0091. PubMed PMID: 31462873; PMCID: PMC6695255.
 45. Berget C, Messer LH, Vigers T, Frohnert BI, Pyle L, Wadwa RP, Driscoll KA, **Forlenza GP**. Six months of Hybrid Closed Loop in the Real-World: An Evaluation of Children and Young Adults using the 670G System. Pediatr Diabetes. 2019. Epub 2019/12/15. doi: 10.1111/pedi.12962. PubMed PMID: 31837064.
 46. Brown SA, Kovatchev BP, Raghinaru D, Lum JW, Buckingham BA, Kudva YC, Laffel LM, Levy CJ, Pinsker JE, Wadwa RP, Dassau E, Doyle FJ, 3rd, Anderson SM, Church MM, Dadlani V, Ekhlaspour L, **Forlenza GP**, Isganaitis E, Lam DW, Kollman C, Beck RW. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. N Engl J Med. 2019. Epub 2019/10/17. doi: 10.1056/NEJMoa1907863. PubMed PMID: 31618560.
 47. Ekhlaspour L, **Forlenza GP**, Chernavsky D, Maahs DM, Wadwa RP, DeBoer MD, Messer LH, Town M, Pinnata J, Kruse G, Kovatchev BP, Buckingham BA, Breton MD. Closed Loop Control in Adolescents and Children During Winter Sports: Use of the Tandem Control-IQ AP System. Pediatr Diabetes. 2019. Epub 2019/05/18. doi: 10.1111/pedi.12867. PubMed PMID: 31099946.

48. **Forlenza GP.** Use of Artificial Intelligence to Improve Diabetes Outcomes in Patients Using Multiple Daily Injections Therapy. *Diabetes technology & therapeutics*. 2019;21(S2):S24–s8. Epub 2019/06/07. doi: 10.1089/dia.2019.0077. PubMed PMID: 31169433.
49. **Forlenza GP,** Buckingham BA, Christiansen MP, Wadwa RP, Peyser TA, Lee JB, O'Connor J, Dassau E, Huyett LM, Layne JE, Ly TT. Performance of Omnipod Personalized Model Predictive Control Algorithm with Moderate Intensity Exercise in Adults with Type 1 Diabetes. *Diabetes technology & therapeutics*. 2019. Epub 2019/03/30. doi: 10.1089/dia.2019.0017. PubMed PMID: 30925077.
50. **Forlenza GP,** Ekhlaspour L, Breton M, Maahs DM, Wadwa RP, DeBoer M, Messer LH, Town M, Pinnata J, Kruse G, Buckingham BA, Chernavvsky D. Successful At-Home Use of the Tandem Control-IQ Artificial Pancreas System in Young Children During a Randomized Controlled Trial. *Diabetes technology & therapeutics*. 2019. Epub 2019/03/20. doi: 10.1089/dia.2019.0011. PubMed PMID: 30888835.
51. **Forlenza GP,** Kushner T, Messer LH, Wadwa RP, Sankaranarayanan S. Factory-Calibrated Continuous Glucose Monitoring: How and Why It Works, and the Dangers of Reuse Beyond Approved Duration of Wear. *Diabetes technology & therapeutics*. 2019. Epub 2019/03/01. doi: 10.1089/dia.2018.0401. PubMed PMID: 30817171.
52. Messer LH, Berget C, **Forlenza GP.** A Clinical Guide to Advanced Diabetes Devices and Closed-Loop Systems Using the CARES Paradigm. *Diabetes technology & therapeutics*. 2019. Epub 2019/05/30. doi: 10.1089/dia.2019.0105. PubMed PMID: 31140878.
53. Messer LH, Berget C, Vigers T, Pyle L, Geno C, Wadwa RP, Driscoll KA, **Forlenza GP.** Real World Hybrid Closed Loop Discontinuation: Predictors and Perceptions of Youth Discontinuing the 670G System in the First 6 months. *Pediatr Diabetes*. 2019. Epub 2019/12/31. doi: 10.1111/pedi.12971. PubMed PMID: 31885123.
54. Saunders A, Messer LH, **Forlenza GP.** MiniMed 670G Hybrid Closed Loop Artificial Pancreas System for the Treatment of Type 1 Diabetes Mellitus: Overview of Its Safety and Efficacy. *Expert Rev Med Devices*. 2019. Epub 2019/09/22. doi: 10.1080/17434440.2019.1670639. PubMed PMID: 31540557.
55. Sherr J, Buckingham BA, **Forlenza G,** Galderisi A, Ekhlaspour L, Wadwa RP, Carria L, Hsu LJ, Berget CL, Peyser TA, Lee JB, O'Connor J, Dumais B, Huyett LM, Layne JE, Ly TT. Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions. *Diabetes technology & therapeutics*. 2019. Epub 2019/10/10. doi: 10.1089/dia.2019.0286. PubMed PMID: 31596130.
56. Sopfe J, Pyle L, Keating AK, Campbell K, Liu AK, Wadwa RP, Verneris MR, Giller RH, **Forlenza GP.** Malglycemia is associated with poor outcomes in pediatric and adolescent hematopoietic stem cell transplant patients. *Blood Adv*. 2019;3(3):350–9. Epub 2019/02/06. doi: 10.1182/bloodadvances.2018021014. PubMed PMID: 30718242.
57. Vigers T, Chan CL, Snell-Bergeon J, Bjornstad P, Zeitler PS, **Forlenza G,** Pyle L. cgmanalysis: An R package for descriptive analysis of continuous glucose monitor data. *PloS one*. 2019;14(10):e0216851. Epub 2019/10/12. doi: 10.1371/journal.pone.0216851. PubMed PMID: 31603912.
58. Alva S, Bailey T, Brazg R, Budiman ES, Castorino K, Christiansen MP, **Forlenza G,** Kipnes M, Liljenquist DR, Liu H. Accuracy of a 14-Day Factory-Calibrated Continuous Glucose Monitoring System With Advanced Algorithm in Pediatric and Adult Population With Diabetes. *J Diabetes Sci Technol*. 2020;1932296820958754. Epub 2020/09/22. doi: 10.1177/1932296820958754. PubMed PMID: 32954812.
59. Berget C, Lange S, Messer L, **Forlenza GP.** A clinical review of the t:slim X2 insulin pump. *Expert opinion on drug delivery*. 2020. doi: 10.1080/17425247.2020.1814734. PubMed PMID: 32842794.
60. Breton MD, Kanapka LG, Beck RW, Ekhlaspour L, **Forlenza GP,** Cengiz E, Schoelwer M, Ruedy KJ, Jost E, Carria L, Emory E, Hsu LJ, Oliveri M, Kollman CC, Dokken BB, Weinzimer SA, DeBoer MD, Buckingham BA, Chernavvsky D, Wadwa RP. A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes. *N Engl J Med*. 2020;383(9):836–45. doi: 10.1056/NEJMoa2004736. PubMed PMID: 32846062.
61. Brown SA, Beck RW, Raghinaru D, Buckingham BA, Laffel LM, Wadwa RP, Kudva YC, Levy CJ, Pinsker JE, Dassau E, Doyle FJ, 3rd, Ambler-Osborn L, Anderson SM, Church MM, Ekhlaspour L, **Forlenza GP,** Levister C, Simha V, Breton MD, Kollman C, Lum JW, Kovatchev BP. Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial. *Diabetes Care*. 2020. Epub 2020/05/31. doi: 10.2337/dc20-0124. PubMed PMID: 32471910.

62. Cobry EC, Berget C, Messer LH, **Forlenza GP**. Review of the Omnipod(®) 5 Automated Glucose Control System Powered by Horizon™ for the treatment of Type 1 diabetes. *Ther Deliv*. 2020. Epub 2020/07/30. doi: 10.4155/tde-2020-0055. PubMed PMID: 32723002.
63. DiMeglio LA, Kanapka LG, DeSalvo DJ, Hilliard ME, Laffel LM, Tamborlane WV, Van Name MA, Woerner S, Adi S, Albanese-O'Neill A, Alonso GT, Anderson BJ, Corathers SD, Fegan-Bohm K, **Forlenza GP**, Gandica RG, Goland RS, Haller MJ, Hanono A, Harrington KR, Ismail HM, Jolivet HA, Kelley JC, Kingery S, MacLeish SA, Majidi S, Miller KM, Minnock PP, Nathan BM, Sheanon NM, Simmons JH, Sunni M, Wadwa RP, Watson SE, Weyman K, Williams KM, Willi SM, Wintergerst KA, Wood J. A Randomized Clinical Trial Assessing Continuous Glucose Monitoring (CGM) Use With Standardized Education With or Without a Family Behavioral Intervention Compared With Finger-stick Blood Glucose Monitoring in Very Young Children With Type 1 Diabetes. *Diabetes Care*. 2020. Epub 2020/12/19. doi: 10.2337/dc20-1060. PubMed PMID: 33334807.
64. Ekhlaspour L, Schoelwer MJ, **Forlenza GP**, DeBoer MD, Norlander L, Hsu LJ, Kingman RS, Boranian E, Berget C, Emory EG, Buckingham BA, Breton MD, Wadwa RP. Safety and Performance of the Tandem t:slim X2 with Control-IQ Automated Insulin Delivery System in Toddlers and Preschoolers. *Diabetes technology & therapeutics*. 2020. Epub 2020/11/24. doi: 10.1089/dia.2020.0507. PubMed PMID: 33226837.
65. **Forlenza GP**, Buckingham BA, Brown S, Bode BW, Levy C, Criego A, Wadwa RP, Cobry E, Slover RJ, Messer L, Berget C, McCoy S, Ekhlaspour L, Kingman RS, Voelmle MK, Boyd J, O'Malley G, Grieme A, Kivilaid K, Kleve K, Dumais B, Vienneau T, Huyett LM, Lee JB, O'Connor J, Benjamin E, Ly TT. First outpatient evaluation of a tubeless automated insulin delivery system with customizable glucose targets in children and adults with type 1 diabetes. *Diabetes technology & therapeutics*. 2020. Epub 2020/12/17. doi: 10.1089/dia.2020.0546. PubMed PMID: 33325779.
66. Garg SK, Rodbard D, Hirsch IB, **Forlenza GP**. Managing New-Onset Type 1 Diabetes During the COVID-19 Pandemic: Challenges and Opportunities. *Diabetes technology & therapeutics*. 2020. doi: 10.1089/dia.2020.0161. PubMed PMID: 32302499.
67. Kanapka LG, Wadwa RP, Breton MD, Ruedy KJ, Ekhlaspour L, **Forlenza GP**, Cengiz E, Schoelwer MJ, Jost E, Carria L, Emory E, Hsu LJ, Weinzimer SA, DeBoer MD, Buckingham BA, Oliveri M, Kollman C, Dokken BB, Cherrñavsky D, Beck RW. Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes. *Diabetes Care*. 2020. Epub 2020/12/24. doi: 10.2337/dc20-1729. PubMed PMID: 33355258.
68. Kovatchev B, Anderson SM, Raghinaru D, Kudva YC, Laffel LM, Levy C, Pinsker JE, Wadwa RP, Buckingham B, Doyle FJ, 3rd, Brown SA, Church MM, Dadlani V, Dassau E, Ekhlaspour L, **Forlenza GP**, Isganaitis E, Lam DW, Lum J, Beck RW. Randomized Controlled Trial of Mobile Closed-Loop Control. *Diabetes Care*. 2020;43(3):607–15. Epub 2020/01/16. doi: 10.2337/dc19-1310. PubMed PMID: 31937608.
69. Messer LH, Campbell K, Pyle L, **Forlenza G**. Basal-IQ technology in the real world: satisfaction and reduction of diabetes burden in individuals with type 1 diabetes. *Diabet Med*. 2020. doi: 10.1111/dme.14381. PubMed PMID: 32767401.
70. O'Malley G, Messer LH, Levy C, Pinsker JE, **Forlenza GP**, Isganaitis E, Kudva YC, Ekhlaspour L, Raghinaru D, Lum J, Brown S. Clinical Management and Pump Parameter Adjustment of the Control-IQ Closed-loop Control System: Results from a 6-month Multicenter Randomized Clinical Trial. *Diabetes technology & therapeutics*. 2020. Epub 2020/11/07. doi: 10.1089/dia.2020.0472. PubMed PMID: 33155824.
71. Ravi SJ, Coakley A, Vigers T, Pyle L, **Forlenza GP**, Alonso T. Pediatric Medicaid Patients With Type 1 Diabetes Benefit From Continuous Glucose Monitor Technology. *J Diabetes Sci Technol*. 2020;1932296820906214. Epub 2020/03/17. doi: 10.1177/1932296820906214. PubMed PMID: 32172603.
72. Shah VN, **Forlenza GP**. Suicide via Intentional Insulin Overdose Through First Commercial Hybrid Closed-Loop. *J Diabetes Sci Technol*. 2020;1932296820905593. Epub 2020/03/07. doi: 10.1177/1932296820905593. PubMed PMID: 32141325.
73. Sopfe J, Campbell K, Keating AK, Pyle L, Liu AK, Verneris MR, Giller RH, **Forlenza GP**. Glycemic variability is associated with poor outcomes in pediatric hematopoietic stem cell transplant patients. *Pediatr Blood Cancer*. 2020;67(11):e28626. Epub 2021/01/23. doi: 10.1002/pbc.28626. PubMed PMID: 33480469.

74. Sopfe J, Vigers T, Pyle L, Giller RH, **Forlenza GP**. Safety and Accuracy of Factory Calibrated Continuous Glucose Monitoring in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation. *Diabetes technology & therapeutics*. 2020. Epub 2020/02/28. doi: 10.1089/dia.2019.0521. PubMed PMID: 32105513.
75. Taylor KA, **Forlenza GP**. Use of Machine Learning and Hybrid Closed Loop Insulin Delivery at Diabetes Camps. *Diabetes technology & therapeutics*. 2020. Epub 2020/02/15. doi: 10.1089/dia.2020.0026. PubMed PMID: 32058821.
76. Zimmerman C, **Forlenza G**, Schatz D. The Discovery and Structure of Human Insulin. *Pediatr Endocrinol Rev*. 2020;17(Suppl 1):131–7. Epub 2020/03/26. doi: 10.17458/per.vol17.2020.zfs.discoverystructureinsulin. PubMed PMID: 32208558.
77. Akturk HK, Vigers T, **Forlenza GP**, Champakanath A, Pyle L. Comparison of cgmanalysis, a free, open-source continuous glucose monitoring (CGM) data management and analysis software to commercially available CGM platforms: Data standardization for diabetes technology research. *Diabetes technology & therapeutics*. 2021. Epub 2021/09/16. doi: 10.1089/dia.2021.0200. PubMed PMID: 34524001.
78. Aleppo G, Parkin CG, Carlson A, Galindo R, Kruger D, Levy C, Umpierrez G, **Forlenza GP**, McGill JB. Lost in Translation. A Disconnect Between the Science and Medicare Coverage Criteria for Continuous Subcutaneous Insulin Infusion (CSII). *Diabetes technology & therapeutics*. 2021. Epub 2021/06/03. doi: 10.1089/dia.2021.0196. PubMed PMID: 34077674.
79. Berget C, Akturk HK, Messer LH, Vigers T, Pyle L, Snell-Bergeon J, Driscoll KA, **Forlenza GP**. Real world performance of hybrid closed loop in youth, young adults, adults and older adults with type 1 diabetes: Identifying a clinical target for hybrid closed loop use. *Diabetes, obesity & metabolism*. 2021. Epub 2021/05/20. doi: 10.1111/dom.14441. PubMed PMID: 34010499.
80. Brown SA, **Forlenza GP**, Bode BW, Pinsker JE, Levy CJ, Criego AB, Hansen DW, Hirsch IB, Carlson AL, Bergenstal RM, Sherr JL, Mehta SN, Laffel LM, Shah VN, Bhargava A, Weinstock RS, MacLeish SA, DeSalvo DJ, Jones TC, Aleppo G, Buckingham BA, Ly TT. Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes. *Diabetes Care*. 2021. Epub 2021/06/09. doi: 10.2337/dc21-0172. PubMed PMID: 34099518.
81. **Forlenza GP**, Breton MD, Kovatchev B. Candidate Selection for Hybrid Closed Loop Systems. *Diabetes technology & therapeutics*. 2021. Epub 2021/06/16. doi: 10.1089/dia.2021.0217. PubMed PMID: 34129375.
82. **Forlenza GP**, Vigers T, Berget C, Messer L, Lal RA, Basina M, Maahs DM, Hood K, Buckingham BA, Wilson DM, Wadwa RP, Driscoll KA, Pyle L. Predicting Success with a First-Generation Hybrid Closed Loop Artificial Pancreas System among Children, Adolescents, and Young Adults with Type 1 Diabetes: a Model Development and Validation Study. *Diabetes technology & therapeutics*. 2021. Epub 2021/11/15. doi: 10.1089/dia.2021.0326. PubMed PMID: 34780306.
83. Isganaitis E, Raghinaru D, Ambler-Osborn L, Pinsker JE, Buckingham BA, Wadwa RP, Ekhlaspour L, Kudva YC, Levy CJ, **Forlenza GP**, Beck RW, Kollman C, Lum JW, Brown SA, Laffel LM. Closed-Loop Insulin Therapy Improves Glycemic Control in Adolescents and Young Adults: Outcomes from the International Diabetes Closed-Loop Trial. *Diabetes technology & therapeutics*. 2021. Epub 2020/11/21. doi: 10.1089/dia.2020.0572. PubMed PMID: 33216667.
84. Messer LH, Berget C, Ernst A, Towers L, Slover RH, **Forlenza GP**. Initiating Hybrid Closed Loop: A Program Evaluation of an Educator-Led Control-IQ Follow-up at a Large Pediatric Clinic. *Pediatr Diabetes*. 2021. Epub 2021/01/28. doi: 10.1111/pedi.13183. PubMed PMID: 33502062.
85. Messer LH, Berget C, Pyle L, Vigers T, Cobry E, Driscoll KA, **Forlenza GP**. Real-World Use of a New Hybrid Closed Loop Improves Glycemic Control in Youth with Type 1 Diabetes. *Diabetes technology & therapeutics*. 2021. Epub 2021/06/08. doi: 10.1089/dia.2021.0165. PubMed PMID: 34096789.
86. Pauley ME, Berget C, Messer LH, **Forlenza GP**. Barriers to Uptake of Insulin Technologies and Novel Solutions. *Med Devices (Auckl)*. 2021;14:339–54.
87. Schoelwer MJ, Kanapka LG, Wadwa RP, Breton MD, Ruedy KJ, Ekhlaspour L, **Forlenza GP**, Cobry EC, Messer LH, Cengiz E, Jost E, Carria L, Emory E, Hsu LJ, Weinzimer SA, Buckingham BA, Lal RA, Oliveri MC, Kollman CC, Dokken BB, Cherňavsky DR, Beck RW, DeBoer MD. Predictors of Time-in-Range (70-180 mg/dL) Achieved Using a Closed-Loop Control System. *Diabetes technology & therapeutics*. 2021. Epub 2021/03/11. doi: 10.1089/dia.2020.0646. PubMed PMID: 33689454.

88. Berget C, Sherr JL, DeSalvo DJ, Kingman RS, Stone SL, Brown SA, Nguyen A, Barrett L, Ly TT, **Forlenza GP**. Clinical Implementation of the Omnipod 5 Automated Insulin Delivery System: Key Considerations for Training and Onboarding People With Diabetes. *Clin Diabetes*. 2022;40(2):168–84. Epub 20220415. doi: 10.2337/cd21-0083. PubMed PMID: 35669307; PMCID: PMC9160549.
89. Cho S, Vigers T, Pyle L, Franklin A, Demedis J, Jeney F, **Forlenza GP**. Composite Metric of Glycemic Control Q-Score is Elevated in Pediatric and Adolescent/Young Adult Hematopoietic Stem Cell Transplant Recipients. *Diabetes technology & therapeutics*. 2022. Epub 20221213. doi: 10.1089/dia.2022.0246. PubMed PMID: 36511871.
90. Ekhlaspour L, Raghinaru D, **Forlenza GP**, Isganaitis E, Kudva YC, Lam DW, Levister C, O'Malley G, Church MM, Lum JW, Buckingham B, Brown SA. Outcomes in Pump- and CGM-Baseline Use Subgroups in the International Diabetes Closed-Loop (iDCL) Trial. *J Diabetes Sci Technol*. 2022:19322968221089361. Epub 20220426. doi: 10.1177/19322968221089361. PubMed PMID: 35473359.
91. **Forlenza GP**, Carlson AL, Galindo R, Kruger D, Levy C, McGill JB, Umpierrez G, Aleppo G. Real World Evidence Supporting Tandem Control-IQ Hybrid Closed Loop Success in the Medicare and Medicaid Type 1 and Type 2 Diabetes Populations. *Diabetes technology & therapeutics*. 2022. Epub 20220628. doi: 10.1089/dia.2022.0206. PubMed PMID: 35763323.
92. **Forlenza GP**, Ekhlaspour L, DiMeglio LA, Fox LA, Rodriguez H, Shulman DI, Kaiserman KB, Liljenquist DR, Shin J, Lee SW, Buckingham BA. Glycemic Outcomes of Children 2-6 Years of Age with Type 1 Diabetes during the Pediatric MiniMed™ 670G System Trial. *Pediatr Diabetes*. 2022. Epub 20220110. doi: 10.1111/pedi.13312. PubMed PMID: 35001477.
93. **Forlenza GP**, Lal RA. Current Status and Emerging Options for Automated Insulin Delivery Systems. *Diabetes technology & therapeutics*. 2022. Epub 20220131. doi: 10.1089/dia.2021.0514. PubMed PMID: 35099302.
94. Galindo RJ, Aleppo G, Parkin CG, Baidal DA, Carlson AL, Cengiz E, **Forlenza GP**, Kruger DF, Levy C, McGill JB, Umpierrez GE. Increase Access, Reduce Disparities: Recommendations for Modifying Medicaid CGM Coverage Eligibility Criteria. *J Diabetes Sci Technol*. 2022:19322968221144052. Epub 20221216. doi: 10.1177/19322968221144052. PubMed PMID: 36524477.
95. Garg SK, Grunberger G, Weinstock RS, Lawson ML, Hirsch IB, DiMeglio LA, Pop-Busui R, Philis-Tsimikas A, Kipnes MS, Liljenquist DR, Brazg RL, Kudva YC, Buckingham BA, McGill JB, Carlson AL, Criego A, Christiansen M, Kaiserman KB, Griffin K, **Forlenza GP**, Bode BW, Slover RH, Keiter A, Ling C, Marinos B, Cordero TL, Shin J, Lee SW, Rhinehart AS, Vigersky RA. Improved Glycemia with Hybrid Closed-Loop (HCL) Versus Continuous Subcutaneous Insulin Infusion (CSII) Therapy: Results from a Randomized Controlled Trial. *Diabetes technology & therapeutics*. 2022. Epub 20221206. doi: 10.1089/dia.2022.0421. PubMed PMID: 36472543.
96. Klonoff DC, Wang J, Rodbard D, Kohn MA, Li C, Liepmann D, Kerr D, Ahn D, Peters AL, Umpierrez GE, Seley JJ, Xu NY, Nguyen KT, Simonson G, Agus MSD, Al-Sofiani ME, Armaiz-Pena G, Bailey TS, Basu A, Battelino T, Bekele SY, Benhamou PY, Bequette BW, Blevins T, Breton MD, Castle JR, Chase JG, Chen KY, Choudhary P, Clements MA, Close KL, Cook CB, Danne T, Doyle FJ, 3rd, Drincic A, Dungan KM, Edelman SV, Ejekjaer N, Espinoza JC, Fleming GA, **Forlenza GP**, Freckmann G, Galindo RJ, Gomez AM, Gutow HA, Heinemann L, Hirsch IB, Hoang TD, Hovorka R, Jendle JH, Ji L, Joshi SR, Joubert M, Koliwad SK, Lal RA, Lansang MC, Lee WA, Leelarathna L, Leiter LA, Lind M, Litchman ML, Mader JK, Mahoney KM, Mankovsky B, Masharani U, Mathioudakis NN, Mayorov A, Messler J, Miller JD, Mohan V, Nichols JH, Nørgaard K, O'Neal DN, Pasquel FJ, Philis-Tsimikas A, Pieber T, Phillip M, Polonsky WH, Pop-Busui R, Rayman G, Rhee EJ, Russell SJ, Shah VN, Sherr JL, Sode K, Spanakis EK, Wake DJ, Waki K, Wallia A, Weinberg ME, Wolpert H, Wright EE, Zilbermint M, Kovatchev B. A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. *J Diabetes Sci Technol*. 2022:19322968221085273. Epub 20220329. doi: 10.1177/19322968221085273. PubMed PMID: 35348391.
97. Messer LH, Berget C, Centi S, McNair B, **Forlenza GP**. Evaluation of a New Clinical Tool to Enhance Clinical Care of Control-IQ Users. *J Diabetes Sci Technol*. 2022:19322968221081890. Epub 20220228. doi: 10.1177/19322968221081890. PubMed PMID: 35227129.
98. Messer LH, Buckingham BA, Cogen F, Daniels M, **Forlenza G**, Jafri RZ, Mauras N, Muir A, Wadwa RP, White PC, Russell SJ, Damiano ER, El-Khatib FH, Ruedy KJ, Balliro CA, Li Z, Marak MC, Calhoun P, Beck RW. Positive Impact of the Bionic Pancreas on Diabetes Control in Youth 6-17 Years

- Old with Type 1 Diabetes: A Multicenter Randomized Trial. *Diabetes technology & therapeutics*. 2022;24(10):712–25. doi: 10.1089/dia.2022.0201.pub. PubMed PMID: 36173237.
99. Pauley ME, Tommerdahl KL, Snell-Bergeon JK, **Forlenza GP**. Continuous Glucose Monitor, Insulin Pump, and Automated Insulin Delivery Therapies for Type 1 Diabetes: An Update on Potential for Cardiovascular Benefits. *Curr Cardiol Rep*. 2022. Epub 20221024. doi: 10.1007/s11886-022-01799-x. PubMed PMID: 36279036.
100. Phillip M, Nimri R, Bergenstal RM, Barnard-Kelly K, Danne T, Hovorka R, Kovatchev BP, Messer LH, Parkin CG, Ambler-Osborn L, Amiel SA, Bally L, Beck RW, Biester S, Biester T, Blanchette JE, Bosi E, Boughton CK, Breton MD, Brown SA, Buckingham BA, Cai A, Carlson AL, Castle JR, Choudhary P, Close KL, Cobelli C, Criego AB, Davis E, de Beaufort C, de Bock MI, DeSalvo DJ, DeVries JH, Dovc K, Doyle FJ, Ekhlaspour L, Shvalb NF, **Forlenza GP**, Gallen G, Garg SK, Gershonoff DC, Gonder-Frederick LA, Haidar A, Hartnell S, Heinemann L, Heller S, Hirsch IB, Hood KK, Isaacs D, Klonoff DC, Kordonouri O, Kowalski A, Laffel L, Lawton J, Lal RA, Leelarathna L, Maahs DM, Murphy HR, Nørgaard K, O'Neal D, Oser S, Oser T, Renard E, Riddell MC, Rodbard D, Russell SJ, Schatz DA, Shah VN, Sherr JL, Simonson GD, Wadwa RP, Ward C, Weinzimer SA, Wilmot EG, Battelino T. Consensus Recommendations for the Use of Automated Insulin Delivery (AID) Technologies in Clinical Practice. *Endocr Rev*. 2022. Epub 20220906. doi: 10.1210/edrv/bnac022. PubMed PMID: 36066457.
101. Polonsky WH, Hood KK, Levy CJ, MacLeish SA, Hirsch IB, Brown SA, Bode BW, Carlson AL, Shah VN, Weinstock RS, Bhargava A, Jones TC, Aleppo G, Mehta SN, Laffel LM, **Forlenza GP**, Sherr JL, Huyett LM, Vienneau TE, Ly TT. How Introduction of Automated Insulin Delivery Systems May Influence Psychosocial Outcomes in Adults with Type 1 Diabetes: Findings from the First Investigation with the Omnipod® 5 System. *Diabetes Res Clin Pract*. 2022:109998. Epub 20220716. doi: 10.1016/j.diabres.2022.109998. PubMed PMID: 35853530.
102. Rosenfeld C, Blevins T, Aleppo G, **Forlenza G**, Isaacs D, Morales J, Seley J, Unger J. Expert Roundtable on Continuous Glucose Monitoring. *Endocr Pract*. 2022. Epub 20220329. doi: 10.1016/j.eprac.2022.03.015. PubMed PMID: 35364329.
103. Russell SJ, Beck RW, Damiano ER, El-Khatib FH, Ruedy KJ, Balliro CA, Li Z, Calhoun P, Wadwa RP, Buckingham B, Zhou K, Daniels M, Raskin P, White PC, Lynch J, Pettus J, Hirsch IB, Goland R, Buse JB, Kruger D, Mauras N, Muir A, McGill JB, Cogen F, Weissberg-Benchell J, Sherwood JS, Castellanos LE, Hillard MA, Tuffaha M, Putman MS, Sands MY, **Forlenza G**, Slover R, Messer LH, Cobry E, Shah VN, Polsky S, Lal R, Ekhlaspour L, Hughes MS, Basina M, Hatipoglu B, Olansky L, Bhangoo A, Forghani N, Kashmiri H, Sutton F, Choudhary A, Penn J, Jafri R, Rayas M, Escaname E, Kerr C, Favela-Prezas R, Boeder S, Trikudanathan S, Williams KM, Leibel N, Kirkman MS, Bergamo K, Klein KR, Dostou JM, Machineni S, Young LA, Diner JC, Bhan A, Jones JK, Benson M, Bird K, Englert K, Permuy J, Cossen K, Felner E, Salam M, Silverstein JM, Adamson S, Cedeno A, Meighan S, Dauber A. Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. *N Engl J Med*. 2022;387(13):1161–72. doi: 10.1056/NEJMoa2205225. PubMed PMID: 36170500.
104. Sawyer A, Sobczak M, **Forlenza GP**, Alonso GT. Glycemic Control in Relation to Technology Use in a Single Center Cohort of Children With Type 1 Diabetes. *Diabetes technology & therapeutics*. 2022. Epub 20220131. doi: 10.1089/dia.2021.0471. PubMed PMID: 35099306.
105. Sherr JL, Bode BW, **Forlenza GP**, Laffel LM, Schoelwer MJ, Buckingham BA, Criego AB, DeSalvo DJ, MacLeish SA, Hansen DW, Ly TT. Safety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial. *Diabetes Care*. 2022. Epub 20220609. doi: 10.2337/dc21-2359. PubMed PMID: 35678724.
106. Tauschmann M, **Forlenza G**, Hood K, Cardona-Hernandez R, Giani E, Hendrieckx C, DeSalvo DJ, Laffel LM, Saboo B, Wheeler BJ, Latpev DN, Yarhere I, DiMeglio LA. ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Glucose monitoring. *Pediatr Diabetes*. 2022;23(8):1390–405. doi: 10.1111/pedi.13451. PubMed PMID: 36537528.
107. Aleppo G, Hirsch IB, Parkin CG, McGill JB, Galindo R, Kruger D, Levy C, **Forlenza GP**, Umpierrez G, Grunberger G, Bergenstal RM. Coverage for Continuous Glucose Monitoring (CGM) for Individuals with Type 2 Diabetes Treated with Non-intensive Therapies: An Evidence-Based Approach to Policy-Making. *Diabetes technology & therapeutics*. 2023. Epub 20230720. doi: 10.1089/dia.2023.0268. PubMed PMID: 37471068.

108. Alonso GT, Triolo TM, Akturk HK, Pauley ME, Sobczak M, **Forlenza GP**, Sakamoto C, Pyle L, Frohnert BI. Increased Technology Use Associated With Lower A1C in a Large Pediatric Clinical Population. *Diabetes Care*. 2023. Epub 20230406. doi: 10.2337/dc22-2121. PubMed PMID: 37023293.
109. Biskupiak JE, Ramos M, Levy CJ, **Forlenza G**, Hopley C, Boyd J, Swift D, Lamotte M, Brixner DI. Cost-effectiveness of the tubeless automated insulin delivery system vs standard of care in the management of type 1 diabetes in the United States. *J Manag Care Spec Pharm*. 2023;1–11. Epub 20230503. doi: 10.18553/jmcp.2023.22331. PubMed PMID: 37133431.
110. Conway RB, Gerard Gonzalez A, Shah VN, Geno Rasmussen C, Akturk HK, Pyle L, **Forlenza G**, Alonso GT, Snell-Bergeon J. Racial Disparities in Diabetes Technology Adoption and Their Association with HbA1c and Diabetic Ketoacidosis. *Diabetes Metab Syndr Obes*. 2023;16:2295–310. Epub 20230802. doi: 10.2147/dmso.S416192. PubMed PMID: 37551339; PMCID: PMC10404403.
111. Cordero TL, Dai Z, Arrieta A, Niu F, Vella M, Shin J, Rhinehart AS, McVean J, Lee S, Slover RH, **Forlenza GP**, Shulman DI, Pop-Busui R, Thasher JR, Kipnes MS, Christiansen M, Buckingham BA, Pihoker C, Sherr JL, Kaiserman KB, Vigersky RA. Glycemic outcomes during early use of the MiniMed™ 780G advanced hybrid closed-loop system with Guardian™ 4 sensor. *Diabetes technology & therapeutics*. 2023. Epub 20230530. doi: 10.1089/dia.2023.0123. PubMed PMID: 37252734.
112. Criego A, Carlson AL, Brown S, **Forlenza GP**, Bode B, Levy C, Hansen D, Hirsch IB, Bergenstal RM, Sherr JL, Mehta S, Laffel LM, Shah VN, Bhargava A, Weinstock RS, MacLeish SA, DeSalvo DJ, Jones TC, Aleppo G, Buckingham BA, Ly TT. Two Years with a Tubeless AID System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes. *Diabetes technology & therapeutics*. 2023. Epub 20231018. doi: 10.1089/dia.2023.0364. PubMed PMID: 37850941.
113. Demedis J, Scarbro S, Suresh K, Maloney K, **Forlenza GP**. Hyperglycemia and Other Glycemic Measures Throughout Therapy for Pediatric Acute Lymphoblastic Leukemia and Lymphoma. *J Pediatr Hematol Oncol*. 2023. Epub 20230112. doi: 10.1097/mp.0000000000002619. PubMed PMID: 36715999.
114. **Forlenza GP**, McVean J, Beck RW, Bauza C, Bailey R, Buckingham B, DiMeglio LA, Sherr JL, Clements M, Neyman A, Evans-Molina C, Sims EK, Messer LH, Ekhlaspour L, McDonough R, Van Name M, Rojas D, Beasley S, DuBose S, Kollman C, Moran A. Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial. *Jama*. 2023. Epub 20230224. doi: 10.1001/jama.2023.2064. PubMed PMID: 36826844; PMCID: PMC9960020.
115. Leung HMC, **Forlenza GP**, Prioleau TO, Zhou X. Noninvasive Glucose Sensing In Vivo. *Sensors (Basel, Switzerland)*. 2023;23(16). Epub 20230809. doi: 10.3390/s23167057. PubMed PMID: 37631595; PMCID: PMC10458980.
116. McVean J, **Forlenza GP**, Beck RW, Bauza C, Bailey R, Buckingham B, DiMeglio LA, Sherr JL, Clements M, Neyman A, Evans-Molina C, Sims EK, Messer LH, Ekhlaspour L, McDonough R, Van Name M, Rojas D, Beasley S, DuBose S, Kollman C, Moran A. Effect of Tight Glycemic Control on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial. *Jama*. 2023. Epub 20230224. doi: 10.1001/jama.2023.2063. PubMed PMID: 36826834; PMCID: PMC9960023.
117. Messer LH, Cook PF, Vaida S, Fiesler C, Fivekiller E, Agrawal C, Xu T, **Forlenza GP**, Sankaranarayanan S. Situational Awareness and Proactive Engagement Predict Higher Time in Range in Adolescents and Young Adults Using Hybrid Closed-Loop. *Pediatr Diabetes*. 2023;2023. Epub 20230518. doi: 10.1155/2023/1888738. PubMed PMID: 37614410; PMCID: PMC10445779.
118. Messer LH, Vigers T, Akturk HK, **Forlenza GP**, Huss KB, Karami AJ, Malecha E, Oser SM, Polsky S, Pyle L, Shah VN, Wadwa RP, Oser TK. Increasing Use of Diabetes Devices: What Do Health Care Professionals Need? *Clin Diabetes*. 2023;41(3):386–98. Epub 20230315. doi: 10.2337/cd22-0092. PubMed PMID: 37456091; PMCID: PMC10338282.
119. Phillip M, Nimri R, Bergenstal RM, Barnard-Kelly K, Danne T, Hovorka R, Kovatchev BP, Messer LH, Parkin CG, Ambler-Osborn L, Amiel SA, Bally L, Beck RW, Biester S, Biester T, Blanchette JE, Bosi E, Boughton CK, Breton MD, Brown SA, Buckingham BA, Cai A, Carlson AL, Castle JR, Choudhary P, Close KL, Cobelli C, Criego AB, Davis E, de Beaufort C, de Bock MI, DeSalvo DJ, DeVries JH, Dovc K, Doyle FJ, Ekhlaspour L, Shvalb NF, **Forlenza GP**, Gallen G, Garg SK, Gershonoff DC, Gonder-Frederick LA, Haidar A, Hartnell S, Heinemann L, Heller S, Hirsch IB, Hood KK, Isaacs D, Klonoff DC, Kordonouri O, Kowalski A, Laffel L, Lawton J, Lal RA, Leelarathna L, Maahs DM, Murphy HR, Nørgaard K, O'Neal D, Oser S, Oser T, Renard E, Riddell MC, Rodbard D, Russell SJ, Schatz DA, Shah VN, Sherr JL, Simonson GD, Wadwa RP, Ward C, Weinzimer SA, Wilmot EG, Battelino T. Consensus Recommendations for the

Use of Automated Insulin Delivery Technologies in Clinical Practice. *Endocr Rev.* 2023;44(2):254–80. doi: 10.1210/edrv/bnac022. PubMed PMID: 36066457; PMCID: PMC9985411.

120. Pihoker C, Shulman DI, **Forlenza GP**, Kaiserman KB, Sherr JL, Thasher JR, Buckingham BA, Kipnes MS, Bode BW, Carlson AL, Lee S, Latif K, Lilienquist DR, Slover RH, Dai Z, Niu F, Shin J, Jonkers RAM, Roy A, Grosman B, Vella M, Cordero TL, McVean J, Rhinehart AS, Vigersky RA. Safety and glycemic outcomes during the MiniMed™ advanced hybrid closed-loop (AHCL) system pivotal trial in children and adolescents with type 1 diabetes. *Diabetes technology & therapeutics.* 2023. Epub 20231002. doi: 10.1089/dia.2023.0255. PubMed PMID: 37782145.

121. Saunders AL, Bodine C, Snell-Bergeon J, **Forlenza GP**, Shah VN. Higher Prevalence of Hypoglycemia and Unsafe Driving Practices in Adults With Type 1 Diabetes. *Diabetes Care.* 2023. Epub 20230127. doi: 10.2337/dc22-2035. PubMed PMID: 36706058.

122. Shah VN, Kanapka LG, Akturk HK, Polsky S, **Forlenza GP**, Kollman C, Beck RW, Snell-Bergeon J. Time in Range is Associated with Incident Diabetic Retinopathy in Adults with Type 1 Diabetes: A Longitudinal Study. *Diabetes technology & therapeutics.* 2023. Epub 20231222. doi: 10.1089/dia.2023.0486. PubMed PMID: 38133643.

123. Wadwa RP, Reed ZW, Buckingham BA, DeBoer MD, Ekhlaspour L, **Forlenza GP**, Schoelwer M, Lum J, Kollman C, Beck RW, Breton MD. Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes. *N Engl J Med.* 2023;388(11):991–1001. doi: 10.1056/NEJMoa2210834. PubMed PMID: 36920756.

124. Brown SA, Laffel LM, Akturk HK, **Forlenza GP**, Shah VN, Wadwa RP, Cobry EC, Isganaitis E, Schoelwer M, Lu VS, Rueda R, Sherer N, Corbett JP, Sasson-Katchalski R, Pinsker JE. Randomized, Crossover Trial of Control-IQ Technology with a Lower Treatment Range and a Modified Meal Bolus Module in Adults, Adolescents, Children, and Preschoolers with Varying Levels of Baseline Glycemic Control. *Diabetes technology & therapeutics.* 2024. Epub 20241126. doi: 10.1089/dia.2024.0501. PubMed PMID: 39601043.

125. Cobry EC, Pyle L, Waterman LA, **Forlenza GP**, Towers L, Karami AJ, Jost E, Berget C, Wadwa RP. Accuracy of a Continuous Glucose Monitor During Pediatric Type 1 Diabetes Inpatient Admissions. *Diabetes technology & therapeutics.* 2024;26(2):119–24. Epub 20240119. doi: 10.1089/dia.2023.0375. PubMed PMID: 38194229.

126. Cobry EC, Vigers T, Berget C, Messer LH, Wadwa RP, Pyle L, **Forlenza GP**. Frequency and Causes of Nocturnal Alarms in Youth and Young Adults With Type 1 Diabetes Using a First-Generation Hybrid Closed-Loop System. *Diabetes spectrum : a publication of the American Diabetes Association.* 2024;37(2):118–23. Epub 20230919. doi: 10.2337/ds23-0003. PubMed PMID: 38756430; PMCID: PMC11093760.

127. DeSalvo DJ, Bode B, **Forlenza GP**, Laffel LM, Buckingham BA, Criego A, Schoelwer M, MacLeish SA, Sherr JL, Hansen D, Ly TT. Glycemic Outcomes Persist for up to 2 Years in Very Young Children with the Omnipod® 5 Automated Insulin Delivery System. *Diabetes technology & therapeutics.* 2024. Epub 20240126. doi: 10.1089/dia.2023.0506. PubMed PMID: 38277156.

128. DeSalvo DJ, Bode BW, **Forlenza GP**, Laffel LM, Buckingham BA, Criego AB, Schoelwer M, MacLeish SA, Sherr JL, Hansen DW, Ly TT. Glycemic Outcomes Persist for up to 2 Years in Very Young Children with the Omnipod(®) 5 Automated Insulin Delivery System. *Diabetes technology & therapeutics.* 2024. Epub 20240221. doi: 10.1089/dia.2023.0506. PubMed PMID: 38277156.

129. Ekhlaspour L, Buckingham B, Bauza C, Clements M, **Forlenza GP**, Neyman A, Norlander L, Schamberger M, Sherr JL, Bailey R, Beck RW, Kollman C, Beasley S, Cobry E, DiMeglio LA, Paprocki E, Van Name M, Moran A. Safety and prescribing recommendations for verapamil in newly diagnosed pediatric type 1 diabetes (T1D): The CLVer experience. *J Clin Transl Endocrinol.* 2024;36:100352. Epub 20240518. doi: 10.1016/j.jcte.2024.100352. PubMed PMID: 38860154; PMCID: PMC11163172.

130. **Forlenza GP**, Dai Z, Niu F, Shin JJ. Reducing Diabetes Burden in Medtronic's Automated Insulin Delivery Systems. *Diabetes technology & therapeutics.* 2024;26(S3):7–16. doi: 10.1089/dia.2023.0459. PubMed PMID: 38377321.

131. **Forlenza GP**, DeSalvo DJ, Aleppo G, Wilmot EG, Berget C, Huyett LM, Hadjiyianni I, Méndez JJ, Conroy LR, Ly TT, Sherr JL. Real-World Evidence of Omnipod(®) 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes. *Diabetes technology & therapeutics.* 2024. Epub 20240216. doi: 10.1089/dia.2023.0578. PubMed PMID: 38375861.

132. **Forlenza GP**, Tabatabai I, Lewis D. Point-Counterpoint: The Need for Do-It-Yourself (DIY) Open Source (OS) AID Systems in Type 1 Diabetes Management. *Diabetes technology & therapeutics*. 2024. Epub 20240426. doi: 10.1089/dia.2024.0073. PubMed PMID: 38669472.
133. Kartik R, Akturk HK, Stewart MW, **Forlenza GP**. Seeing the Road Ahead-The Need to Address Accessibility of Diabetes Technology. *Diabetes technology & therapeutics*. 2024. Epub 20241223. doi: 10.1089/dia.2024.0412. PubMed PMID: 39714954.
134. Khatter NJ, Hum SW, Mark JA, **Forlenza G**, Triolo TM. Longitudinal Quality of Life and Glycemic Outcomes of Total Pancreatectomy With Islet Autotransplantation in Children With Chronic Pancreatitis Followed in a Pediatric Multidisciplinary Pancreas Clinic. *Pediatric transplantation*. 2024;28(5):e14813. doi: 10.1111/ptr.14813. PubMed PMID: 38895780.
135. Levy CJ, Bailey R, Laffel LM, **Forlenza G**, DiMeglio LA, Hughes MS, Brown SA, Aleppo G, Bhargava A, Shah VN, Clements MA, Kipnes M, Bruggeman B, Daniels M, Rodriguez H, Calhoun P, Lum JW, Sasson-Katchalski R, Pinsker JE, Pollom R, Beck RW. Multicenter Evaluation of Ultra-Rapid Lispro Insulin with Control-IQ Technology in Adults, Adolescents, and Children with Type 1 Diabetes. *Diabetes technology & therapeutics*. 2024. Epub 20240522. doi: 10.1089/dia.2024.0048. PubMed PMID: 38696672.
136. MacLeish SA, Hood KK, Polonsky WH, Wood JR, Bode BW, **Forlenza GP**, Laffel LM, Buckingham BA, Criego AB, Schoelwer MJ, DeSalvo DJ, Sherr JL, Hansen DW, Conroy LR, Huyett LM, Vienneau TE, Ly TT. Psychosocial outcomes with the Omnipod® 5 Automated Insulin Delivery System in caregivers of very young children with type 1 diabetes. *Diabetes, obesity & metabolism*. 2024. Epub 20240920. doi: 10.1111/dom.15906. PubMed PMID: 39300963.
137. Moser O, Zaharieva D, Adolfsson P, Battelino T, Bracken RM, Buckingham BA, Danne T, Davis EA, Dovc K, **Forlenza GP**, Gillard P, Hofer SE, Hovorka R, Jacobs PJ, Mader JK, Mathieu C, Nørgaard K, Oliver NS, O'Neal DN, Pemberton J, Rabasa-Lhoret R, Sherr JL, Sourij H, Tauschmann M, Yardley JE, Riddell MC. The Use of Automated Insulin Delivery around Physical Activity and Exercise in Type 1 Diabetes: A Position Statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD). *Horm Res Paediatr*. 2024:1–28. Epub 20241210. doi: 10.1159/000542287. PubMed PMID: 39657609.
138. Waterman L, Pyle L, **Forlenza GP**, Towers L, Karami A, Jost E, Berget C, Wadwa RP, Cobry E. Accuracy of a Real-Time Continuous Glucose Monitor in Pediatric Diabetic Ketoacidosis Admissions. *Diabetes technology & therapeutics*. 2024. Epub 20240305. doi: 10.1089/dia.2023.0542. PubMed PMID: 38441904.
139. Waterman LA, Pyle L, **Forlenza GP**, Towers L, Karami AJ, Jost E, Berget C, Wadwa RP, Cobry EC. Accuracy of a Real-Time Continuous Glucose Monitor in Pediatric Diabetic Ketoacidosis Admissions. *Diabetes technology & therapeutics*. 2024. Epub 20240320. doi: 10.1089/dia.2023.0542. PubMed PMID: 38441904.
140. Xu T, Jost E, Messer LH, Cook PF, **Forlenza GP**, Sankaranarayanan S, Fiesler C, Volda S. "Obviously, Nothing's Gonna Happen in Five Minutes": How Adolescents and Young Adults Infrastructure Resources to Learn Type 1 Diabetes Management. *Proc SIGCHI Conf Hum Factor Comput Syst*. 2024;2024. Epub 20240511. doi: 10.1145/3613904.3642612. PubMed PMID: 38846748; PMCID: PMC11153724.
141. Bergenstal RM, Heller A, Breton MD, Vigersky R, Brown SA, **Forlenza GP**, Sherr JL, Hovorka R, Russell SJ, Damiano ER, Putman MS, Beck RW, Renard E, Lal R, Cobelli C, Dassau E, Akturk HK, Weiss MA, Skyler JS. Evolution of the Artificial Pancreas: Components and Integration-CGMs, Insulin, and AP Systems. *J Diabetes Sci Technol*. 2025;19(4):883–94. Epub 20250701. doi: 10.1177/19322968251342239. PubMed PMID: 40590461.
142. Berget C, Annan SF, Biester T, Choudhary P, **Forlenza GP**, Peters AL, Renard E, Deiss D. Practical considerations for using the Omnipod® 5 Automated Insulin Delivery System: Clinical experience from the United States and Europe. *Diabetes, obesity & metabolism*. 2025. Epub 20250402. doi: 10.1111/dom.16321. PubMed PMID: 40171758.
143. Berget C, Cobry E, Escobar E, Towers L, Sakomoto C, Taylor K, Trojanowski PJ, Wadwa RP, **Forlenza GP**. Sustained improvements in glycaemic and psychosocial outcomes for youth and caregivers using Omnipod 5 AID for 12 months. *Diabetes, obesity & metabolism*. 2025;27(9):4942–9. Epub 20250624. doi: 10.1111/dom.16538. PubMed PMID: 40555697.
144. Jacobs PG, Levy CJ, Brown SA, Riddell MC, Cinar A, Boughton CK, Breton MD, Dassau E, **Forlenza G**, Henderson RJ, Hovorka R, Maahs DM, Munshi M, Murphy H, Polsky S, Pratley R, Putman

- MS, Shah VN, Wilson LM, Zisser H, Ekhlaspour L. Research Gaps, Challenges, and Opportunities in Automated Insulin Delivery Systems. *Diabetes technology & therapeutics*. 2025;27(S3):S60–s71. doi: 10.1089/dia.2025.0129. PubMed PMID: 40590746.
145. Leung HMC, Gong C, Geiser L, Fivekiller EE, Bui N, Vu T, Prioleau T, **Forlenza GP**, Liu Q, Zhou X. Clinical evaluation of a polarization-based optical noninvasive glucose sensing system. *Sci Rep*. 2025;15(1):8877. Epub 20250314. doi: 10.1038/s41598-025-92515-6. PubMed PMID: 40087308; PMCID: PMC11909277.
146. Levy CJ, Carlow D, Swift D, Rittgers-Simonds R, Gronroos NN, Walker V, Buysman EK, **Forlenza G**. Real-World HbA1c Following Initiation of the Omnipod 5 Automated Insulin Delivery System. *Diabetes technology & therapeutics*. 2025. Epub 20251120. doi: 10.1177/15209156251395014. PubMed PMID: 41311199.
147. Lopach CM, Dobbs TJ, Zimmerman C, **Forlenza GP**, Alonso GT, Nadeau KJ. Glucagon-like Peptide-1 Receptor Agonists (GLP-1-RA) and GLP-1/Gastrointestinal Peptide RA (GLP-1/GIP-RA) Use in Adolescents and Young Adults with Type 1 Diabetes and Overweight or Obesity. *Diabetes Technology and Obesity Medicine*. 2025;1(1):50–5. doi: 10.1089/dtom.2025.0018.
148. Messer LH, **Forlenza GP**, Gonder-Frederick L, Hood K, Ebekozién O, Barnard-Kelly K, Laffel LM, Sherr JL, Lal R, Weinzimer SA. Practical Considerations and Implementation of Automated Insulin Delivery Systems. *Diabetes technology & therapeutics*. 2025;27(S3):S72–s8. doi: 10.1089/dia.2025.0132. PubMed PMID: 40590748.
149. Moscoso-Vasquez M, Ekhlaspour L, Brown SA, DeBoer MD, Berget C, Cobry EC, Wadwa RP, Capodanno G, Cengiz E, Wong JC, Pryor EC, Villa-Tamayo MF, Fathi AEL, Holmes V, Davis Prince S, Escobar E, Towers L, Hosseiniinpour Y, Narayan A, Koravi CLK, Nguyen T, Fulkerson D, Barnett CL, Oliveri MC, Breton MD, **Forlenza GP**. Safety and Feasibility of a Fully Automated Insulin Delivery System: FCL@Home, a Multicenter Randomized Clinical Trial in Individuals With Type 1 Diabetes. *Diabetes Care*. 2025. Epub 20251216. doi: 10.2337/dc25-1526. PubMed PMID: 41401082.
150. Nally LM, Sherr JL, Garg SK, Marks BE, Laffel LM, Pihoker C, Accacha SD, Thrasher JR, Abuzzahab MJ, Reed JH, Ekhlaspour L, Belapurkar S, Shulman DI, Sunil B, MacLeish SA, Latif K, **Forlenza GP**, Castorino K, Lal RA, Bode BW, Broyles FE, Carlson AL, Nwosu BU, Shin J, Ma H, Salbato A, Cordero TL, Treminio Y, McVean JJ, Rhinehart AS, Vigersky RA. Safety and Glycemic Outcomes of the MiniMed 780G System with a Disposable All-in-One Sensor. *Diabetes technology & therapeutics*. 2025. Epub 20250818. doi: 10.1177/15209156251368928. PubMed PMID: 40824839.
151. Neyman A, DiMeglio LA, Bauza C, Buckingham B, Clements MA, **Forlenza GP**, Sherr JL, Kanapka L, Beck RW, Kollman C, Beasley S, Cobry E, Norlander L, McDonough R, Van Name M, Moran A. Associations of CGM Metrics With Stimulated C-Peptide Measures in Youth With Recent-Onset Type 1 Diabetes. *Diabetes Care*. 2025. Epub 20250604. doi: 10.2337/dc25-0291. PubMed PMID: 40465453.
152. Patti ME, Aleppo G, Kruger D, Levy CJ, Bushman J, Umpierrez G, Galindo RJ, **Forlenza GP**, Carlson AL, McGill JB. The Importance of Expanding Medicare Continuous Glucose Monitoring Coverage for High-Risk Hypoglycemia. *Diabetes technology & therapeutics*. 2025. Epub 20251121. doi: 10.1177/15209156251396120. PubMed PMID: 41271215.
153. Saboo B, Garg S, Bergenstal RM, Battelino T, Ceriello A, Choudhary P, De Bock M, Elbarbary N, **Forlenza G**, Gomez AM, Corrales BG, Mader J, O'Neal D, Schwarz P. A Call-to-Action to Eliminate Barriers to Accessing Automated Insulin Delivery Systems for People with Type 1 Diabetes. *Diabetes technology & therapeutics*. 2025. Epub 20250221. doi: 10.1089/dia.2025.0028. PubMed PMID: 39981664.
154. Sawyer A, **Forlenza GP**, Wadwa RP. An overview of the t:slim X2 and Mobi insulin pumps with Control-IQ technology: patient safety and device efficacy. *Expert Rev Med Devices*. 2025. Epub 20251101. doi: 10.1080/17434440.2025.2585061. PubMed PMID: 41175172.
155. Sobczak M, Pyle L, Sawyer A, **Forlenza GP**, Alonso GT. Correlation Between A1c and Continuous Glucose Monitor Time in Range in a Cohort of Pediatric Patients with Type 1 Diabetes. *Diabetes technology & therapeutics*. 2025. Epub 20250212. doi: 10.1089/dia.2024.0500. PubMed PMID: 39937145.
156. Tabatabai Md I, **Forlenza G**. Current State of Automated Insulin Delivery Options For Diabetes Management: A Primer For The Clinician. *SMART-MD Journal of Precision Medicine*. 2025;2(2):e139 – e48. doi: 10.69734/92xeed68.
157. Zisser H, Hovorka R, Basu A, Battelino T, Boughton CK, Breton MD, Buckingham BA, Brown SA, Cherňavsky DR, Dassau E, DeBoer MD, Doyle FJ, 3rd, Ekhlaspour L, Fabris C, **Forlenza GP**, Haidar A,

Klonoff DC, Kovatchev B, Kowalski AJ, Levy CJ, Kudva YC, Maahs DM, Phillip M, Renard E, Russell SJ, Shah VN, Steil GM, Wadwa RP, Weinzimer SA. Early Stages of Automated Insulin Delivery. *Diabetes technology & therapeutics*. 2025;27(S3):S33–s47. doi: 10.1089/dia.2025.18802.hz. PubMed PMID: 40590745.

158. Akturk HK, Nally LM, Lal RA, Warren ML, Demeterco-Berggren C, **Forlenza GP**, Reed JC, Shulman DI, Kipnes MS, Bode BW, Dewan AK, Liljenquist DR, Kudva YC, Niu F, Yovanovich C, Shin JJ, Cordero TL, McVean JJF, Vigersky RA, Bergenstal RM. Safety and Effectiveness of MiniMed™ 780G Advanced Hybrid Closed-Loop Use with Ultrarapid Insulin Lispro-AABC in Pediatric and Adult Type 1 Diabetes. *Diabetes technology & therapeutics*. 2026:15209156261444994. Epub 20260428. doi: 10.1177/15209156261444994. PubMed PMID: 42050782.

159. Cook PF, Jost E, **Forlenza G**, Messer LH, Thompson S, Peck E, Volda S. Situational awareness predicts self-management of type I diabetes in adolescents and young adults. *Health Psychol*. 2026. Epub 20260119. doi: 10.1037/hea0001547. PubMed PMID: 41556933.

160. Faggionato E, Schiavon M, Ekhlaspour L, Kingman RS, Sherr JL, **Forlenza GP**, Buckingham BA, Dalla Man C. Quantifying the Effect of Fat and Protein on the Postprandial Glucose Excursion in Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System. *J Diabetes Sci Technol*. 2026:19322968261440943. Epub 20260424. doi: 10.1177/19322968261440943. PubMed PMID: 42029052; PMCID: PMC13109242.

161. Garg SK, Akturk HK, Garg S, Beck RW, Bellini NJ, Bjornstad P, Carlson AL, Carroll J, Close K, De Block C, Dovc K, **Forlenza GP**, Giorgino F, Heverly J, Hirsch IB, Lewer M, Marks BE, Mathieu C, Nimri R, Beatson C, Nørgaard K, O'Neal DN, Pasquel FJ, Phillip M, Polsky S, Saboo B, Shah VN, Shao H, Sherr JL, Snell-Bergeon JK, Ueki K, Battelino T. Adjunctive Treatment with GLP-1 and Dual GLP-1/GIP Receptor Agonists for People with Type 1 Diabetes: Consensus Report and Practical Guidelines for Safe Use. *Diabetes technology & therapeutics*. 2026:15209156261449879. Epub 20260605. doi: 10.1177/15209156261449879. PubMed PMID: 42246488.

162. Sawyer A, Wilmot EG, Do D, Miller KM, Ly TT, **Forlenza GP**. Settings Associated with Optimal Glycemic Outcomes with the Omnipod® 5 Automated Insulin Delivery System: Evidence from Real-World Users with Type 1 Diabetes. *Diabetes technology & therapeutics*. 2026:15209156261456826. Epub 20260624. doi: 10.1177/15209156261456826. PubMed PMID: 42338327.

163. Van Name M, Sherr J, Bauza C, Buckingham BA, **Forlenza GP**, Neyman A, Beck RW, Kanapka L, Kollman C, Beasley S, Cobry E, Norlander L, McDonough R, DiMeglio LA, McVean J, Moran A. Raising the Bar: High Time in Range During the First Year of Diagnosis of Type 1 Diabetes in Children and Adolescents Using Automated Insulin Delivery with Intense Support. *Diabetes technology & therapeutics*. 2026:15209156261454758. Epub 20260524. doi: 10.1177/15209156261454758. PubMed PMID: 42178737.

164. Van Name M, Sherr JL, Bauza C, Buckingham BA, **Forlenza GP**, Neyman A, Beck R, Bailey R, Kollman C, Beasley S, Cobry E, Norlander L, McDonough R, Sims EK, DiMeglio LA, Moran A. Impact of Early Initiation of Automated Insulin Delivery on Glycemia Two Years from Type 1 Diabetes Diagnosis. *Horm Res Paediatr*. 2026:1–14. Epub 20260603. doi: 10.1159/000552649. PubMed PMID: 42234600.

Other Publications

1. **Forlenza GP**, M. H. It's Summer, Get Ready for Diabetes Camp! Camps for youth and children with diabetes are invaluable. *Review of Endocrinology*. 2008;2(7 July):19-20.

2. **Forlenza GP**, Maahs DM. Diabetes Technology and Therapy in the Pediatric Age Group. *US Endocrinology*. 2016;12(1):22-3. Epub 4/15/2016.

3. **Forlenza GP**, Deshpande S, Ly TT, Howsmon DP, Cameron F, Baysal N, Mauritzen E, Marcal T, Towers L, Bequette BW, Huyett LM, Pinsker JE, Gondhalekar R, Doyle FJ, 3rd, Maahs DM, Buckingham BA, Dassau E. Erratum. Application of Zone Model Predictive Control Artificial Pancreas During Extended Use of Infusion Set and Sensor: A Randomized Crossover-Controlled Home-Use Trial. *Diabetes Care* 2017;40:1096-1102. *Diabetes Care*. 2017;40(11):1606. Epub 2017/09/10. doi: 10.2337/dc17-er11a. PubMed PMID: 28887408; PMCID: PMC5652589.

4. **Member of study group for:** Miller KM, Hermann J, Foster N, Hofer SE, Rickels MR, Danne T, Clements MA, Lilienthal E, Maahs DM, Holl RW. Longitudinal Changes in Continuous Glucose Monitoring Use Among Individuals With Type 1 Diabetes: International Comparison in the German and Austrian DPV and U.S. T1D Exchange Registries. *Diabetes Care*. 2019. Epub 2019/11/02. doi: 10.2337/dc19-1214. PubMed PMID: 31672703.

5. **Member of study group for:** Kovatchev B, Anderson SM, Raghinaru D, Kudva YC, Laffel LM, Levy C, Pinsker JE, Wadwa RP, Buckingham B, Doyle FJ, 3rd, Brown SA, Church MM, Dadlani V, Dassau E, Ekhlaspour L, **Forlenza GP**, Isganaitis E, Lam DW, Lum J, Beck RW. Erratum. Randomized Controlled Trial of Mobile Closed-Loop Control. *Diabetes Care* 2020;43:607-615. *Diabetes Care*. 2020. Epub 2020/04/05. doi: 10.2337/dc20-er06. PubMed PMID: 32245747.
6. **Member of study group for:** Mizokami-Stout KR, Li Z, Foster NC, Shah V, Aleppo G, McGill JB, Pratley R, Toschi E, Ang L, Pop-Busui R. The Contemporary Prevalence of Diabetic Neuropathy in Type 1 Diabetes: Findings From the T1D Exchange. *Diabetes Care*. 2020. Epub 2020/02/08. doi: 10.2337/dc19-1583. PubMed PMID: 32029635.
7. **Member of study group for:** Nimri R, Battelino T, Laffel LM, Slover RH, Schatz D, Weinzimer SA, Dovc K, Danne T, Phillip M. Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes. *Nature medicine*. 2020;26(9):1380-4. Epub 2020/09/11. doi: 10.1038/s41591-020-1045-7. PubMed PMID: 32908282.
8. **Member of study group for:** A Randomized Clinical Trial Assessing Continuous Glucose Monitoring (CGM) Use With Standardized Education With or Without a Family Behavioral Intervention Compared With Fingerstick Blood Glucose Monitoring in Very Young Children With Type 1 Diabetes. *Diabetes Care*. 2021;44(2):464-72. Epub 2020/12/19. doi: 10.2337/dc20-1060. PubMed PMID: 33334807.
9. **Member of study group for:** Cobry EC, Kanapka LG, Cengiz E, Carria L, Ekhlaspour L, Buckingham BA, Hood KK, Hsu LJ, Messer LH, Schoelwer MJ, Emory E, Ruedy KJ, Beck RW, Wadwa RP, Gonder-Frederick L. Health-Related Quality of Life and Treatment Satisfaction in Parents and Children with Type 1 Diabetes Using Closed-Loop Control. *Diabetes technology & therapeutics*. 2021. Epub 2021/01/07. doi: 10.1089/dia.2020.0532. PubMed PMID: 33404325.
10. **Member of study group for:** Kudva YC, Laffel LM, Brown SA, Raghinaru D, Pinsker JE, Ekhlaspour L, Levy CJ, Messer LH, Kovatchev BP, Lum JW, Beck RW, Gonder-Frederick L. Patient-Reported Outcomes in a Randomized Trial of Closed-Loop Control: The Pivotal International Diabetes Closed-Loop Trial. *Diabetes technology & therapeutics*. 2021;23(10):673-83. Epub 2021/06/12. doi: 10.1089/dia.2021.0089. PubMed PMID: 34115959.
11. **Member of study group for:** Levy CJ, O'Malley G, Raghinaru D, Kudva YC, Laffel LM, Pinsker JE, Lum JW, Brown SA. Insulin Delivery and Glucose Variability Throughout the Menstrual Cycle on Closed Loop Control for Women with Type 1 Diabetes. *Diabetes technology & therapeutics*. 2022. Epub 20220221. doi: 10.1089/dia.2021.0431. PubMed PMID: 35099294.
12. **Member of study group for:** Ware J, Boughton CK, Allen JM, Wilinska ME, Tauschmann M, Denvir L, Thankamony A, Campbell FM, Wadwa RP, Buckingham BA, Davis N, DiMeglio LA, Mauras N, Besser REJ, Ghatak A, Weinzimer SA, Hood KK, Fox DS, Kanapka L, Kollman C, Sibayan J, Beck RW, Hovorka R. Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial. *Lancet Digit Health*. 2022. Epub 20220307. doi: 10.1016/s2589-7500(22)00020-6. PubMed PMID: 35272971.
13. **Member of study group for:** Castellanos LE, Russell SJ, Damiano ER, Beck RW, Shah VN, Bailey R, Calhoun P, Bird K, Mauras N. The Insulin-Only Bionic Pancreas Improves Glycemic Control in Non-Hispanic White and Minority Adults and Children With Type 1 Diabetes. *Diabetes Care*. 2023. Epub 20230331. doi: 10.2337/dc22-1478. PubMed PMID: 37000680.
14. **Member of study group for:** Commissariat PV, DiMeglio LA, Kanapka LG, Laffel LM, Miller KM, Anderson BJ, Hilliard ME. Twelve-month Psychosocial Outcomes of Continuous Glucose Monitoring with Behavioral Support in Parents of Young Children with Type 1 Diabetes. *Diabet Med*. 2023:e15120. Epub 20230421. doi: 10.1111/dme.15120. PubMed PMID: 37083018.
15. **Member of study group for:** Criego A, Carlson AL, Brown S, Forlenza GP, Bode B, Levy C, Hansen D, Hirsch IB, Bergenstal RM, Sherr JL, Mehta S, Laffel LM, Shah VN, Bhargava A, Weinstock RS, MacLeish SA, DeSalvo DJ, Jones TC, Aleppo G, Buckingham BA, Ly TT. Two Years with a Tubeless AID System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes. *Diabetes technology & therapeutics*. 2023. Epub 20231018. doi: 10.1089/dia.2023.0364. PubMed PMID: 37850941.
16. **Forlenza GP**, Schamberger MS, Buckingham BA. Verapamil and Pancreatic Beta Cell Function in Pediatric Type 1 Diabetes-Reply. *Jama*. 2023;330(4):380. doi: 10.1001/jama.2023.9113. PubMed PMID: 37490087.
17. **Forlenza GP**, Sherr JL. Response to: MiniMed 780G System Outperforms Other Automated Insulin Systems Due to Algorithm Design, Not Bias - Response to Inaccurate Allegations. *Diabetes technology & therapeutics*. 2024. Epub 20240321. doi: 10.1089/dia.2024.0125. PubMed PMID: 38512386.

Book Chapters

1. Polychronakos C, Bellin M, Wood J, **Forlenza GP**, Rosenbloom A, Silverstein J. "Diabetes Mellitus" chapter in *Pediatric Endocrinology and Inborn Errors of Metabolism 2nd Ed* edited by Sarafoglou K. 2017.
2. **Forlenza GP**, Moran A, Nathan B. "Atypical Diabetes" chapter in *Diabetes in America* published by the National Institutes of Health. 2018.
3. Roberts AJ, **Forlenza GP**, Maahs DM, Taplin CE. "Type 1 Diabetes Mellitus and Exercise" chapter in *Diabetes and Exercise 2nd Ed* edited by Regensteiner J. 2018.
4. Kushner T, Bequette BW, Cameron F, **Forlenza G**, Maahs D, Sankaranarayanan S. "Models, Devices, Properties, and Verification of Artificial Pancreas System" in *Automated Reasoning for Systems Biology Medicine 1st Ed*. 2019.
5. **Forlenza GP**, Messer LH, Maahs DM, Chernavsky DR. "Artificial Pancreas in Pediatrics" in *The Artificial Pancreas – Current Situation and Future Directions 1st Ed* edited by Sanchez-Pena RS and Chernavsky DR. 2019.

Scientific Abstracts from Scientific Meetings

Competitive Abstracts

1. **Forlenza GP**, Chinnakotla S, Schwarzenberg SJ, Cook M, Radosevich D, Manchester C, Gupta S, Nathan B, Bellin M. Near Euglycemia Can be Achieved Safely in Pediatric Total Pancreatectomy Islet Auto-Transplant Recipients Using an Adapted Intravenous Insulin Infusion Protocol. *Poster (Forlenza presenting author) at the Presidential Poster Session of the Pediatric Endocrine Society National Conference, Vancouver 2014. PRESS Conference poster (Forlenza presenting author) in Minneapolis, MN, 2014.*
2. **Forlenza GP**, Nathan B, Moran A, Dunn T, Beilman G, Pruett T, Bellin M. Efficacy and Feasibility of Fully Automated Closed Loop Insulin Pump Therapy after Islet Auto-Transplantation. *Poster (Forlenza presenting author) at the Pancreas Fest National Conference, Pittsburgh, PA, 2014.*
3. **Forlenza GP**, Nathan B, Moran A, Dunn TB, Beilman GJ, Pruett TL, Bellin M. Efficacy and Feasibility of Fully Automated Closed Loop Insulin Pump Therapy after Islet Auto-Transplantation. *Poster (Forlenza presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Paris, France, 2015.*
4. **Forlenza GP**, Fischer L, Janicke DM, Lim CS, Mathews A, Dumont-Driscoll M, Alber JM, Silverstein JH. Feasibility and Preliminary Outcomes of Fun & Fit Families: a Family-Based Community-Centered Behavioral Lifestyle Intervention for Pediatric Obesity. *Poster (Forlenza presenting author) at the Pediatric Endocrine Society National Conference, San Diego, CA, 2015.*
5. **Forlenza GP**, Nathan B, Moran A, Dunn TB, Beilman GJ, Pruett TL, Bellin M. Successful Implementation of Fully Automated Closed Loop Therapy after Islet Auto-Transplantation. *Poster (Forlenza presenting author) and selected audio tour content at the American Diabetes Association National Conference, Boston, MA 2015. Platform oral presentation (Forlenza presenting author) at the PRESS conference in Minneapolis, MN, 2015.*
6. Mann EA, **Forlenza GP**, Kogler A, Miller BS, Nathan B. Educating Diabetes Camp Counselors: Identifying the Gap Between Perceptions and Knowledge – A Quality Improvement Project. *Poster (Mann presenting author) at the Pediatric Endocrine Society National Conference, San Diego, CA 2015. Platform oral talk (Mann presenting author) at the PRESS conference in Minneapolis, MN, 2015.*
7. **Forlenza GP**. Progress Towards an Artificial Pancreas: Status in 2015. *Platform oral talk (Forlenza presenting author) at WAVE Retina Conference in Wailea, HI, 2015.*
8. Huyett LM, Ly TL, Reuschel-DiVirgilio SR, Clay MS, Bevier W, Gondhalekar R, Dassau E, **Forlenza GP**, Doyle FJ, Pinsky JE, Maahs DM, Buckingham BA. Outpatient Closed-Loop Control with Unannounced Moderate Exercise in Adolescents using Zone Model Predictive Control. *Platform oral presentation (Huyett presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Milan, Italy, 2016.*
9. **Forlenza GP**, Pyle LL, Maahs DM, Dunn TC. Ambulatory Glucose Profile Characterization of Juvenile Diabetes Research Foundation-Continuous Glucose Monitoring Trial Data. *Poster (Forlenza presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Milan, Italy, 2016.*

10. **Forlenza GP**, Nathan BM, Moran AM, Dunn TB, Beilman GJ, Pruett TL, Kovatchev BP, Bellin MB. Accuracy of Continuous Glucose Monitoring in Patients after Major Abdominal Surgery. *Poster (Forlenza presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Milan, Italy, 2016.*
11. **Forlenza GP**, Cameron F, Baysal N, Buckingham BA, Clinton P, Lam D, Levy C, Levister C, Ly TL, Maahs DM, Messer LH, Patek SD, Westfall E, Xie YY, Bequette BW. Effect of Meal Detection Suppression on Postprandial Glycemic Excursion in Fully Closed Loop Artificial Pancreas with Unannounced Unscheduled Large Meals. *Poster (Forlenza presenting author) at the American Diabetes Association Conference, New Orleans, LA, 2016.*
12. Cameron F, Ly TL, Buckingham BA, Bequette BW, **Forlenza GP**, Maahs DM, Levy C. Hotel Trial of a Fully Closed Loop Artificial Pancreas with Unannounced Unscheduled Large Meals. *Poster (Bequette presenting author) at the American Diabetes Association Conference, New Orleans, LA, 2016.*
13. **Forlenza GP**, Cameron FM, Ly TT, Lam D, Howsmon D, Baysal N, Messer L, Clinton P, Levister C, Patek SD, Levy CJ, Wadwa RP, Maahs DM, Bequette BW, Buckingham BA. Fully Closed Loop Multiple Model Probabilistic Predictive Controller (MMPPC) Artificial Pancreas (AP) Performance in Adolescents and Adults in a Supervised Hotel Setting. *Poster (Forlenza presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Paris, France, 2017.*
14. **Forlenza GP**, Deshpande S, Ly T, Howsmon DP, Cameron F, Baysal N, Towers L, Marcal T, Bequette BW, Gondhalekar R, Doyle FJ, Maahs DM, Buckingham B, Dassau E. Application of Zone Model Predictive Control (Zone-MPC) Artificial Pancreas (AP) During Extreme Fault Detection Testing Conditions: A Randomized Crossover-Controlled Home-Use Trial. *Poster (Forlenza presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Paris, France, 2017.*
15. **Forlenza GP**, Chernavsky DR, DeBoer M, Robic J, Kovatchev BP, Wadwa RP, Messer L, Maahs DM, Breton MD. The Artificial Pancreas (AP) Improves Glycemic Control During Extended Exercise at Ski Camp in Adolescents with Type 1 Diabetes (T1D). *Poster (Forlenza presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Paris, France, 2017.*
16. Messer L, **Forlenza GP**, Wadwa RP, Westfall E, Jost E, Alonso GT, Maahs DM, Slover R. Hybrid Closed-Loop (HCL) Therapy in Adolescents and Young Adults with Type 1 Diabetes (T1D) Increases Time in Range. *Platform Oral Presentation (Messer presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Paris, France, 2017.*
17. Howsmon DP, Baysal N, Hahn J, Buckingham B, Ly TT, Maahs DM, **Forlenza GP**, Bequette BW. Real-Time Detection of Losses in Infusion Set Actuation (LISAS) in a Closed-Loop Artificial Pancreas. *Poster (Howsmon presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Paris, France, 2017.*
18. Berget C, Driscoll KA, Hanes S, Marcal T, Towers L, Maahs DM, Howsmon DP, Deshpande S, Gondhalekar R, **Forlenza G**, Bequette BW, Cameron F, Dassau E, Ly T, Doyle FJ, Buckingham B, Hood K. Does the Artificial Pancreas Reduce Diabetes Distress and Hypoglycemia Worry in Individuals with Type 1 Diabetes? *E-Poster (Berget presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Paris, France, 2017.*
19. Tinti D, Marcal T, Towers L, Doiev J, Ly T, Messer L, **Forlenza GP**, Maahs D, Buckingham B. Continuous Glucose Monitor (CGM) Survival and Accuracy Over 21 Consecutive Days. *Poster (Tinti presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Paris, France, 2017.*
20. **Forlenza GP**, Wadwa RP, Slover R, O'Brien R, Mouse TJ, Lum J, Berget C, Marcal T, Beck RW, Buckingham BA, Ly TT. Inpatient Safety and Feasibility of the Tandem Predictive Low Glucose Suspend (PLGS) Insulin Pump. *Platform Oral Presentation (Forlenza presenting author) at the American Diabetes Association Conference, San Diego, CA, 2017.*
21. **Forlenza GP**, Raghinaru D, Cameron F, Bequette BW, Chase HP, Wadwa RP, Maahs DM, Jost E, Ly TT, Wilson DM, Clinton P, Lum JW, Kollman C, Beck RW, Buckingham BA. Predictive Hyperglycemia and Hypoglycemia Minimization (PHHM) in Children with Type 1 Diabetes (T1D): In-Home Evaluation of Safety, Feasibility and Efficacy. *Poster (Forlenza presenting author) at the American Diabetes Association Conference, San Diego, CA, 2017.*
22. Buckingham BA, **Forlenza GP**, Schneider J, Peyser TA, Dassau E, Lee JB, O'Connor J, Layne J, Ly TT. Safety and Feasibility of Ominpod Hybrid Closed-Loop in Adolescents with Type 1 Diabetes

- Using a Personalized Model Predictive Control Algorithm. *Poster (Buckingham presenting author) at the American Diabetes Association Conference, San Diego, CA, 2017.*
23. Buckingham BA, **Forlenza GP**, Schneider J, Peyser TA, Dassau E, Lee JB, O'Connor J, Layne J, Ly TT. Safety and Feasibility of Omnipod Hybrid Closed-Loop in Children Aged 6-12 Years with Type 1 Diabetes Using a Personalized Model Predictive Control Algorithm. *Late-Breaking Poster (Buckingham presenting author) at the American Diabetes Association Conference, San Diego, CA, 2017.*
 24. Garg S, Slover RH, Giordano D, **Forlenza GP**, Lee SW, Shin J, Kaufman FR. Maintaining Glucose Control at One + Year of MiniMed 670G System Home Use; Single Center Experience. *Late-Breaking Poster (Garg presenting author) at the American Diabetes Association Conference, San Diego, CA, 2017.*
 25. Sopfe J, Keating AK, Pyle L, Campbell K, Liu AK, Wadwa RP, Verneris M, Giller R, **Forlenza GP**. Malglycemia in Pediatric Hematopoietic Stem Cell Transplant Recipients. *Poster (Sopfe presenting author) at the Pediatric Blood & Marrow Transplant Consortium Conference Montreal, Quebec, 2017.*
 26. Sopfe J, Keating AK, Pyle L, Campbell K, Liu AK, Wadwa RP, Verneris M, Giller R, **Forlenza GP**. Malglycemia is Associated with Increased Infection in Pediatric Hematopoietic Stem Cell Transplant Recipients. *Poster (Sopfe presenting author) at the American Society of Hematology Annual Meeting, Atlanta, GA, 2017.*
 27. Sopfe J, Keating AK, Pyle L, Campbell K, Liu AK, Wadwa RP, Verneris M, Giller R, **Forlenza GP**. Malglycemia is Associated with Increased Mortality in Pediatric Hematopoietic Stem Cell Transplant Recipients. *Platform Oral Presentation (Sopfe presenting author) at the American Society of Blood and Marrow Transplantation BMT Tandem Meeting, Salt Lake City, UT, 2018.*
 28. Buckingham B, Pinsker J, **Forlenza GP**, Cengiz E, Pettus J, Swanson V, Li Z, Lum J, Kollman C, Beck R. PROLOG: A Randomized Clinical Trial to Assess the Efficacy of Predictive Low Glucose Suspend versus Sensor-Augmented Pump Therapy in the Management of Type 1 Diabetes. *Platform Oral Presentation (Buckingham presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Vienna, Austria, 2018.*
 29. Buckingham B, Christiansen MP, **Forlenza GP**, Wadwa RP, Peyser TA, Lee JB, O'Connor J, Layne JE, Ly TL. Performance of Omnipod Personalized Model Predictive Control Algorithm with Specific Meal Challenges in Adults with Type 1 Diabetes. *Platform Oral Presentation (Buckingham presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Vienna, Austria, 2018.*
 30. **Forlenza GP**, Buckingham BA, Christiansen MP, Wadwa RP, Peyser TA, Lee JB, O'Connor J, Layne JE, Ly TL. Performance of Omnipod Personalized Model Predictive Control Algorithm with Moderate Intensity Exercise and Variable Setpoints in Adults with Type 1 Diabetes. *Poster (Forlenza presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Vienna, Austria, 2018.*
 31. Buckingham BA, Shulman DI, **Forlenza GP**, Bode BW, Pinhas-Hamiel O, Wood MA, Kaiserman KB, Liljenquist DR, Bailey TS, Shin J, Huang S, Cordero TL, Kaufman FR. Glycemic Outcomes During Minimed 670G System Use in Children with T1D. *Platform Oral Presentation (Buckingham presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Vienna, Austria, 2018.*
 32. **Forlenza GP**, Shulman DI, Wood MA, Bode BW, Pinhas-Hamiel O, Buckingham BA, Kaiserman KB, Liljenquist DR, Bailey TS, Shin J, Huang S, Cordero TL, Lee SW, Kaufman FR. Evaluation of the Minimed 670G System Predictive Low Glucose Management Feature in Children. *Platform oral Presentation (Forlenza presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Vienna, Austria, 2018.*
 33. Berget C, Messer L, Pyle L, Westfall E, **Forlenza GP**, Driscoll K. Real World Use of Hybrid Closed Loop Therapy in Pediatric Patients with Type 1 Diabetes. *Oral guided poster (Berget presenting author) at the American Diabetes Association Conference, Orlando, FL, 2018.*
 34. Buckingham BA, Sherr J, **Forlenza GP**, Peyser TA, Lee JB, O'Connor JB, Dumas B, Huyett LM, Layne JE, Ly TT. Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults with Type 1 Diabetes Over 5 Days Under Free-Living Conditions. *Platform oral presentation (Buckingham presenting author) at the American Diabetes Association Conference, Orlando, FL, 2018.*
 35. **Forlenza GP**, Buckingham BA, Sherr J, Peyser TA, Lee JB, O'Connor JB, Dumas B, Huyett LM, Layne JE, Ly TT. Safety and Performance of the Omnipod Hybrid Closed-Loop System in

- Adolescents with Type 1 Diabetes Over 5 Days Under Free-Living Conditions. *Poster (Forlenza presenting author) at the American Diabetes Association Conference, Orlando, FL, 2018.*
36. Sherr J, **Forlenza GP**, Buckingham BA, Peyser TA, Lee JB, O'Connor JB, Dumas B, Huyett LM, Layne JE, Ly TT. Safety and Performance of the Omnipod Hybrid Closed-Loop System in Children Aged 6-12 years with Type 1 Diabetes Over 5 Days Under Free-Living Conditions. *Poster (Sherr presenting author) at the American Diabetes Association Conference, Orlando, FL, 2018.*
 37. **Forlenza GP**, Shulman DI, Wood MA, Bailey TS, Bode BW, Buckingham BA, Huang S, Shin J, Lee SW, Cordero TL, Kaufman FR. Overnight to Early Morning Glycemic Outcomes in Children Using the MiniMed 670G Hybrid Closed-Loop (HCL) System. *Platform oral presentation (Forlenza presenting author) at the American Diabetes Association Conference, Orlando, FL, 2018.*
 38. Berget C, Messer LH, Vigers TR, Wadwa RP, Slover R, Pyle L, Driscoll KA, **Forlenza GP**. Real World Use of Hybrid Closed Loop Therapy in Pediatric Patients with Type 1 Diabetes: A Clinical Observation Study. *Platform oral presentation (Berget presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Berlin, Germany, 2019.*
 39. Norlander L, Tabatabai I, Ekhlaspour L, Buckingham B, Sethi M, **Forlenza G**. Glycemic Outcomes and System Adherence Between Age Groups in Pediatric Subjects Using a Hybrid Closed-Loop Pump. *Platform oral presentation (Norlander presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Berlin, Germany, 2019.*
 40. Lange S, Messer LH, Berget C, **Forlenza G**, Slover R. Exercise using Hybrid Closed Loop Therapy: Lessons from Pediatrics. *Poster (Lange presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Berlin, Germany, 2019.*
 41. Vigers T, Chan CL, Snell-Bergeon J, Bjornstad P, Zeitler PS, **Forlenza G**, Pyle L. An R Package for Analysis of Continuous Glucose Monitor Data. *Poster (Vigers presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Berlin, Germany, 2019.*
 42. Messer LH, Hanes S, Tabatabai I, DiMeglio LA, Hannon T, **Forlenza G**, Woerner S, Lange S, Driscoll K, Hood K, Rodriguez H, Buckingham BA. Novel Telehealth Support Intervention for Young Children Using HCL. *Poster (Messer presenting author) at the American Diabetes Association Conference, San Francisco, CA, 2019.*
 43. Ekhlaspour L, **Forlenza G**, Berget C, Bird K, Englert K, Hsu L, Balliaro C, Mauras N, Wadwa RP, Buckingham B, El-Khatib F, Damiano E, Russell S. First Test of the iLet, a Purpose-Built Bionic Pancreas Platform, in Children and Adolescents with Type 1 Diabetes. *Poster (Ekhlaspour presenting author) at the American Diabetes Association Conference, San Francisco, CA, 2019.*
 44. Buckingham BA, **Forlenza GP**, Sherr J, Galderisi A, Ekhlaspour L, Lee JB, O'Connor JB, Dumais B, Huyett LM, Layne JE, Ly TT. Safety and Performance of the Omnipod Hybrid Closed-Loop System in Young Children Aged 2-6 Years with Type 1 Diabetes. *Platform oral presentation (Buckingham presenting author) at the American Diabetes Association Conference, San Francisco, CA, 2019.*
 45. Wong JJ, Clay SM, **Forlenza GP**, Hanes S, Wadwa RP, Hood KK. Evaluating Early Initiation of Continuous Glucose Monitoring (CGM) Among Youth Diagnosed with Type 1 Diabetes (T1D). *Poster (Wong presenting author) at the American Diabetes Association Conference, San Francisco, CA, 2019.*
 46. Bailey TS, Bode BW, Buckingham BA, **Forlenza GP**, Pinhas-Hamiel O, Kaiserman K, Liljenquist DR, Shulman DI, Wood MA, Chen X, Shin J, Cordero TL, Lee SW, Kaufman FR. Glycemic Outcomes in the MiniMed 670G System Pivotal Trials in Patients 2-75 Years of Age. *Poster (Bailey presenting author) at the American Diabetes Association Conference, San Francisco, CA, 2019.*
 47. Sopfe J, Scarbro S, Suresh K, Maloney K, **Forlenza GP**. Hyperglycemia and Adverse Outcomes in Pediatric Acute Lymphoblastic Leukemia/Lymphoma Patients. *Poster (Sopfe presenting author) at the American Society of Pediatric Hematology/Oncology Conference, New Orleans, LA, 2019.*
 48. Ekhlaspour L, Raghinaru D, **Forlenza GP**, Isganaitis E, Kudva YC, Lam DW, Levister C, O'Malley G, Lum JW, Brown SA. Outcomes in Pump- and CGM-Naïve Subgroups in the International Diabetes Closed-Loop (IDCL) Trial. *Poster (Ekhlaspour presenting author) at the Diabetes Technology Meeting, Bethesda, MA, 2019.*
 49. O'Malley G, Raghinaru, Levy CJ, Pinsker JE, **Forlenza GP**, Messer L, Isganaitis E, Ekhlaspour L, Lum J, Brown SA. Clinical Management of a Closed-Loop Control System: Results from a 6-Month Multicenter Randomized Clinical Trial. *Poster (O'Malley presenting author) at the Diabetes Technology Meeting, Bethesda, MA, 2019.*

50. Messer LH, Campbell K, Manning M, Habib S, **Forlenza GP**. Satisfaction and reduction in diabetes burden with predictive low glucose suspend in individuals with type 1 diabetes. *Poster (Messer presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Madrid, Spain, 2020.*
51. Kushner T, Messer L, **Forlenza G**. Translating Standard Clinical Protocol into Tuning Procedures for Hybrid Closed Loop Systems: 670G, Control-IQ, and Loop. *Poster (Kushner presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Madrid, Spain, 2020.*
52. **Forlenza GP**, DeSalvo DJ, Huyett L, Jantz J, Chang A, Vienneau T, Ly TT. Frequent Bolusing is associated with Better Glycemic Control in 7,494 Youth with Type 1 Diabetes Using the Omnipod Insulin Management System. *Poster (Forlenza presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Madrid, Spain, 2020.*
53. Weinstock RS, Hirsch IB, **Forlenza GP**, DeSalvo DJ, Jantz J, Huyett L, Chang A, Vienneau T, Ly TT. Regular Users of Temporary Basal Rate or Extended Bolus Have Better Glycemic Outcomes in 11,997 Omnipod Insulin Management System Users with Type 1 Diabetes. *Poster (Weinstock presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Madrid, Spain, 2020.*
54. Sherr JL, Buckingham BA, **Forlenza GP**, Galderisi A, Ekhlaspour L, Wadwa RP, Zgorski M, Kingman R, Berget C, Lee JB, O'Connor J, Dumais B, Vienneau T, Huyett LM, Ly TT. Performance of Omnipod Personalized Model Predictive Control with Multiple Setpoints, and Meal and Exercise Challenges in Children aged 2-12 years with Type 1 Diabetes. *Poster (Sherr presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Madrid, Spain, 2020.*
55. **Forlenza GP**, Buckingham BA, Sherr JL, Wadwa RP, Galderisi A, Ekhlaspour L, Berget C, Hsu L, Zgorski M, Lee JB, O'Connor J, Dumais B, Vienneau T, Huyett LM, Ly TT. Performance of Omnipod Personalized Model Predictive Control Algorithm with Multiple Setpoints and Meal and Exercise Challenges in Adults and Adolescents with Type 1 Diabetes. *Poster (Forlenza presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Madrid, Spain, 2020.*
56. Hanes S, Wadwa RP, Weber I, **Forlenza G**, Buckingham B, Hood K. Continuous Glucose Monitoring (CGM) initiation at diagnosis versus six months later: Which is Best? *Poster (Hanes presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Madrid, Spain, 2020.*
57. Wong JJ, Hanes S, **Forlenza G**, Weber I, Wadwa RP, Hood K. Early Initiation of Continuous Glucose Monitoring Among Children and Adolescents: Benefits and Timing. *Poster (Wong presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Madrid, Spain, 2020.*
58. Berget C, Messer LH, Vigers T, Pyle L, Driscoll KA, **Forlenza G**. Twelve Month Clinical Observation of Youth with Type 1 Diabetes Using 670G HCL in the Real-World. *Platform oral presentation (Berget presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Madrid, Spain, 2020.*
59. Cobry E, Berget C, Messer L, Wadwa RP, Driscoll KA, Pyle L, Vigers T, **Forlenza G**. Psychosocial Outcomes After One Year of Real-World Hybrid Closed-Loop Therapy in Youth and Young Adults with Type 1 Diabetes. *Poster (Cobry presenting author) at the Advanced Technologies and Treatments for Diabetes International Conference, Madrid, Spain, 2020.*
60. **Forlenza GP**. Continuous Glucose Monitor Use in Hospital Settings. *Invited oral platform presentation (Forlenza presenting author) at American Diabetes Association Conference, Chicago, IL (virtual), 2020.*
61. Ekhlaspour L, **Forlenza GP**, Schoelwer M, DeBoer M, Kingman R, Berget C, Emory E, Wadwa RP, Buckingham B, Breton M. Safety and Performance of the Tandem T:slim X2 with Control-IQ Automated Insulin Delivery System in Preschoolers, age 2-6 Years Old. *Oral abstract (Ekhlaspour presenting author) at American Diabetes Association Conference, Chicago, IL (virtual), 2020.*
62. **Forlenza GP**, Buckingham BA, Criego A, Brown SA, Bode BW, Levy CJ, Ly TT. First Home Evaluation of the Omnipod Horizon Automated Glucose Control System at Specific Glucose Targets in Children with Type 1 Diabetes. *Oral abstract (Forlenza presenting author) at American Diabetes Association Conference, Chicago, IL (virtual), 2020.*
63. Buckingham BA, **Forlenza GP**, Criego A, Brown SA, Bode BW, Levy CJ, Ly TT. First Home Evaluation of the Omnipod Horizon Automated Glucose Control System in Children with Type 1

- Diabetes. *Poster (Buckingham presenting author) at American Diabetes Association Conference, Chicago, IL (virtual), 2020.*
64. Brown SA, Bode BW, Levy CJ, **Forlenza GP**, Buckingham BA, Criego A, Ly TT. First Home Evaluation of the Omnipod Horizon Automated Glucose Control System at Specific Glucose Targets in Adults with Type 1 Diabetes. *Poster (Brown presenting author) at American Diabetes Association Conference, Chicago, IL (virtual), 2020.*
 65. Brown SA, Bode BW, Levy CJ, **Forlenza GP**, Buckingham BA, Criego A, Ly TT. First Home Evaluation of the Omnipod Horizon Automated Glucose Control System in Adults with Type 1 Diabetes. *Poster (Brown presenting author) at American Diabetes Association Conference, Chicago, IL (virtual), 2020.*
 66. **Forlenza GP**, Buckingham BA, Sherr JL, Wadwa RP, Galderisi A, Ekhlaspour L, Berget C, Hsu L, Zgorski M, Lee JB, O'Connor J, Dumais B, Vienneau T, Huyett LM, Ly TT. Omnipod Personalized MPC Algorithm at Target Glucose of 110 mg/dL is Safe in Adults and Adolescents without Increasing Risk of Hypoglycemia. *Poster (Forlenza presenting author) at American Diabetes Association Conference, Chicago, IL (virtual), 2020.*
 67. Sherr JL, Buckingham BA, **Forlenza GP**, Galderisi A, Ekhlaspour L, Wadwa RP, Zgorski M, Kingman R, Berget C, Lee JB, O'Connor J, Dumais B, Vienneau T, Huyett LM, Ly TT. Omnipod Personalized MPC Algorithm at Target Glucose of 110 mg/dL is Safe in Children Aged 2-12 without Increasing Risk of Hypoglycemia. *Poster (Sherr presenting author) at American Diabetes Association Conference, Chicago, IL (virtual), 2020.*
 68. **Forlenza GP**, Buckingham BA, Criego A, Brown SA, Bode BW, Levy CJ, Ly TT. First home evaluation of the Omnipod Horizon Automated Glucose Control System in Children with Type 1 Diabetes. *Platform oral presentation (Forlenza presenting author) at the European Association for the Study of Diabetes conference, Vienna, Austria (virtual), 2020.*
 69. Brown SA, Bode BW, Levy CJ, **Forlenza GP**, Buckingham BA, Criego A, Ly TT. First home evaluation of the Omnipod Horizon Automated Glucose Control System in adults with Type 1 Diabetes. *Platform oral presentation (Brown presenting author) at the European Association for the Study of Diabetes conference, Vienna, Austria (virtual), 2020.*
 70. Criego A, Buckingham BA, **Forlenza GP**, Brown SA, Bode BW, Levy CJ, Ly TT. First Home Evaluation of the Omnipod Horizon Automated Glucose Control System in Children with Type 1 Diabetes. *ePoster (Criego presenting author) at the International Society for Pediatric and Adolescent Diabetes Conference, Abu Dhabi, UAE (virtual), 2020.*
 71. Cobry E, Berget C, Messer LH, Escobar E, Jost E, Dong F, Driscoll K, **Forlenza GP**. Sleep Mode Use in Pediatric Patients with Type 1 Diabetes Using Control-IQ. *ePoster (Cobry presenting author) at the International Society for Pediatric and Adolescent Diabetes Conference, Abu Dhabi, UAE (virtual), 2020.*
 72. Berget C, Messer LH, Dong F, Escobar E, Jost E, Cobry E, Slover RH, Driscoll KA, **Forlenza GP**. Increased time in range in the first month of Control-IQ use in a clinical sample of youth with T1D. *ePoster (Berget presenting author) at the International Society for Pediatric and Adolescent Diabetes Conference, Abu Dhabi, UAE (virtual), 2020.*
 73. Messer LH, Berget C, Towers L, Otten B, Ernst A, Karami A, Thomas S, Cobry E, Alonso GT, Slover R, Wadwa RP, **Forlenza GP**. Evaluation of a Control-IQ Follow-up Program by Diabetes Educators. *ePoster (Messer presenting author) at the International Society for Pediatric and Adolescent Diabetes Conference, Abu Dhabi, UAE (virtual), 2020.*
 74. Boranian E, Messer LH, Berget C, Cobry E, Wadwa RP, Slover R, **Forlenza GP**. Success and challenges with CGM in children and adolescents with T1D. *ePoster (Boranian presenting author) at the International Society for Pediatric and Adolescent Diabetes Conference, Abu Dhabi, UAE (virtual), 2020.*
 75. Bode B, Levy C, Brown S, Carlson A, Shah V, Pinsker J, Bhargava A, Mehta S, Laffel L, Jones T, Aleppo G, **Forlenza G**, Ly T. Performance of Omnipod 5 Automated Insulin Delivery System at Specific Glucose Targets from 110-1150 mg/dL Over Three Months in Adults and Adolescents with Type 1 Diabetes. *Platform oral presentation (Bode presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Virtual, 2021.*
 76. Sherr J, **Forlenza G**, Buckingham B, Criego A, Hansen D, Bode B, Brown S, Macleish S, Pinsker J, Desalvo D, Mehta S, Laffel L, Bhargava A, Ly T. Performance of Omnipod 5 Automated Insulin Delivery System at Specific Glucose Targets from 110-150 mg/dL Over Three Months in Children

- with Type 1 Diabetes (T1D). *Platform oral presentation (Sherr presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Virtual, 2021.*
77. **Forlenza G**, Brown S, Bode B, Levy C, Criego A, Hansen D, Hirsch I, Carlson A, Bergenstal R, Sherr J, Mehta S, Laffel L, Shah V, Bhargava A, Weinstock R, MacLeish S, DeSalvo D, Jones T, Aleppo G, Buckingham B, Ly T. Safety Evaluation of the Ominpod 5 Automated Insulin Delivery System over 3 Months of Use in Adults and Children with Type 1 Diabetes. *Platform oral presentation (Forlenza presenting author) at the European Association for the Study of Diabetes conference, Virtual, 2021.*
 78. Sawyer A, Sobczak M, **Forlenza G**, Alonso GT. Continuous Glucose Monitor Use, but Not Insulin Pump Use, in Pediatric Patients with Type 1 Diabetes Consistently Associated with Lower A1c. *Platform oral presentation (Sawyer presenting author) at the Pediatric Academic Societies Conference, Virtual 2021.*
 79. Sherr J, Bode B, **Forlenza G**, Laffel L, Brown S, Buckingham B, Criego A, DeSalvo D, Macleish S, Hansen D, Ly T. Evaluation of the Omnipod 5 Automated Insulin Delivery System in Very Young Children with Type 1 Diabetes (T1D). *Platform oral presentation (Sherr presenting author) at the American Diabetes Association 2021 Scientific Sessions, Virtual, 2021.*
 80. Shah V, Criego A, Carlson A, Bhargava A, Bode B, Brown S, **Forlenza G**, Levy C, Mehta S, Laffel L, Aleppo G, Buckingham B, DeSalvo D, Hirsch I, Macleish S, Pinsker J, Ly T. Transition from Multiple Daily Injection (MDI) to Omnipod 5 Automated Insulin Delivery System Improves A1c in Type 1 Diabetes (T1D). *Platform oral presentation (Shah presenting author) at the American Diabetes Association 2021 Scientific Sessions, Virtual, 2021.*
 81. Carlson A, Criego A, **Forlenza G**, Bode B, Levy C, Hansen D, Hirsch I, Brown S, Bergenstal R, Sherr J, Mehta S, Laffel L, Shah V, Bhargava A, Weinstock R, Macleish S, DeSalvo D, Jones T, Aleppo G, Buckingham B, Ly T. Glycemic Management over 6 Months with the Omnipod 5 Automated Insulin Delivery System. *Platform oral presentation (Carlson presenting author) at the American Diabetes Association 2021 Scientific Sessions, Virtual, 2021.*
 82. **Forlenza G**, Vigers T, Berget C, Messer L, Lal R, Basina M, Maahs D, Hood K, Buckingham B, Wilson D, Wadwa RP, Driscoll K, Pyle L. Predicting Success with a First-Generation Hybrid Closed Loop Artificial Pancreas System Among Children, Adolescents, and Young Adults with Type 1 Diabetes: a Model Development and Validation Study. *ePoster (Forlenza presenting author) at the International Society for Pediatric and Adolescent Diabetes Conference, Virtual 2021.*
 83. **Forlenza G**, DeSalvo D, Hadjiyianni I, Huyett L, Lowen S, Chang A, Vinneau T, Ly T. Glycemic Profiles and Treatment Patterns in 1,464 Children and Adolescents with Type 1 Diabetes Using the Omnipod DASH Insulin Management System with Continuous Glucose Monitoring and Cloud-Based Data Management. *ePoster (Forlenza presenting author) at the International Society for Pediatric and Adolescent Diabetes Conference, Virtual 2021.*
 84. Sobczak M, Sawyer A, Alonso GT, **Forlenza G**. Continuous Glucose Monitoring (CGM) Use with or without Insulin Pump Use is Associated with Lower A1c in Pediatric Patients with Type 1 Diabetes (T1D). *ePoster (Sobczak presenting author) at the International Society for Pediatric and Adolescent Diabetes Conference, Virtual 2021.*
 85. Sherr J, Bode B, **Forlenza G**, Laffel L, Schoelwer M, Buckingham B, Criego A, DeSalvo D, MacLeish S, Hansen D, Ly T. Evaluation of the Omnipod 5 Automated Insulin Delivery System in Very Young Children with Type 1 Diabetes. *Platform oral presentation (Sherr presenting author) at the International Society for Pediatric and Adolescent Diabetes Conference, Virtual 2021.*
 86. Escobar E, Towers L, Berget C, Vigers T, Pyle L, Messer L, Cobry E, Slover R, Wadwa RP, Driscoll K, **Forlenza G**. Psychosocial Impacts of the t:slim X2 Pump with Control-IQ Technology (CIQ) in a Clinical Population of Youth with Type 1 Diabetes (T1D) After 6 Months of Use. *ePoster (Escobar presenting author) at the International Society for Pediatric and Adolescent Diabetes Conference, Virtual 2021.*
 87. **Forlenza GP**, Vigers T, Berget C, Messer L, Karami A, Towers L, O'Donnell H, Wadwa RP, Pyle L. Predicting 12-Month Success with a Second-Generation Hybrid Closed Loop Artificial Pancreas System. *Platform oral presentation (Forlenza presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Barcelona, 2022.*
 88. Berget C, Messer L, Vigers T, Pyle L, Cobry E, **Forlenza G**. Sustaining Improvement in Glycemic Control for Youth Using Control-IQ (CIQ) for One Year. *Platform oral presentation (Berget presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Barcelona, 2022.*

89. Macleish S, Sherr J, Bode B, **Forlenza G**, Laffel L, Schoelwer M, Buckingham B, Criego A, DeSalvo D, Hansen D, Ly T, Omnipod 5 in Preschoolers Study Group. *Platform oral presentation (Macleish presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Barcelona, 2022.*
90. Boranian E, Vigers T, O'Donnell H, Berget C, Messer L, Pyle L, Wadwa RP, **Forlenza GP**. The Relationship Between Time-In-Range (TIR), Mean Glucose and HbA1c in Youth with Type 1 Diabetes. *Platform oral presentation (Boranian presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Barcelona, 2022.*
91. Ekhlaspour L, Buckingham B, Huyett L, Criego A, Carlson A, Brown S, Weinstock R, Hansen D, Bode B, **Forlenza G**, Levy C, Macleish S, DeSalvo D, Hirsch I, Jones T, Mehta S, Laffel L, Sherr J, Bhargava A, Shah V, Dumais B, Ly T, Omnipod 5 Study Group. Performance of the Omnipod 5 Automated Insulin Delivery System with and Without Pre-Meal Bolus. *ePoster (Ekhlaspour presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Barcelona, 2022.*
92. Berget C, Centi S, McNair B, **Forlenza G**, Messer L. Feasibility of a Clinical Tool to Support Clinicians in Caring for Persons with Diabetes Using Automated Insulin Delivery. *ePoster (Berget presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Barcelona, 2022.*
93. Messer L, Volda S, Cook P, **Forlenza G**, Feisler C, Fivekiller E, Sankaranarayanan S. Development of a "Cognitive Awareness Artificial Pancreas Enhancement" (CAPE) to Help Adolescents with T1D Optimize Their Use of Artificial Pancreas Systems. *ePoster (Messer presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Barcelona, 2022.*
94. Criego AB, Carlson AL, **Forlenza GP**, Bode BW, Levy CJ, Hansen DW, Hirsch IB, Brown SA, Bergenstal RM, Sherr J, Mehta SN, Laffel LM, Shah V, Bhargava A, Weinstock RS, Macleish S, DeSalvo D, Jones TC, Aleppo G, Buckingham BA, Ly TL, Omnipod 5 Research Group. Glycemic Outcomes over 15 Months with the Omnipod 5 Automated Insulin Delivery System. *Poster presentation (Criego presenting author) at the American Diabetes Association 2022 Scientific Sessions, New Orleans, 2022.*
95. DeSalvo D, Bode B, **Forlenza GP**, Laffel LM, Buckingham BA, Criego AB, Schoelwer M, Macleish SA, Sherr J, Hansen DW, Ly TT, Omnipod 5 In Preschool Study Group. ADA Presidents' Select Abstract: Glycemic Outcomes over 12 Months in Very Young Children with the Omnipod 5 Automated Insulin Delivery (AID) System. *Platform oral presentation (DeSalvo presenting author) at the American Diabetes Association 2022 Scientific Sessions, New Orleans, 2022.*
96. **Forlenza GP**, Bode BW, Carlson AL, Criego AB, Brown SA, Weinstock RS, Hansen DW, Buckingham BA, Mehta SN, Laffel LM, Sherr J, Levy CJ, Hirsch IB, Macleish SA, DeSalvo D, Shah V, Bhargava A, Jones TC. Glycemic Outcomes with the Omnipod 5 Automated Insulin Delivery (AID) System Stratified by Baseline Hypoglycemia Risk Among People with Type 1 Diabetes (T1D) Ages 2 to 70 Years. *Poster presentation (Forlenza presenting author) at the American Diabetes Association 2022 Scientific Sessions, New Orleans, 2022.*
97. Schoelwer M, Bode BW, Carlson AL, Criego AB, **Forlenza GP**, Weinstock RS, Hansen DW, Buckingham BA, Mehta SN, Laffel LM, Sherr J, Levy CJ, Hirsch IB, Macleish SA, DeSalvo D, Shah V, Bhargava AJ, Jones TC, Aleppo G, Gurlin RE, Ly TT, Omnipod 5 Research Group. Glycemic Outcomes across Total Daily Insulin Doses with the Omnipod 5 Automated Insulin Delivery System (AID) among People with Type 1 Diabetes (T1D) Ages 2 to 70 Years. *Poster presentation (Schoelwer presenting author) at the American Diabetes Association 2022 Scientific Sessions, New Orleans, 2022.*
98. Messer LH, Vigers TB, Akturk HK, **Forlenza GP**, Huss KB, Karami AJ, Malecha E, Oser S, Polsky S, Pyle L, Shah V, Wadwa RP, Oser T. Health Care Professional (HCP) Perspectives on Support Tools for Diabetes Devices. *Late-breaking poster presentation (Messer presenting author) at the American Diabetes Association 2022 Scientific Sessions, New Orleans, 2022.*
99. Ly TT, DeSalvo DJ, Bode BW, **Forlenza GP**, Laffel LM, Buckingham BA, Criego AB, Schoelwer MJ, MacLeish SA, SHerr JL, Hansen DW. Glycemic outcomes over 12 months in very young children with Omnipod 5 automated insulin delivery system. *Platform oral presentation (Ly presenting author) at the International Society for Pediatric and Adolescent Diabetes Conference, Abu Dhab, UAE, 2022.*
100. Ekhlaspour L, Buckingham BA, Huyett LM, Criego AB, Brown SA, Hansen DW, Bode BW, **Forlenza GP**, MacLeish SA, DeSalvo DJ, Mehta SN, Laffel LM, SHerr JL, Bhargava A, Dumais B, Ly

- TT. Performance of the Omnipod 5 automated insulin delivery system with and without pre-meal bolus. *Platform oral presentation (Ekhlaspour presenting author) at the International Society for Pediatric and Adolescent Diabetes Conference, Abu Dhabi, UAE, 2022.*
101. Escobar E, O'Donnell H, Lange S, Vigers T, Karami AJ, Berget C, Messer L, Wadwa RP, Pyle L, **Forlenza GP**. Promotion of successful hybrid closed loop utilization via targeted bolusing behavioral intervention among adolescents with type 1 diabetes (T1D) and their families. *Poster (Escobar presenting author) at the International Society for Pediatric and Adolescent Diabetes Conference, Abu Dhabi, UAE, 2022.*
 102. Geiser L, Berget C, Tellez G, Spiegel G, **Forlenza G**, Gerard-Gonzalez A. Expanding access to automated insulin delivery (AID) within the Lantix pediatric type 1 diabetes (T1D) population. *Poster (Geiser presenting author) at the International Society for Pediatric and Adolescent Diabetes Conference, Abu Dhabi, UAE, 2022.*
 103. **Forlenza G**, McVean J, Beck R, Bauza C, Bailey R, Buckingham B, DiMeglio L, Sherr, J, Clements M, Neyman A, Evans-Molina C, Sims E, Messer L, Ekhlaspour L, McDonough R, Van Name M, Rojas D, Beasley S, Dubose S, Kollman C, Moran A. Can Hybrid Closed Loop and/or Verapamil Prolong Islet Survival in New Onset Type 1 Diabetes? Results from the CLVer Trial. *Platform oral presentation (Forlenza presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Berlin, 2023.*
 104. **Forlenza G**. Data Ownership and Use of Data Aggregators in Clinical Care. *Invited platform oral presentation (Forlenza presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Berlin, 2023.*
 105. Ekhlaspour L, Berget C, Sherr J, DeSalvo D, Kingman R, Brown S, **Forlenza G**, Nguyen A, Barrett L, Huyett L, Ly T. Setting up for Success: Data-Driven Insights for Determining Insulin to Carbohydrate Ratios with the Omnipod 5 Automated Insulin Delivery System. *ePoster (Ekhlaspour presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Berlin, 2023.*
 106. Ekhlaspour L, Berget C, Kingman R, Buckingham B, DeBoer M, **Forlenza G**, Norlander L, Schoelwer M, Wadwa P, Reed Z, Lum J, Breton M. Glycemic Outcomes Improve Regardless of Demographics and Baseline Control for Young Children with Type 1 Diabetes Using Control-IQ – Results from the PEDAP Trial. *ePoster (Ekhlaspour presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Berlin, 2023.*
 107. Cobry E, Pyle L, Towers L, Jost E, Karami A, Berget C, **Forlenza G**, Waterman L, Wadwa P. Accuracy of the Dexcom G6 Continuous Glucose Monitor in Hospitalized Pediatric Patients with Type 1 Diabetes. *ePoster (Cobry presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Berlin, 2023.*
 108. Fivekiller E, Cook P, Volda S, Sankaranarayanan S, Fiesler C, Agrawal C, Xu T, **Forlenza G**, Messer L. Situational Awareness Independently Predicts Time in Range in Adolescents and Young Adults Using the t:slim X2 with Control-IQ System on a Daily Basis. *ePoster (Fivekiller presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Berlin, 2023.*
 109. Waterman L, Pyle L, Towers L, Jost E, Karami AJ, Berget C, **Forlenza GP**, Wadwa RP, Cobry E. Accuracy of Dexcom G6 Continuous Glucose Monitor in Pediatric Diabetes Ketoacidosis Admissions. *Poster (Waterman presenting author) at the American Diabetes Association 2023 Scientific Sessions, San Diego, 2023.*
 110. Breton MD, Buckingham BA, DeBoer MD, Ekhlaspour L, **Forlenza GP**, Schoelwer M, Wadwa RP, Lum JW, Beck R. AID-Driven TIR Improvements in Young DMI Children Are Indistinguishable from Their Pump-Using Peers – A PEDAP Subanalysis. *Platform oral presentation (Breton presenting author) at the American Diabetes Association 2023 Scientific Sessions, San Diego, 2023.*
 111. Ekhlaspour L, Reed Z, Buckingham BA, DeBoer MD, **Forlenza GP**, Kingman RS, Schoelwer M, Wadwa RP, Lum JW, Kollman C, Beck R, Breton MD. Glycemic Outcomes Improved and Maintained Regardless of Demographic Characteristics of Young Children with Type 1 Diabetes Using Closed-Loop System. *Poster (Ekhlaspour presenting author) at the American Diabetes Association 2023 Scientific Sessions, San Diego, 2023.*
 112. Vargas E, Mark J, **Forlenza GP**, Triolo TM. Diagnosis and Treatment of Diabetes Mellitus in Pediatric Patients with Pancreatitis Followed in Multidisciplinary Clinic. *Late-Breaking Poster (Vargas presenting author) at the American Diabetes Association 2023 Scientific Sessions, San Diego, 2023.*

113. Trojanowski PJ, Escobar E, Berget C, **Forlenza GP**, O'Donnell HK. Assessment of Eating Disorder Risk in Adolescents and Young Adults Starting an On-Body Automated Insulin Delivery (AID) System. *Poster (Trojanowski presenting author) at the American Diabetes Association 2023 Scientific Sessions, San Diego, 2023.*
114. Shah VN, Sakamoto C, Pyle L, Akturk HK, Polsky S, **Forlenza GP**, Snell-Bergeon JK. Time in Range is Associated with Incident Diabetic Retinopathy in Adults with Type 1 Diabetes – A Seven-Year Longitudinal Study. *Platform oral presentation (Shah presenting author) at the American Diabetes Association 2023 Scientific Sessions, San Diego, 2023.*
115. Geiser L, Leung HC, Berget C, Gong C, Liu Q, Zhou X, **Forlenza GP**. Preliminary Accuracy Analysis of a Noninvasive Optical Glucose Sensing Prototype. *Poster (Geiser presenting author) at the American Diabetes Association 2023 Scientific Sessions, San Diego, 2023.*
116. **Forlenza GP**, Sherr, JL, DeSalvo, DL, Huyett LM, Snow K, Mendez JJ, Hadjiyianni, Ly TT. Real-World Glycemic Outcomes with the Omnipod 5 Automated Insulin Delivery System (AID) in Under-Resourced Groups: Results from the United States Medicaid Population. *Poster (Forlenza presenting author) at The International Society for Pediatric and Adolescent Diabetes Conference, Rotterdam, Netherlands, 2023.*
117. Towers L, Escobar E, Berget C, Sakamoto C, Cobry E, Wadwa RP, **Forlenza GP**. Association Between Bolus Overrides and Time in Range (TIR) with the Insulet Omnipod (OP5) System in Youth with Type 1 Diabetes (T1D). *Poster (Towers presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Florence, Italy, 2024.*
118. Levy C, Bailey R, Laffel L, **Forlenza G**, DiMeglio L, Lal R, Brown S, Aleppo G, Bhargava A, Shah V, Clements M, Kipnes M, Bruggeman B, Daniels M, Rodriguez H, Beck R, Sasson-Katchalski R, Pinsker J, Pollom R. High Satisfaction with Control-IQ 1.5 and Lyumjev Insulin in Children, Adolescents and Adults with Type 1 Diabetes. *Poster (Levy presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Florence, Italy, 2024.*
119. Escobar E, Towers L, Berget C, Wadwa RP, Sakamoto C, **Forlenza GP**. Inspire Questionnaire Responses of Parents of Youth with Type 1 Diabetes (T1D) During the First 6 Months Utilizing Omnipod 5 (OP5). *Poster (Escobar presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Florence, Italy, 2024.*
120. Waterman LA, Cobry EC, Sakamoto C, Pyle L, **Forlenza GP**, Shah VN, Alonso GT. Sustained Impact of Automated Insulin Delivery on Hemoglobin A1c in the Emerging Adult Type 1 Diabetes Population. *Poster (Waterman presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Florence, Italy, 2024.*
121. **Forlenza GP**, Dai Z, Shin J. Reducing Diabetes Burden with Automated Insulin Delivery Systems. *Poster (Forlenza presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Florence, Italy, 2024.*
122. **Forlenza GP**, DeSalvo DJ, Huyett LM, Mendez JJ, Hadjiyianni I, Ly TT. Use of the Omnipod 5 Automated Insulin Delivery (AID) System with Low (<5 units) Insulin Requirements: Real-World Evidence. *Poster (Forlenza presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Florence, Italy, 2024.*
123. Waterman LA, Alonso GT, Sakamoto C, Pyle L, **Forlenza GP**, Shah VN, Cobry EC. Impact of Automated Insulin Delivery Systems by Baseline HbA1c in Emerging Adults with Type 1 Diabetes. *Poster (Waterman presenting author) at the American Diabetes Association 2024 Scientific Sessions, Orlando, FL, 2024.*
124. Waterman LA, Cobry EC, Sakamoto C, Pyle L, **Forlenza GP**, Shah VN, Alonso GT. Impact of Discontinuation of Automated Insulin Delivery Systems in Emerging Adult with Type 1 Diabetes. *Poster (Waterman presenting author) at the American Diabetes Association 2024 Scientific Sessions, Orlando, FL, 2024.*
125. Jost E, Cho S, Lange S, Berget C, Pinsker JE, Hartman L, **Forlenza GP**. The Use of Hybrid Closed-Loop Insulin Delivery in Adolescents and Young Adults with High-Risk Acute Lymphoblastic Leukemia during Induction Chemotherapy. *Poster (Jost presenting author) at the American Diabetes Association 2024 Scientific Sessions, Orlando, FL, 2024.*
126. Tabatabai I, Alonso GT, **Forlenza GP**. Diabetes Technology Outcomes in the Vulnerable Early Childhood Population at a Large Diabetes Clinic. *Poster (Tabatabai presenting author) at the American Diabetes Association 2024 Scientific Sessions, Orlando, FL, 2024.*

127. Tabatabai I, **Forlenza GP**. Data Driven Dosing Formulas in Early Childhood Type 1 Diabetes. *Poster (Tabatabai presenting author) at the American Diabetes Association 2024 Scientific Sessions, Orlando, FL, 2024.*
128. Berget C, Forlenza GP, Sherr JL, DeSalvo D, Aleppo G, Wilmot EG, Huyett LM, Hadjiyianni I, Mendez JJ, Conroy L, Ly TT. Virtual and Self-Guided Omnipod 5 Automated Insulin Delivery (AID) System Onboarding – Real-World Outcomes by Training Type. *Poster (Berget presenting author) at the American Diabetes Association 2024 Scientific Sessions, Orlando, FL, 2024.*
129. **Forlenza GP**, Macleish SA, Shulman DI, Nwosu BU, Accacha S, Garg SK, Carlson AL, Castorino KN, Marks BE, Lal R, Pihoker C, Thrasher J, Laffel LM, Sunil B, Bode BW, Sherr JL, Ekhlaspour L, Reed JH, Abuzzahab MJ, Church MM, Dai Z, Ma H, Solomon J, Treminio Y, Shin J, Rhinehart AS, McVean J, Vigersky RA. Safety and Glycemic Outcomes Using the MiniMed 780G System with a Disposable All-in-One Sensor with Transmitter. *Poster (Forlenza presenting author) at the American Diabetes Association 2024 Scientific Sessions, Orlando, FL, 2024.*
130. **Forlenza GP**, Sherr JL, DeSalvo D, Aleppo G, Wilmot EG, Berget C, Huyett LM, Hadjiyianni I, Mendez JJ, Conroy L, Ly TT. Real-World Outcomes with the Omnipod 5 Automated Insulin Delivery (AID) System for >7,500 Users with High HbA1c (>9%) at Baseline. *Platform oral presentation (Forlenza presenting author) at the American Diabetes Association 2024 Scientific Sessions, Orlando, FL, 2024.*
131. **Forlenza G**, Nally L, Shulman D, Demeterco-Berggren C, Reiner B, Kudva Y, Bode B, Dewan A, Kipnes M, Niu F, Yovanovich C, Shin J, Codero T, McVean J, Rhinehart A, Vigersky R. Pediatric Safety and Glycemic Outcomes Using the Advanced Hybrid Closed-Loop (aHCL) System with Ultra-Rapid Insulin Lispro-aabc. *Poster (Forlenza presenting author) at The International Society for Pediatric and Adolescent Diabetes Conference, Lisbon, Portugal, 2024.*
132. **Forlenza G**, Vigers T, Escobar E, Lange S, Jost E, Berget C, Wadwa RP, Driscoll K, Pyle L, O'Donnell H. Problem-Solving Intervention Improves Time in Range 70-180 mg/dL (TIR) Among Adolescents with Type 1 Diabetes (T1D) Using Hybrid Closed Loop (HCL) in a Randomized Controlled Clinical Trial. *Platform oral Presentation (Forlenza presenting author) at The International Society for Pediatric and Adolescent Diabetes Conference, Lisbon, Portugal, 2024.*
133. **Forlenza G**, Aleppo G, Miller, E, Berget, C, Oser S, Desalvo D, Pasquel F, Sherr J, Peters A, Wilmot E, Huyett L, Hadjiyianni I, Mendez J, Conroy L, Ly T. Impact of Lowering Target Glucose Setting with the Omnipod 5 Automated Insulin Delivery (AID) System: Evidence from Real-World Use. *Platform Oral Presentation (Forlenza presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Amsterdam, Netherlands, 2025.*
134. Wedding C, **Forlenza G**, Kushner T. Menstrual Cycle Phase-Specific Pattern Detection via Block-Based Recurrence Quantification Analysis (BLOCKRQA) for Targeted Insulin Control in Women with Type 1 Diabetes (T1D). *Platform Oral Presentation (Wedding presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Amsterdam, Netherlands, 2025.*
135. DiMeglio L, Bauza C, Buckingham B, Clements M, **Forlenza G**, Sherr J, Beck R, Kanapka L, Kollman C, Beasley S, Cobry E, Norland L, McDonough R, Van Name M, Moran A. Associations of CGM Metrics with Stimulated C-Peptide Measures in Youth with Recent-Onset Type 1 Diabetes. *Platform Oral Presentation (DiMeglio presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Amsterdam, Netherlands, 2025.*
136. Levy C, Carlow D, Swift D, Rittgers-Simonds R, Gronoroos N, Buysman E, Walker V, **Forlenza G**. Real-World HbA1c Following Initiation of the Omnipod 5 Automated Insulin Delivery System. *Short Oral Presentation (Levy presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Amsterdam, Netherlands, 2025.*
137. Moscoso-Vasquez M, Brown S, Deboer M, Afreen S, Fuller M, Holmes V, Ekhlaspour L, **Forlenza G**, Breton M. Demonstration of the Viability of Insulin-Only Fully Closed Loop Therapy in Adults with Type 1 Diabetes (T1D) at Home. *Short Oral Presentation (Moscoso-Vasquez presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Amsterdam, Netherlands, 2025.*
138. Taylor K, Escobar E, Sakamoto C, **Forlenza G**, Wadwa P, Cobry E, Berget C. Impact of the Omnipod 5 System on Glycemic Control and Psychosocial Outcomes in Very Young Children with Type 1 Diabetes (T1D). *Short Oral Presentation (Taylor presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Amsterdam, Netherlands, 2025.*

139. Moscoso-Vasquez M, Brown S, Deboer M, Afreen S, Fuller M, Holmes V, Ekhlaspour L, **Forlenza G**, Breton M. Safety Evaluation of Insulin-Only Fully Closed-Loop Therapy in Adults with Type 1 Diabetes (T1D) During Moderate Physical Activity. *Poster Presentation (Moscoso-Vasquez presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Amsterdam, Netherlands, 2025.*
140. Van Name M, Sherr J, Bauza C, Buckingham B, Clements M, **Forlenza G**, Neyman A, Beck R, Bailey R, Kollman C, Beasley S, Cobry E, Norland L, McDonough R, DiMeglio L, Moran A. Impact of Early Initiation of Automated Insulin Delivery on Glycemia Two Years from Diagnosis of Type 1 Diabetes. *Poster Presentation (Van Name presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Amsterdam, Netherlands, 2025.*
141. Neemuchwala Z, **Forlenza G**, Berget C. Tuning Optimization for the Insulet Omnipod 5 Among New Pediatric Users with Type 1 Diabetes. *Poster Presentation (Forlenza presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Amsterdam, Netherlands, 2025.*
142. Tabatabai I, **Forlenza G**. Barriers to Automated Insulin Delivery (AID) Use, Attitudes Towards Beta Bionics iLet Pump, and Desired Improvements in AID Pumps in High-Risk Youth with T1D. *Poster Presentation (Tabatabai presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Amsterdam, Netherlands, 2025.*
143. Karami AJ, Akturk H, Fivekiller EE, **Forlenza G**, Huss K, Klein MP, Mason E, McQueen RB, Oser S, Oser T, Parascando J, Pyle L, Sakamoto C, Wadwa RP, Polsky S. Effectiveness of Shared Empowerment for Early Device Success (SEEDS) Pilot Resources Used by Healthcare Providers (HCPs) for Successful Device Initiation in Persons with Diabetes (PwD). *Poster Presentation (Karami presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Amsterdam, Netherlands, 2025.*
144. Hosseinipour JY, **Forlenza G**, Ekhlaspour L, Wong JC, Escobar E, Cobry EC, Moscoso-Vasquez M, Brown SA. Evaluating Type 1 Diabetes (T1D) Care Across All Ages with Automated Insulin Delivery Adaptive Network (AIDANET) System in Fully Closed Loop (FCL). *Poster Theater Presentation (Hosseinipour presenting author) at the American Diabetes Association 2024 Scientific Sessions, Chicago, IL, 2025.*
145. Wong JC, Moscoso-Vasquez M, Ekhlaspour L, Brown SA, Breton MD, **Forlenza GP**. Use of a Fully Closed Loop (FCL) System Improves Glycemic Outcomes in Youth and Adults with Type 1 Diabetes (T1D) Not Meeting Glycemic Goals. *Poster Theater Presentation (Wong presenting author) at the American Diabetes Association 2024 Scientific Sessions, Chicago, IL, 2025.*
146. Tabatabai I, **Forlenza GP**. Barriers to Automated Insulin Delivery System (AID) Use and Desired AID Improvements in Youth with Type 1 Diabetes (T1D) with Elevated HbA1c. *Poster Presentation (Tabatabai presenting author) at the American Diabetes Association 2024 Scientific Sessions, Chicago, IL, 2025.*
147. Maher M, Akturk HK, Oser SM, Wadwa RP, **Forlenza GP**, Sakamoto C, Shrit Y, Etlas E, Huss KB, Karami AJ, Klein MP, Mason E, McQueen R, Parascando J, Fivekiller E, Oser T, Polsky S. Analysis of Provider Feedback on the Shared Empowerment for Early Device Success (SEEDS) Pilot Study. *Poster Presentation (Polsky presenting author) at the American Diabetes Association 2024 Scientific Sessions, Chicago, IL, 2025.*
148. Moscoso-Vasquez M, Flanagan D, Clancy-Oliveri M, Escobar E, Fulkerson D, **Forlenza GP**, Ekhlaspour L, Brown SA, Breton MD. Fully Closed Loop (FCL) System Improves Glycemic Control through Personalized Adaptation of Individual Insulin Needs in Adults, Young Adults, and Adolescents with Type 1 Diabetes (T1D). *Poster Presentation (Moscoso-Vasquez presenting author) at the American Diabetes Association 2024 Scientific Sessions, Chicago, IL, 2025.*
149. Moscoso-Vasquez M, Hosseinipour JY, Flanagan D, Fulkerson D, Brown SA, Ekhlaspour L, **Forlenza GP**, Breton MD, Cengiz E. Sex Differences in Glycemic Outcomes Using Fully Automated Closed Loop (FCL) System in Type 1 Diabetes (T1D) – Insights and Implications. *Poster Presentation (Moscoso-Vasquez presenting author) at the American Diabetes Association 2024 Scientific Sessions, Chicago, IL, 2025.*
150. **Forlenza GP**, Moscoso-Vasquez M, Brown SA, Capodanno G, Cengiz E, Cobry EC, DeBoer MD, Wadwa R, Wong JC, Ekhlaspour L, Breton MD. AI-Based Fully Closed Loop (FCL) Achieves Improved Glycemia vs. Hybrid Closed Loop (HCL) in People with Type 1 Diabetes (T1D). *Poster*

Presentation (Forlenza presenting author) at the American Diabetes Association 2024 Scientific Sessions, Chicago, IL, 2025.

151. Towers L, Escobar E, Narayan A, Hosseinipour JY, Moscoso-Vasquez M, Ekhlaspour L, Breton MD, **Forlenza GP**. People with Type 1 Diabetes (T1D) with High Baseline A1cs Experience Drastic Glycemic Outcomes from Use of the Automated Insulin Delivery as Adaptive Network (AIDANET) Fully Closed Loop (FCL) System. *Poster Presentation (Towers presenting author) at the American Diabetes Association 2024 Scientific Sessions, Chicago, IL, 2025.*
152. Escobar E, Towers L, **Forlenza GP**, Cobry EC, Hosseinipour JY, Narayan A, Brown SA, Wong JC. Perceptions and Acceptance of Technology in an Automated Insulin Delivery Adaptive Network (AIDANET) Fully Closed Loop (FCL) System. *Poster Presentation (Escobar presenting author) at the American Diabetes Association 2024 Scientific Sessions, Chicago, IL, 2025.*
153. Ekhlaspour L, Hosseinipour JY, Narayan A, Perez ZD, Holmes V, Berton MD, Brown SA, **Forlenza GP**, Cengiz E. Meal Composition and Postprandial Glucose (PPG) Excursions in a Fully Closed-Loop (FCL) Study. *Poster Presentation (Ekhlaspour presenting author) at the American Diabetes Association 2024 Scientific Sessions, Chicago, IL, 2025.*
154. Fisher Z, Xu T, Jost E, **Forlenza GP**, Volda S. Data Privacy and Trust Concerns among Adolescent and Young Adults (AYAs) with T1D Using Hybrid-Closed Loop Systems. *Poster Presentation (Forlenza presenting author) at the American Diabetes Association 2024 Scientific Sessions, Chicago, IL, 2025.*
155. **Forlenza GP**, Stoterau K, Chen A, Huyett LM, Conroy L, Ly TT. iPhone App Adoption Improves Bolusing Frequency in Adolescents and Young Adults with Type 1 Diabetes (T1D) – Insights from Real-World Omnipod 5 Automated Insulin Delivery (AID) System Use. *Late Breaking Poster Presentation (Forlenza presenting author) at the American Diabetes Association 2024 Scientific Sessions, Chicago, IL, 2025.*
156. **Forlenza G**, Sawyer A, Wilmot E, Do D, Miller K, Ly T. Settings Associated with Optimal Outcomes with the Omnipod 5 Automated Insulin Delivery (AID) System: Evidence from Real-World Users with Type 1 Diabetes (T1D). *Oral Presentation (Forlenza presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Barcelona, Spain, 2026.*
157. Laffel L, **Forlenza G**, DeSalvo D, Do D, Huyett L, Miller K, Ly T. Glycemic Outcomes with the Omnipod 5 Automated Insulin Delivery (AID) System in Users with Low Insulin Requirements (Fewer Than 5 Units/Day): Evidence from Real-World Users. *Oral Presentation (Laffel presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Barcelona, Spain, 2026.*
158. Wood J, DeSalvo D, **Forlenza G**, Do D, Huyett L, Miller K, Ly T. Glycemic Outcomes with the Omnipod 5 Automated Insulin Delivery (AID) System in Infants and Toddlers. *Oral Presentation (Wood presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Barcelona, Spain, 2026.*
159. Sawyer A, Towers L, Lange S, Berget C, **Forlenza G**. Using Simplified Meal Boluses Versus Carbohydrate Counting in Adolescents with Automated Insulin Delivery (AID) Systems: A Randomized Crossover Trial. *Short Oral Presentation (Sawyer presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Barcelona, Spain, 2026.*
160. Huyett L, **Forlenza G**, Sawyer A, Wilmot E, Do D, Miller K, Ly T. Settings Associated with Optimal Outcomes with the Omnipod 5 Automated Insulin Delivery (AID) System: Evidence from Real-World Users with Type 1 Diabetes (T1D). *Oral Presentation (Huyett presenting author) at Advanced Technologies and Treatments for Diabetes International Conference, Barcelona, Spain, 2026.*
161. Peters A, Kruger D, Carlson A, Laffel L, Sherr J, **Forlenza G**, Raghinaru D, Beck RW, Ly T, Kipnes M. Performance of a Next-Generation Algorithm for Omnipod in Adults with Type 2 Diabetes: Finding from the STRIVE Randomized Trial. *Oral Presentation (Peters presenting author) at the American Diabetes Association 2026 Scientific Sessions, New Orleans, LA, 2026.*
162. Sawyer A, Stein AB, Towers L, Lange S, Berget C, **Forlenza G**. Using a Simple Meal Bolus Strategy with Adolescents on Automated Insulin Delivery Systems. *Poster Presentation (Sawyer presenting author) at the American Diabetes Association 2026 Scientific Sessions, New Orleans, LA, 2026.*
163. **Forlenza G**, Kruger D, Castorino K, Aleppo G, DeSalvo DJ, Kipnes M, Peters A, Sherr J, Criego A, Macleish S, Carlson A, Raghinaru D, Beck RW, Ly TT, Laffel LM. Multicenter, Randomized Trial of a Next-Generation Algorithm for Omnipod in Individuals with Type 1 or Type 2 Diabetes: The STRIVE

Trial. *Oral presentation (Laffel presenting author) at the American Diabetes Association 2026 Scientific Sessions, New Orleans, LA, 2026.*

164. DeSalvo D, **Forlenza G**, Laffel LM, Criego A, Castorino K, Macleish S, Raghinaru D, Beck RW, Ly TT, Sherr J. Performance of a Next-Generation Algorithm for Omnipod in Children with Type 1 Diabetes: Findings from the STRIVE Randomized Trial. *Poster Presentation (DeSalvo presenting author) at the American Diabetes Association 2026 Scientific Sessions, New Orleans, LA, 2026.*
165. Kruger D, Aleppo G, Laffel LM, **Forlenza G**, Raghinaru D, Beck RW, Ly TT, Castorino K. Performance of a Next-Generation Algorithm for Omnipod in Adolescents and Adults with Type 1 Diabetes: Findings from the STRIVE Randomized Trial. *Oral Presentation (Kruger presenting author) at the American Diabetes Association 2026 Scientific Sessions, New Orleans, LA, 2026.*